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Abstract 
The three-dimensional (3-D) architecture of the bone marrow (13M) supports the renewal, 
maintenance, proliferation and differentiation of haernatopoietic stem cells (HSCs). Efforts 
have been made towards the reconstruction of an ex vivo HSC culture system, which could 
have several potential applications, such as the detailed understanding of normal and 
leukaemic haernatopoiesis and expansion of haernatopoietic stem cells for use in bone 
marrow transplantation (BMT). In this thesis, a numerical model has been developed to 
investigate the fluid flow, shear stress, and nutrient distribution within a purpose-designed 
scaffold placed inside a Rotating Wall Perfused Bioreactor (RWPB). A multi-lineage cellular 
growth model of haernatopoietic cells was incorporated in order to mimic the complexity of 
the BM. Subsequently, the model has been extended further to investigate the advanced 
aspects of haernatopoiesis such as the regulatory effects of growth factors including 
granulocyte colony-stimulating factor (G-CSF), thrombopoietin (TPO) and erythropoietin 
(EPO) on the production of chronic myeloid leukaemia (CML) cells. The simulation results 
demonstrate that: (1) the average fluid velocity in the scaffold is 0.1 mm/s, which is 
qualitatively similar to sinusoidal blood flow found in the BM, (2) the inlet conditions 
(oxygen concentration = 20% v/v, inoculum density = 2xIO5 celIS/CM3), transport properties 
(scaffold porosity = 95% and pore size = 250 tim) and reaction parameters (consumption 
rates) are sufficient to support the growth of haernatopoietic cells required for BMT 
applications, (3) different combinations and concentrations of cytokines can alter the self- 
renewal and differentiation of CML cells and this effect is also dependent upon operation 
conditions and scaffold properties, (4) the cellular growth kinetics are in good agreement 
with both published data and experimental results, validating the major finding predicted by 
I 
the computation model. The numerical model presented here enables the optimisation of 
scaffold design parameters, fluid dynamics and mass transfer environment necessary for 
developing a suitable ex vivo haernatopoietic system. 
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Nomenclature 
A, V Amplification factor of leukocyte 
. 4, q Amplification factor of erythrocyte 
Aj, Amplification factor of platelet 
a_, po Hill coefficient in Eq. 3.40,6.10 
aTpo Hill coefficient in Eq. 6.9 
B Total number of stages 
B Body force 
b Tube thickness 
b Number of stages 
C Mass concentration 
C Cell density 
CG Glucose concentration 
co Cell concentration for the previous stage 
C, Cell concentration for the present stage 
C02 Oxygen concentration 
CLS Concentration of limiting substrate 
CS Concentration of secondary substrate 
C Kozeny constant 
D Diffusivity of the species 
Do Diffusivity of 0 
dp Pore diameter 
E Concentrations of EPO 
f Component of the convective or diffusive flux vector in the direction 
normal to the CV face 
Value of f at location 'e' 
8 
fd Diffusive flux 
fe Convective flux 
f. Hill coefficient in Eq. 3.38,6.2 
G Concentrations of G-CSF 
H, Hydraulic radius 
Hill coefficient in Eq. 3.38,6.2 
Hill coefficient in Eq. 3.40,3.41,6.4,6.10 
Hill coefficient in Eq. 3.43,6.3,6.9 
KEpO Hill coefficient in Eq. 3.40,6.10 
KTpO Hill coefficient in Eq. 3.43,6.9 
K. Monod constant 
K. 
Ls 
Monod constant for limiting substrate 
K. 
s 
Monod constant for secondary substrate 
K. Rate limiting constant 
K Area porosity tensor/permeability 
k, kj, k2 Reaction term 
kG Kinetic coefficients for glucose 
km Dissociation constant of neutrophils 
k, Growth kinetics 
k. Cellular consumption 
k,, Maximum recruitment rate from non-proliferative phase 
k02 Kinetic coefficients for oxygen 
kGcsF Hill constant used in Eq. 6.2 
kEpO Hill constant used in Eq. 6.4 
kTpO Hill constant used in Eq. 6.3 
9 
k, x Self-expansion term 
k' d Generation term 
kd' Y Differentiation term 
kkx Death term 
k0 Sink/source of 
L Length 
A Mass flux through the 'e' face 
N Number of leukocytes 
n Unit vector 
P Number of platelets 
P Pressure 
PI Modified pressure 
Q Number of stem cells 
QjI Number of stem cells in proliferating phase 
q Flow rate 
R Number of erythrocytes 
91 Resistance 
ro Outer radius 
r, Pore radius 
S The surface enclosing CV 
SA Surface area per unit bulk volume/porous medium 
SAI Surface area per unit volume of solid (not porous) material 
SP The proportional part of source term 
SU The constant part of the source terrn 
S. The surface at location 'e' 
S. Mean shear stress 
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S,, S,, S, Shear stresses in the x, y and z-direction 
T Concentration of TPO 
T, Time delay 
T Transpose 
t Time 
V Control volume 
V.. Rate constant describing the maximal cell-specific nutrient uptake 
V. 
ax, LS Rate constant for the limiting substrate in the reaction 
V max Maximum production rate of G-CSF 
V Velocity 
X Position on x -coordinate in Cartesian space 
Y Position on y -coordinate in Cartesian space 
Greek Letters 
a,, a2 Constants 
Re-entry rate of CML stem cells into proliferating phase 
Death rate 
13M Specific death rate of mature cells in the tenninal stage 
15N Death rate of leukocyte 
8P Death rate of platelet 
(5Q Death rate of stem cell 
8R Death rate of erythrocyte 
45EPO Destruction or decaying rate of EPO 
'5GCSF Elimination of G-CSF by neutrophils 
STPO Half-life of TPO 
9 Hill coefficient in Eq. 3.36 
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Number of mature cells 
Number of active cells 
Number of quiescent cells 
0 Any conserved intensive property 
Os Any conserved intensive property at location 'E' 
OP Any conserved intensive property at location 'P' 
0, Any conserved intensive property at location 'e' 
r Diffusivity of the quantity 
7 Porosity 
'Id Differentiation rate 
179 Cell specific growth rate 
17, Self renewal probability 
77 a Active to quiescent transition rate 
77 q Quiescent to active transition rate 
KN Differentiation rates of stem cells into leukocytes 
KP Differentiation rates of stem cells platelets 
KR Differentiation rates of stem cells into erythrocytes 
Hill coefficient in Eq. 3.41,6.4 
KP Hill coefficient in Eq. 3.43,6.3 
Linear interpolation factor 
Viscosity of the fluid 
P, Effective viscosity 
01 Hill coefficient in Eq. 3.38 
02 Hill coefficient in Eq. 3.36 
P Density 
a Stress tensor 
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aL Limiting coefficient 
TN Time delay for leukocyte maturation 
rpm Time delay for platelet maturation 
, rPS Time delay for platelet aging due to senescence 
'rRM Time delay for reticulocyte 
TS Time delay for stem cell proliferation 
T.. Time delay for erythrocyte 
ri Angular velocity 
K2D Extend of differentiation ranging between 0 and I 




AEA Atomic Energy Authority 
BFU-E Burst forming unit-erythroid (erythroid progenitor) 
BM Bone marrow 
BMT Bone marrow transplantation 
CB MNCs Cord blood mononuclear cells 
CDS Central-difference approximation/ linear interpolation 
CFC Colony forming cells 
CFD Computational fluid dynamics 
CFU-C Colony forming units 
CFU-Eo Colony forming unit-eosinophils 
CFU-GM Colony forming unit--granulocyte, macrophage 
CFU-mast Mouse mast cell progenitors 
CFU-MEG Colony forming unit-megakaryocyte 
CFU-mix Multipotential progenitor 
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CSF Colony stimulating factor 
Cv Control volume 
DDE Delay differential equation 
DMM Double Monod kinetics 
DO Dissolved oxygen 
ECM Extracellular matrix 
ECS Extracapillary space 
EPO Erythropoietin 
FBS Fetal bovine serum 
FD Finite difference 
FE Finite element 
FV Finite volume 
G-CSF Granulocyte colony stimulating factor 
GF Growth factor 
GM-CSF Granulocyte/macrophage colony stimulating factor 
HIM Haematopoietic inductive microenvironment 
HSC Haematopoieitc stem cell 
ID Inoculum. density 
IL Interleukin 
IMDM Iscove's modified Dulbecco's medium 
LTC Long-term culture 
LTC_IC Long-term culture initiating cell 
LySC Lymphoid stem cell 
M-CSF Monocytes colony stimulating factor 
MGF Mast cell growth factor 
MNC Mononuclear cell 
MYSC Myeloid stem cell 
NK Natural killer 
NMR Nuclear magnetic resonance 
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PB Peripheral blood 
PBCs Periodic boundary conditions 
PET Polyethylene terephthalate 
Ph+ Philadelphia 
PIV Particle-image velocimetry 
QUICK Quadratic upwind interpolation 
Re Reynolds number 
RWPB Rotating wall perfused bioreactor 
RWV Rotating wall vessel 
Sc Committed stem cell 
SCF Stem cell factor 
SD Standard deviation 
SF Steel factor 
SIMPLE Semi-implicit method for pressure-linked equation 
SIMPLER Revised semi-implicit method for pressure-linked equation 
TCPB Tantalum coated porous biornaterial 
TPO Thrombopoietin 




An ex vivo system capable of mimicking the in vivo environment of bone marrow (BM) can 
provide a valuable model for studying blood cell formation under normal and pathological 
conditions. Such a culture system could have potential applications in new drug screening, 
and toxicity studies, as well as stem cell expansion for bone marrow transplantation (Koller 
and Palsson 1993; Chapman et al. 1999). However, mimicking haernatopoiesis ex vivo poses 
many challenges as haernatopoietic cultures are complex because there are many interplaying 
factors which influence blood cell formation. Simulation methods, such as computational 
fluid dynamics (CFD), can be utilized to obtain detailed flow pattern and species 
concentration, thereby helping to optimize the design and operational parameters of ex vivo 
culture system for haernatopoietic cell cultures. 
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1.1 Motivation 
Aleix Carrel, a French scientist working at the Rockefeller Institute (New York) in the early 
1900s, is generally credited with starting the current revolution in Tissue Engineering. With 
over a century's worth of experimentation, it is now believed that stem cells are the key to the 
growth of tissues. There are many scientists, clinicians and industrialists who believe that 
haernatopoietic stem cells are the way forward to delivering therapeutic strategies for treating 
bone marrow disease, as it is more effective to manipulate the blood's primitive components 
ex vivo than through factors or small molecules in vivo. 
Furthermore, drug resistance and lack of bone marrow donors have always limited the choice 
of treatment for bone marrow diseases. As a result, there is an increasing demand for research 
into haematopoiesis and the development of new curative strategies. Consequently, there 
have been continued efforts towards the development of novel haematopoietic stem cell 
expansion systems. By providing a comprehensive level of monitoring and control over 
specific parameters in 3-D cultures, bioreactors can provide the technological means to 
perform controlled studies aimed at understanding the role that specific biological, chemical 
or physical parameters plays in a defined tissue. 
Apart from stem cell isolation, one of the most challenging aspects in the reconstitution of 
tissue/organs is the ex vivo expansion of stem cells. Originally, it was assumed that the 
expansion stage would be relatively simple based on the Dexter culture system (see Chapter 
2) (Dexter et al. 1973; Dexter et al. 1977). In reality, human haematopoietic cells die within 
10 weeks (Moore and Sheridan 1979). The following key factors have been identified to 
cause the failure of haematopoietic stem cells to reproduce in an ex vivo environment: 1) lack 
of three-dimensional (3-D) geometry to recreate the haematopoietic inductive 
microenvironment (HIM), 2) poor medium exchange of fresh media and metabolic waste, 3) 
17 
limited space for the highly proliferative cells and 4) lack of stroma cells or endogenous 
growth factors. 
Considerable efforts have been made within this area to overcome the limitation highlighted 
above. In particular, it is important to integrate the knowledge acquired from a variety of 
disciplines to aid the development of haematopoietic stem cell expansion systems. For 
example, in vivo BM physiological characteristic obtained through modelling means, such as 
the significance of delivery system (BM Microcirculation) and transportive properties 
(convection and diffusion) (Kumar et al. 2004) can aid the development of the ex vivo 
system. Contributions from Material Engineer's characterising scaffold properties (Safinia et 
al. 2007) provide an opportunity to analyse and mimic the in vivo microenvironment. Stem 
cell engineers utilise their expertise to optimise the 'right' combination of cytokines necessary 
for the haernatopoietic stem cell expansion (Lim et al. 2007). 
1.2 Why Modelling? 
The development of a stable ex vivo system for the growth of haernatopoietic cells would be 
invaluable for the study of the mechanisms controlling haernatopoiesis. However, the 
complex kinetics and transient nature of the cells and intricate interactions between culture 
parameters make it difficult to define the optimum factors and culture conditions that can 
enhance production of haematopoietic cells. An optimisation methodology using 
experimental techniques would be impractical due to time and cost concerns. Thus a 
modelling approach is undertaken as an alternative to experimental method to design the 
optimal experimental condition(s) to study haematopoiesis. 
Detailed knowledge of the momentum and mass transport characteristics of the bioreactor in 
different operating conditions is necessary for the successful operation of the system 
(Williams et al. 2002). This can be done by using a computational fluid dynamic (CFD) 
software to simulate the flow conditions in the bioreactor and to define the properties of the 
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model environment wherein biological tissues are grown. It can also be used to optimize the 
specifications of the culture system and operating conditions, such as the porosity and 
perfusion flow rate so as to achieve the best possible conditions for cell growth, resulting in 
improved quality and quantity of the generated tissue (Begley and Kleis 2000). 
1.3 Research Objectives 
The main objective of this thesis is to investigate the fluid dynamical aspects (e. g. fluid flow 
and shear stress), mass transport (oxygen, glucose and growth factors) and cellular growth 
within the bioreactor for BM culture. The Rotating Wall Perfused Bioreactor (RWPB- 
Synthecon, Inc) has been chosen to be a suitable culture system for this study. The perfusion 
and rotation operation conditions of this culture system provide a dynamic culture 
environment to the cellular components with low shear stress and high mass transfer rates. 
The model presented in this work does not, at present consider rotational aspects of the 
bioreactor. 
Furthermore, a scaffold is designed and embedded in the bioreactor to provide a three- 
dimensional environment mimicking the in vivo bone marrow microenvironment for stem 
cell expansion. Finally, to simulate the growth characteristics of HSCs under various 
operating conditions, different stem cell models are incorporated to mimic the complexity of 
the BM. This is achieved by taking the following steps: 
i) To develop a multi-lineage model to capture the complex functionality of the BM 
according to its known physiology. 
ii) To extend the above model by incorporating the regulatory effects of growth 
factors in the production of different cell types. 
iii) To apply the model to diseased BM; specifically chronic myeloid leukaemia. 
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1.4 Thesis Outline 
This thesis presents the numerical study of fluid flow, mass transfer and cell growth in a 
three-dimensional bioreactor for bone marrow culture. A comprehensive literature review of 
the bone marrow structure, blood formation process and haernatopoietic cell culture systems 
is given in Chapter 2. The modelling aspect of the work is presented in Chapter 3, where 
modelling techniques are introduced and available haernatopoiesis models are presented and 
analysed. Chapter 4 presents a fluid dynamics, mass transport and multi-lineage cell growth 
model. In Chapter 5, comparison of numerical results with existing published data and 
additional experimental work is presented to serve as a preliminary validation. Chapter 6 
extends the previous model application into BM under pathological condition, such as 
chronic myeloid leukaemia. The conclusions of the work are given in Chapter 7 




2.1 Bone Marrow Structure 
Bone marrow is one of the largest organs in the human body located inside the bone cavities. 
Structurally, BM has an intricate three dimensional architecture that consists of an 
intravascular (blood vessel network) and an extravascular (haematopoietic) space (Lichtman 
1981; Abboud and Lichtman 2001), as shown in Figure 2.1. The intravascular space 
comprises of the arteriolar and the sinusoidal networks, with the major arterial supply to the 
marrow coming from the nutrient artery. The nutrient artery bifurcates into ascending and 
descending arteries with radial branches extending towards the cortex. On returning towards 
the central bone cavity, these vessels form sinusoids, which supply blood to the extravascular 
space. The marrow sinus system is a highly branched network providing the channels where 
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blood flows through the marrow cavity and drains into the central sinus and the emissary 
veins (Brookes 1971; Lichtman 1981). 
The extravascular space is the site of haernatopoiesis or blood cell formation. Haernatopoiesis 
is a complex process involving a variety of specialized blood cell types, including as white 
and red blood cells. These cells are generated and differentiate continuously throughout adult 
life from a relatively small population of multipotent haernatopoietic stem cells (HSCs), 
located primarily in the bone marrow (Zandstra et al. 1994; Koller et al. 1998; Nielsen 1999) 
(Figure 2.2). 
2.2 Haematopoietic Cell Hierarchy: Stem Cell Differentiation 
On average, an adult produces nearly 400 billion mature blood cells per day in order to 
replace the natural turnover and to maintain homeostasis (Koller and Palsson 1993; Nielsen 
1999). This continuous regeneration of mature cells involves complex and highly regulated 
differentiation pathways that begin from a common precursor-HSC. HSC is multipotent and 
has the capacity to differentiate into any type of mature blood cells. It divides by 
asymmetrical division that results in one differentiated daughter cell and one undifferentiated 
stem cell (Koller et al. 1998). The differentiated daughter cell commits to enter either the 
lymphoid or the myeloid lineage (Williams 2000). The common lymphoid progenitors 
generate B and T lymphocytes, and natural killer (NK) cells, while the common myeloid 
progenitors give rise to red cells, platelets, granulocytes, and monocytes. Further 
downstream, the myeloid and lymphoid stem cells form more mature progenitors, and with 
each differentiation stage, they lose proliferative potential, i. e. become more restricted in the 



























Figure 2.1: The blood supply of bone marrow [modified from Lichtman 19811. Blood comes 
from nutrient artery, bifurcates into medullary arteries and travels to the cortex through radial 
artery. In the cortex, arterial blood from nutrient artery mixes with blood from periosteal 
arteriole. On returning towards marrow cavity, cortical capillaries form sinusoids, which 
supply blood to the extravascular region (shown in pink). These sinuses collect into a large 
central sinus and drain into the emissary vein. 
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Platelets B, T and NK cells 
Figure 2.2: The haernatopoietic process [modified from da Silva et al. 2003]. A single 
committed HSC can produce approximately 106 mature blood cells after 20 divisions 
(Hoffbrand et al. 200 1 ). 
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Progenitor cells give rise to monopotential blast cells called precursor cells that can only 
differentiate into a single mature cell type. After the blood cells mature, they exit the 
sinusoids and enter the blood stream. Ultimately, the terminally differentiated cells produced 
can neither divide nor undergo apoptosis after a period of time, which ranges from hours (for 
neutrophils) to decades (for some lymphocytes) (Smith 2003). The series of differentiations 
highlighted above involves many levels of control (Koller and Palsson 1993; Zandstra et al. 
1994). These intricate processes are regulated by the haematopoietic inductive 
microenvironment (HIM), a 3-D structural and chemical microenvironment that regulates, 
through positive and negative signals, the survival, proliferation, differentiation and 
maturation of HSCs (Smith 2003; Mantalaris et al. 2004). Abnormalities in the regulation of 
haematopoiesis may lead to the development of bone marrow disorders, such as leukaemia. 
2.3 Bone Marrow Microenvironment 
The bone marrow provides a HIM that promotes and regulates the haernatopoiesis (Chertkov 
1986). This HIM comprises of a complex network of stromal. cells and their products, such as 
cytokines and extracellular matrix (ECM) (Hoffbrand et al. 2001) (Figure 2.3). 
2.3.1 Stromal Cells 
Marrow stromal cells promote and regulate stem cell self-renewal, commitment 
differentiation and proliferation through their secreted cytokines. Other components, such as 
collagen, glycoproteins (fibronectin and thrombospondin) and glycosaminoglycans 
(hyaluronan and chondroitin derivatives) form the extracellular matrix (ECM) (Hoffbrand et 
al. 2001). In addition, the haernatopoietic stroma supports the vasculature (Weiss 1976; 
Weiss 1995; Verfaillie 2000; Williams 2000). 
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ECM Growth factor receptor 
Figure 2.3: Components of bone marrow microenvironment. Stromal cells interact with HSCs 
via cell-cell contact, and produce ECM and cytokines. Cytokines may present to the HSC 
during the direct interaction between i) stromal cell and HSC or ii) HSC and ECM. This 
unique microenvironment regulates the self-renewal, proliferation and differentiation of 
HSCs. 
Reticular and endothelial cells are the major component of stromal cells. A complete luminal 
layer of endothelial cells and an incomplete abluminal layer of adventitial reticular cells line 
the wall of the vascular sinuses. On maturation, the blood cells from the haernatopoietic 
compartments pass through the adventitial reticular cells, and the endothelial cells to enter 
the sinus lumen. Adventitial reticular cells regulate cell passage across the venous sinuses by 
covering or uncovering the endotheliurn as needed (Weiss 1995). The other components of 
the stromal cells include, macrophages, which are responsible for the homeostasis of the 
haernatopoiesis and the production of cytokines and ECM. 
Through long-term bone marrow cultures (LTC), stromal-mediated haematopoiesis has been 
shown (Dexter et al. 1977). In such systems, the stromal cells form an adherent layer to 
which the haernatopoietic cells attach loosely. More primitive progenitors, termed long-term 
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Cytoldne - Adhesive interactions 
culture initiating cells (LTC-IC), can be detected between or under the stromal cells. During 
maturation, blood cells are then released into the non-adherent compartment, and as a 
consequence differentiated progeny, including colony-forming cells (CFC), and more mature 
precursors can be found in or suspended above the stromal layer (Wang et al. 1995). Further 
studies have also shown the development of an adherent layer of stromal cells supporting the 
expansion of progenitor cells (Bagley et al. 1999) and the forming of cell colonies 
(Dorshkind et al. 1985). 
The haematopoietic stroma makes major contributions in the construction of a 3-D 
haernatopoietic microenvironment (Weiss 1995); the intimate association facilitates cell-to- 
cell and cell-to-matrix interactions (Glowacki et al. 1998; Li et al. 2001). It is believed that 
this 3-D geometry with close structural and functional relationship with the stromal cells of 
the bone marrow plays a crucial role in maintaining haernatopoietic progenitor viability and 
pluripotency (Bagley et al. 1999). 
2.3.2 Cytokines 
Cytokines are a group of glycoproteins that act as messengers regulating haernatopoiesis, 
namely the proliferation and differentiation of haernatopoietic stem progenitor, and precursor 
cells (Bain and Gupta 2003). The process is controlled by the feedback mechanisms of the 
cytokines that transmit positive or negative signals to maintain the number of blood cells and 
return to normal conditions post any upset. Essentially, the biological effects of cytokines are 
mediated through the specific receptors on the surface of the cells. 
Over 20 haernatopoietic regulators have been identified including erythropoietin (EPO), 
thrombopoietin (TPO), interleukin (IL)-I, IL-3, IL-6, IL-I 1, granulocyte/macrophage (GM)- 
CSF, granulocyte (G)-CSF, monocytes (M)-CSF, and c-kit ligand (stem cell factor (SCF), 
Steel factor (SF), or mast cell growth factor (MGF)). Major production sources of the growth 
factors are the stromal cells in the bone marrow except for erythropoietin and 
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thrombopoietin, which are largely synthesised in the kidneys and liver, respectively 
(Hoffbrand et al. 2001). Secretion of cytokines can vary significantly with changes in in vivo 
oxygen tension, pH, and shear stress (Nielsen 1999). In vivo studied have demonstrated that 
cytokines facilitate the formation of colonies (Tun et al. 2002). Additionally, cytokines act to 
either activate or inhibit the proliferation, differentiation, maturation, and apoptosis of blood 
cell during the blood formation process. 
2.3.3 Location of Haematopoietic Cells within the Marrow Cavity 
Within the marrow cavity, haernatopoietic cells show distinct patterns of lodgment. Studies 
have demonstrated that the more differentiated cells lie against the vascular (sinuses) wall, 
while the more undifferentiated cells are the most distant from the venous vasculature. 
Nilssen et al. (2001) reported that the most primitive haernatopoietic stem cells are enriched 
within the endosteal (bone) region, whereas terminally mature differentiated and lineage- 
committed cells are selectively and predominantly located in the central marrow region 
(Nilsson et al. 2001). 
Spatial distribution of lineage-specific cell types has also been described in the bone marrow 
(Nilsson et al. 2001). Maturing red cells (erythroblasts) are produced near sinuses; clusters of 
erythroblasts surround a central macrophage in the bone marrow to form erythroblastic 
islands (erythroblastic islets), which occurs in close proximity to the adventitial surface of 
vascular sinuses. Megakaryocytes and lymphocytes lie over the adventitial surface of the 
vascular sinuses and in clusters surrounding the radial arteries, respectively (Weiss 1995; 
Nilsson et al. 2001). Granulocytes are usually produced at sites close to arterioles and away 
from the sinuses wall; when they become mature, they migrate towards the sinuses wall to be 
released into the circulation. These well-defined structures suggest the existence of 
haematopoietic cell "niches" that are involved in the self-renewal, proliferation and 
differentiation of the cells. 
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2.4 Chronic Myeloid Leukaemia 
Each year, 24,000 new cases of leukaemia are diagnosed in the United Kingdom, and among 
these, about 750 were of the Chronic Myeloid Leukaemia type (Leukaemia Research Fund 
2006). CML is a clonal myeloproliferative disorder that is characterised by the abnormal 
amplification of myeloid lineages, especially granulocytes, and sometimes platelets. Mutation 
of normal haernatopoietic stem cells into leukaemic cells at the cellular level contributes to 
the excessive production of granulocytes. This increase in cell production leads to increased 
cellularity in the bone marrow, approximately 3-5 fold more than healthy individuals. The 
unique feature of CML is the presence of the Philadelphia (Ph+) chromosome that directs the 
production of a fusion protein which is responsible for most of the physiological alterations 
of the cells. The resultant overproduction of granulocytes in in vivo and in vitro is a 
consequence of such genetic abnormality which attributed is to the alteration in cell kinetics, 
adhesion/homing and feedback mechanism. A summary of the abnormalities of CML cells 
are described in Table 2.1. 
Regulation of activation, proliferation, differentiation, maturation and apoptosis of 
haematopoietic cell is controlled by cytokines. It plays an important role in up and down 
regulation of the number of cells in BM and blood. In certain forms of CML, regular 
oscillation of blood cell numbers has been observed, ranging between 70-80 days (Adimy et 
al. 2006b). The leukocyte lineages show the most frequent oscillation, of approximately 40- 
80 days (Fortin and Mackey 1999). Similar oscillatory patterns have been observed in the 
platelet and reticulocyte lineages. In healthy individuals, certain cytokines are known to 
temit' either a positive or negative signal to maintain normal blood cell levels, and, 
consequently, it is believed that the oscillations are due to the abnormalities in the feedback 
mechanism between the regulators and blood cells (Colijn and Mackey 2005). 
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Functional alteration Growth characteristics in CNIL cells 
Adhesion and homing a Impaired cell surface adhesion receptors lead to and facilitate 
the release of premature cells into the circulating blood 
(Gordon et al. 1987). 
0 Abnormal sinus endothelium layer has more pores compared to 
normal BM cells, therefore allowing passage of immature 
CML cells through the sinus. These contribute to the expansion 
in the premature progenitor and precursor circulation 
population in blood (Petrides and Dittmann 1990). 
Cell kinetics Apoptosis 
" Reduced apoptosis: it has been observed that the circulating 
granulocytes have longer life span than normal mature 
granulocytes (Ogawa et al. 1970). 
" Abnormal gene in CML patients suppress apoptosis and 
enhance survival (Bedi et al. 1994). 
Self renewal and proliferative potential 
" CML leads to the decrease in self-renewal capability and 
concomitant increase in differentiation probability (Petzer et al. 
1997) 
" Majority of the primitive progenitors, LTC-IC, are Ph-, 
whereas, many of the differentiated progeny, CFCs, are Ph+ in 
patients' cells (Podesta et al. 1997). 
& vivo study shows long term culture-initiating leukaemic 
cells disappear rapidly from the culture (Udomsakdi et al. 
1992; Luna-Bautista et al. 2003), whereas the colony-forming 
leukaemic cells population increase significantly (Petzer et al. 
1997). 
Feedback Mechanism a Distorted 
N Response to cytokines is less dependent 
Table 2.1: Abnormalities of cell kinetics in CIVIL 
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Various studies have shown that CML cells altered proliferation and maturation patterns in 
response to cytokines stimulation. It has been shown that CML cells are growth factor 
dependent and the addition of different combinations of cytokines can facilitate CML cells to 
differentiate into different lineages (Luna-Bautista et al. 2003). However, a recent study 
demonstrated that CML cultures were less dependent on external cytokines and showed 
better maintenance than normal BM cells without cytokines (Chavez-Gonzalez et al. 2004). 
The possible explanation is that CML cells have enhanced sensitivity to growth factors in 
inducing division and maturation, thus contributing to the abnormal expansion of CML cells 
compared to their normal counterparts (13hatia et al. 2000). Furthermore, it has been 
demonstrated that CML cells have the ability to produce growth factor IL-3 and G-CSF 
under culture conditions (Jiang et al. 1999). 
2.5 Development of ex vivo Bioreactor for Haematopoietic Cell 
Culture 
Successfully constructing an ex vivo haematopoietic cell culture system would serve as a 
valuable tool for understanding the mechanisms of haematopoiesis under normal or 
pathological states. Further, such a system can be use for drug screening studies of the 
dynamics and mechanisms of pharmacological and toxicological actions and also has 
potential clinical applications in bone marrow transplantation (BMT) (Kirschstein and 
Skirboll 2001; Wu et al. 2006). 
In order to reconstitute the bone marrow in an ex vivo environment, the ideal design of an ex 
vivo culture system should structurally and biologically simulate the in vivo state to match in 
vivo haematopoiesis as closely as possible. The design of such a system poses challenges 
because of the complex kinetics of the heterogeneous cell populations and the intricate 
interactions between culture parameters. A lot of effort has been made to investigate the 
crucial design parameters (e. g. reactor type and materials) and operational conditions (e. g. 
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oxygen level, feeding schedule) for the ex vivo expansion of stem cell cultures. In the 
following section, key design parameters that are known to successfully establish primary 
haernatopoietic cell cultures are reviewed and discussed. 
2.5.1 Operational and Cultural Parameters 
2.5.1.1. Inoculum Density (ID) 
Seeding density has been demonstrated to influence the performance of haernatopoietic 
cultures. Zandstra et al. (1994) showed that inoculum density might play a key role in the 
prolonged production of CFC and total cells in suspension cultures. High inoculum cell 
density cultures (IX106 cells/ml) do show significant increase in LTC-lCs and CFCs 
(Zandstra et al. 1994). However, other researchers reported that the expansion of total cell 
number and colony forming unit--granulocyte, macrophage (CFU-GM) was inversely 
proportional to the seeding density (Palsson et al. 1993). Erythropoietic Burst Formation cells 
(BFU-E), however, did not follow this pattern and were not influenced significantly by the 
seeding density. Palsson and co-workers proposed that the optimal seeding density appeared 
to depend on the cell type(s) desired. 
To obtain the maximum expansion or number of cells, consideration needs to be given not 
only to inoculum density but also surface area. Surface area can become a limiting factor for 
generating the desired number of haematopoietic cells (Palsson et al. 1993). Koller et al. 
(1996) reported lower inoculurn density favored cell expansion ratio and higher ID favored 
total cell output. As ID increased, cells (CFU-CM and LTC-IC) output increased, but the 
actual expansion efficiency decreased due to the fact that there was limited availability in the 
culture system (Koller et al. 1996). Similarly, Takagi et al. (2002) demonstrated that limited 
surface area of each porous carrier restricted cell growth; the final cell concentration did not 
show dependency on the inoculum cell density even when cells were supplied with extra 
glucose, glutamine and dissolved oxygen. Therefore, special attention is required when 
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cultivating the more primitive cells, such as CD34-enriched cell cultures; they must be 
inoculated at relatively low density because of their high expansion potential (Koller et al. 
1998). The typical reported inoculum density of mononuclear cells (MNC) is l-3xI 06 
cells/ml and 0.5-lxl 04 cells/ml for CD34+ cells (Brugger et al. 1993; Zandstra et al. 1994; 
Koller et al. 1996; Collins et al. 1998b; Bagley et al. 1999). 
2.5.1.2. Dissolved Oxygen Tension 
Control and regulation of dissolved oxygen level is especially important because undesirable 
oxygen level can cause toxicity or anoxia, and hence influence the expansion of 
haematopoietic cells (Palsson et al. 1993). 
Several studies have reported that oxygen tension in the bone marrow is between 10 and 50 
mmHg (Ishikawa and Ito 1988; Koller and Palsson 1993). That means, approximately, 5% 02 
will be sufficient to provide an environment similar to the in vivo bone marrow 
microenvironment (Lindop and Rotblat 1960; Wright and Bewley 1960). On the other hand, 
in in vitro studies, different oxygen concentration levels produced various results in the 
pattern of cell expansion. Studies have shown that low oxygen concentration increases cell 
expansion, causes the formation of more and larger cell colonies in colony assay cultures, 
favours the differentiation of progenitor cells (Koller et al. 1992a), enhances colony forming 
units (CFU-C), erythroid progenitors (BFU-E), multipotential progenitors (CFU-mix) and 
mouse mast cell progenitors (CFU-mast) (Ishikawa and Ito 1988). Other studies have showed 
that, when comparing culture performance in different oxygen levels in the gas phase, 20% 
oxygen level resulted in enhanced total cell, BFU-E and CFU-GM expansion than the 5% and 
60% oxygen (Palsson et al. 1993). Recently very low oxygen concentration (0.5-5%) has 
been shown to favor the expansion and maintenance of CD34+ by controlling the cell cycle 
of these primitive HSCs (Ivanovic et al. 2000; Hermitte et al. 2006) 
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Most experiments in expanding bone marrow cultures (and other animal cell cultures) are 
carried out using 20% oxygen. Although high concentration of oxygen in the gas phase may 
enhance the mass transfer rate, the oxygen concentration may reach an inhibitory level, which 
can be toxic to cells (Ishikawa and Ito 1988; Palsson et al. 1993). Thus, a well-designed 
system with optimal gas phase oxygen concentration at non-inhibitory levels and sufficient 
driving force for good mass transfer of oxygen to accommodate the higher cell density 
prolific cultures is needed. In addition, special attention is necessary on the diffusion rate of 
dissolved oxygen (DO) in 3-D culture systems, especially when cells are maintained at a high 
density (Glowacki et al. 1998). 
2.5.1.3. Endogenous Growth Factors 
Cytokines play an important role in the regulation of cell expansion and differentiation. 
Different combinations of recombinant molecules or human growth factors have been utilised 
in ex vivo cultures of HSCs to achieve an increased expansion of haernatopoietic stem cells 
and do enable maintenance of long term bone marrow cultures (Koller et al. 1993a; Poloni et 
al. 1997; Balducci et al. 2003). 
In general, some growth factors are more selective, acting on either progenitor cells or their 
differentiated progenies; while other growth factors are less specific, acting on most types of 
cells. For example, CSFs act primarily on relatively committed cells that are not pluripotent 
except for IL-3, while C-kit ligand appears to be one of the critical factors required for early 
cell expansion (Koller and Palsson 1993). Other haematopoietic regulators, such as 
erythropoietin (EPO) and thrombopoietin (TPO), have been identified to mediate the 
production of erythrocytes and platelets, respectively (Metcalf and Nicola 1995). The growth 
factor, granulocyte colony-stimulating factor (G-CSF), is a major growth factor that controls 
the neutrophil regulatory system by controlling the apoptosis rate of neutrophil precursors 
and the rate of HSC differentiation into the neutrophil precursor compartment (Metcalf and 
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Nicola 1995; Bernard et al. 2003). In vitro studies also show that different combination and 
concentration of exogenous cytokine affects HSC expansion and differentiation; thus 
cytokine consumption and supply is an important parameter that requires careful control 
(Koller et al. 1992b; Brugger et al. 1993; Koller et al. 1995a) 
2.5.2 Bioreactor Design and Operation 
As highlighted in the previous sections, the idea of cultivating haematopoietic cells along 
with stromal cells in two-dimensional (2-D) flask cultures was initially suggested by Dexter 
in the late 1970s (Dexter et al. 1973; Dexter et al. 1977). He and his co-workers postulated 
that stromal cells could provide the appropriate growth environment and the required 
signalling molecules for the survival of the haernatopoietic cells. Flask cultures with a 
monolayer growth environment limit the proliferation potential and the viability of cells, and 
though stromal cells were used as the feeding layer, it lack of the 3-13 microenvironment 
observed in in vivo system. The 2-D system leads to significant changes in cell-cell contact 
and cell-substrate interactions (Tun et al. 2002). Furthermore, Dexter cultures operate 
predominantly at static conditions and therefore cannot provide effective mass transfer, 
leading to accumulation of metabolic waste and insufficient nutrient supply for cell growth 
(Wang et al. 1995; Glowacki et al. 1998; Bagley et al. 1999). Although experimental work on 
culture dishes and flasks has provided invaluable information, there are important limitations 
in 2-D systems, which ultimately result in the lack of long-term culture maintenance and 
multi-lineage differentiation. These limitations include the inability to provide a controlled 
culture environment, which can be overcome through the use of bioreactors. 
Bioreactor culture systems have been developed to overcome the limitations of 2-D static 
cultures for haematopoietic stem cell expansion (Koller and Palsson 1993). Most research has 
been focused on developing a bioreactor that mimics the haematopoietic system ex vivo with 
a 3-D arrangement and perfusion features (Wang et al. 1995; Glowacki et al. 1998; 
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Mantalaris et al. 1998; Jelinek et al. 2002). It is reasonable to assume that more effective 
cultures of these cells could occur in an environment that resembles the architecture and 
function of the bone marrow as closely as possible (Highfill et al. 1996). 
The development of a bioreactor system has several advantages over the traditional 2-D static 
methods of culturing haernatopoietic cells. (Nielsen 1999): 1) An automatic control of 
bioreactors can minimize labour-intensive daily feeding and daily culture condition cycles. 
Less physical disruption and contamination can significantly improve the productivity and 
longevity of haematopoietic cultures (Koller and Palsson 1993). Also, some automatic 
systems can monitor pH, 02, nutrients and temperature levels. 2) Higher surface area to 
volume ratio is able to support high cell density growth, in contrast to traditional culture 
systems. This is especially important for high proliferative haematopoietic stem cell research 
for BMT. 3) Dynamic environment with low shear stress conditions within the bioreactor, 
and 4) Allow rapid medium exchange to minimize accumulation of metabolites and to 
increase mass transport. 
2.5.2.1. Shear Stress 
Due to the lack of a cell wall, mammalian cells are susceptible to forces in their environment, 
such as shear stress. Exposure to high shear stress can lead to cell denaturation and 
degradation. However, to achieve cell growth, agitation and aeration may be necessary to 
supply cells with sufficient nutrients and oxygen thus creating shear forces in the culture 
environment. 
Cherry and Papoutsakis (1986) investigated the hydrodynamics effects on cells bounded on 
microcarriers in a stirred reactor, they noted that the possible mechanisms of cell damage 
appeared to result from collision of microcarriers with another microcarriers or the reactor 
walls (Cherry and Papoutsakis 1986). They suggested that a level beyond the threshold of 3- 
10 dyneS/CM2 would be enough to cause cell damage. Cherry and Papoutsakis further 
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suggested the importance of this consideration in the design and operation of bioreactors. 
Among the convectional bioreactors, it was demonstrated that the Rotating Wall Vessel 
(RWV) design is able to provide low shear stress environment for cellular growth while 
supplying sufficient nutrient and oxygen. Goodwin et al. (1993) demonstrated that increasing 
the calculated shear stress from 0.51 to 0.92 dynes/cm 2 in the RWV decreased the 
proliferation and aggregation of cells on microcarriers. They suggested that under low shear 
environment cells focused on the structural and functional growth rather than constantly 
repairing damaging cells in the high shear condition. 
2.5.2.2. Surface Area 
Bone marrow tissue is an extremely prolific tissue; insufficient surface area or space will 
restrict cell growth (Oh et al. 1994), therefore, estimating the proliferative capacity of human 
bone marrow is an important step before designing a culture system. 
In 2-D culture systems, inadequate space causes the cells to saturate with some cell densities 
showing 5-10 cell layers of thickness, so that cells in the bottom layers are far from the 
nutrient and oxygen source. To overcome this limitation, Oh and others (1994) suggested 
periodically to harvest half of the cell population, thereby increasing surface area for cell 
expansion. Increased surface area can effectively reduce cell surface densities, therefore 
improving oxygen and nutrients transfer to the expanding cells. Their study showed that 
frequent harvesting allowed longer growth periods and greater cell expansion than the 
previous single batch expansion protocol (Oh et al. 1994). Another parameter that needs to be 
considered along with periodic harvesting is the time of harvest because different types of 
progenitors show expansion maxima time points. CFU-GM progenitor cell density increases 
with time and reaches a maximum at day 10, while BFU-E reaches a maximum expansion 
point on day 7 (Palsson et al. 1993). 
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Monolayer 2-D growth limits the opportunity for studying high cell density growth in the 3-D 
environment (Glowacki et al. 1998). Many studies have now emphasized the significance of 
the use of 3-D polymeric scaffolds for the growth of HSCs both in static and dynamic culture 
(Bagley et al. 1999; Holy et al. 2000; Tomimori et al. 2000; Banu et al. 2001; Li et al. 2001; 
Tun et al. 2002; Ehring et al. 2003). 
2.5.2.3. Feeding Schedule and Medium Exchange 
Medium exchange rate is a key variable in ex vivo human bone marrow cultivation. Effective 
mass transport can avoid depletion of nutrients and accumulation of metabolites. Martiat et 
al. (1987) found that in vivo perfasion rate in the bone marrow is approximately 10 ml 
blood/100 CM3 marrow/minute (Martiat et al. 1987). To capture such features, the culture 
medium is generally replaced on a daily basis when using the Dexter culture inoculum 
density. However, traditional Dexter cultures require the manual exchange of culture medium 
once or twice a week (Dexter et al. 1977). This medium exchange rate is inadequate, which 
results in maintenance of human haernatopoietic cells that rarely exceeds 12 weeks. 
The Dexter protocol does not provide an optimal environment for maintaining 
haematopoietic cells. However, modifications can be made to the process to enhance cell 
differentiation by increasing the medium exchange rate (Schwartz et al. 1991b). This is 
achieved by developing an automated bioreactor based system to perform the necessary 
medium exchange for the supply of nutrients and the removal of metabolic wastes (Palsson et 
al. 1993). Studies have demonstrated that frequent feeding enhances progenitor cell 
expansion over traditional static cultures and also increases the production of growth factors 
by human stroma (Caldwell et al. 1991; Schwartz et al. 1991a; Schwartz et al. 1991b). 
Similarly, Schwartz's group also demonstrated that rapid perfusion can improve stem cell 
maintenance and proliferation (Schwartz et al. 1991b). When Dexter-type cultures were 
carried out with rapid medium exchange rates, they supported progenitor cell production for 
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at least 20 weeks, which was considerably longer than the static cultures that were previously 
reported by Hocking and Toogood's group (Hocking and Golde 1980; Toogood et al. 1980; 
Schwartz et al. 1991 b). 
2.5.2.4. Bioreactors 
Varying types of bioreactors exist for the expansion of human haematopoietic cells. These 
include: airlift (Sardonini and Wu 1993; Highf ill et al. 1996), hollow fibre (Sardonini and Wu 
1993), suspension (Sardonini and Wu 1993; Zandstra et al. 1994) and perfusion bioreactors 
(Koller et al. 1993a; Koller et al. 1993b; Palsson et al. 1993; Sardonini and Wu 1993; Koller 
et al. 1995a; Sandstrom et al. 1995; Wang et al. 1995; Sandstrom et al. 1996; Mantalaris et al. 
1998; Liu et al. 2006). However, the success rates for such applications are varied. 
Interestingly, the geometry and operating conditions of the bioreactors have been reported to 
affect the cell culture performance (Peng and Palsson 1996; Cabrita et al. 2003). A summary 
of different bioreactors used for haernatopoietic cell cultures is shown in Table 2.2. 
STIRRED/SUSPENSION CULTURE SYSTEM. BM, peripheral blood (PB) and cord blood 
mononuclear cells (CB MNCs) have been successfully propagated in stirred culture systems 
(Sardonini and Wu 1993; Zandstra et al. 1994; Pierson et al. 1996; Collins et al. 1998b; 
Jelinek et al. 2002). Sardonini et al. (1993) reported that BM MNC have the largest relative 
expansion in a suspension bioreactor as compared to hollow fibre and airlift culture systems 
(Sardonini and Wu 1993). Stirred suspension culture system has also been used by Zandstra 
et al. (1994) to support haernatopoiesis using normal human bone marrow cells. The results 
from these studies demonstrated that such systems supports continuous and significant net 
expansion of primitive normal human haematopoietic progenitor cells and stromal cell 
precursors over extended periods (Zandstra et al. 1994). Collin et al. (1998) further 
demonstrated that haernatopoietic cultures, such as peripheral blood and cord blood cells, 
grow well in spinner vessels with or without serum medium (Collins et al. 1998b). 
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Type of Bioreactor Advantages Disadvantages 
SuspensionlStirred N Homogenous environment 0 Do not permit cell-cell 
0 Easy Sampling interaction 
N Easy to scale up N Mechanical agitation induce 
shear stress 
Airlift 0 Easy to scale up N Bubble breakage cause cell 
N Homogenous environment damages 
0 Support high density growth 
N Support stromal layer 
Hollow-fibre N Continuous process N Difficulty in retrieving cells 
2 Shear-free N Difficulty in monitoring 
parameters 
0 Spatial inhomogeneous 
environment 
Perfusion 0 Continuous process a Scale up difficulties 
5 Support stromal layer 0 Difficult to monitor the 
a Clinical Application parameters 
Table 2.2: Summary of different culture systems which has been used for haernatopoietic cell 
culture. 
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One of the advantages of stirred suspension culture systems is that it can provide a 
homogenous environment Of 02 tension (Ferziger and Peric 2001), cytokine concentrations, 
serum components, medium exchange rates and other culture parameters for haernatopoietic 
cells to proliferate and differentiate. In addition, a stirred culture system is more amenable for 
sampling, data collection, control of medium conditions and scale-up (Collins et al. 1996). 
Although they offer several advantages of homogeneity (Zandstra et al. 1994), suspension 
cultures do not permit cell-cell or cell-matrix interactions which are known to be important, 
in particular for haernatopoietic activities (Highfill et al. '1996). Also, the fluid dynamics 
conditions inside the vessel are far from the in vivo environment (Highfill et al. 1996), 
mechanical agitation and fluid shear in the suspension cultures may negatively affect the cell 
growth pattern (Sardonini and Wu 1993). Haernatopoietic cells are relatively sensitive to 
shear (Collins et al. 1996). High shear rate is thought to be unsuitable for ex vivo expansion 
of stem cells and it is very likely that the cells will suffer physical damages (Nielsen 1999). 
AIRLIFT BIOREACTOR. Sardonini and others employed an airlift bioreactor for the cultivation 
of human haernatopoietic stem cells but experienced poor expansion (Sardonini and Wu 
1993). The undesirable results may be due to gas sparging that leads to bubble shear and 
breakage, which may cause cell damages. Though it failed to support human haernatopoietic 
bone marrow cultures, Highfill et al. (1996) demonstrated that this system supports the co- 
culture growth of murine bone marrow and stromal cells (Highfill et al. 1996). 
The advantage of an airlift bioreactor system is that it has low shear stress and can be scaled 
up. Further, it can provide a well-mixed environment, which eliminates many of the 
undesirable aspects of common tissue culture methods such as gradient difference, 
intermittent feeding, static fluid conditions, and limited pH and dissolved oxygen controls. 
HOLLow-FIBRE BIOREACTOR. Sardonini and co-workers compared the expansion of total and 
progenitor cell populations in different bioreactors (Sardonini and Wu 1993). The results 
from the hollow fibre reactor system showed neither growth nor expansion of haernatopoietic 
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cells; possibly due to difficulties and/or inefficiencies in retrieving cells from the 
extracapillary space (ECS) of the bioreactor. They suggested optimizing parameters such as 
fiber type, flow rates and improved methods for cell retrieval could lead to an increase in cell 
yields (Sardonini and Wu 1993). 
2-D PERFUSION BIOREACTOR. Koller et al. (1993) has demonstrated that continuous 
perfusion in the flatbed bioreactor has the ability to expand human haernatopoietic LTC-IC 
and progenitor cells from BM MNC. Their results showed that total cell number increased 10 
fold by day 14, CFU-GM number expanded 21 fold by day 14, BFU-E number expanded 12 
fold by day 8 and LTC-IC number expanded 7.5 fold. A continuously perfused system can in 
fact support the full spectrum of marrow cell development ex vivo and is able to selectively 
expand the number of stem and progenitor cells to transplantable levels (Koller et al. 1993b). 
Research by PaIsson et al. (1993) has also shown that a flatbed perfusion bioreactor system 
inoculated with human MNCs give rise to a 20- to 25-fold and a 10- to 30-fold expansion in 
human MNC and CFU-GM progenitor cells, respectively, over a two-week period (Palsson et 
al. 1993). By frequent harvesting of human bone marrow cells from the perfusion system, Oh 
et al. reported a 100-fold expansion of the total cell population and a 30-fold increase in 
CFU-GM over a 27-day period (Oh et al. 1994). Sandstrom et al. (1996) developed a 
modified perfusion reactor with a "grooved" chamber for the expansion of PB MNCs. The 
system can retain cells while allowing for rapid medium exchange. Their results also showed 
that the perfusion system enhanced CFU-GM expansion and LTC-IC maintenance with the 
addition of IL-3, IL-6, G-CSF and stem cell factor (SCF) (Sandstrom et al. 1996). 
A flow perfusion bioreactor can maintain a uniform distribution of cells on the scaffolds and 
provide adequate levels of oxygen, nutrients and growth factors (Bancroft et al. 2002; Gomes 
et al. 2003). Perfusion bioreactor systems such as flat bed and groove design are able to 
support the stromal layer. However, each perfusion chamber can only sustain limited cell 
densities and scale up is difficult (Nielsen 1999). 
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3-D PERFUSION CULTURE SYSTEM As highlighted previously, an important feature of the 
bone marrow's haernatopoietic inductive environment is its 3-D organisation, which is 
required in controlling in vivo haernatopoietic process. Consequently, the utilisation of 
support matrices that support cells a 3-D growth environment by enhancing cell-cell contact, 
promoting the spatial arrangement of cells, and supporting a high cell density due to their 
high surface area to volume ratio, has been explored (Rosenzweig et a]. 1997; Bagley et al. 
1999; Agrawal and Ray 2001; Banu et al. 2001; Li et al. 2001; Tun et al. 2002). 
To mimic this 3-D cell growth configuration, a 3-D packed bed bioreactor was developed for 
culturing human bone marrow cells on porous microspheres (Wang et al. 1995; Glowacki et 
al. 1998; Mantalaris et al. 1998; Jelinek et al. 2002). The culture system is continuously 
perfused with medium to avoid cycling of the cell growth pattern caused by weekly medium 
exchange (Toksoz et al. 1980). It has also been shown that this type of culture system is able 
to support the differentiation of different lineages in vitro for several weeks (Wang et al. 
1995; Mantalaris et al. 1998). Further, perfusion of medium through 3-D collagen sponges 
enhances viability and functionality of both marrow stromal and haernatopoietic cells. This 
perfused system also supports stromal layer and enhances matrix production and cellular 
migration (Glowacki et al. 1998; Mantalaris et al. 1998; Jelinek et al. 2002). 
Recently, rotating wall vessel (RWV) was used to culture cord blood cells (Figure 2.4). The 
design of this bioreactor overcomes the major limitations of other types of bioreactors: high 
shear stress, inhomogeneous environment, and bubble formation/breakage. RWV is able to 
provide laminar flow, low shear stress and efficient mass transport environment to support 
cell growth (Begley and Kleis 2000; Begley and Kleis 2002). Liu et al. (2006) demonstrated 
that with supply of low dose cytokines and frequent harvest, total expansion increased more 
than 400 times in this type of bioreactor within 10 days (Liu et al. 2006). 
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Figure 2.4: Rotating-Wall Perfused Vessel Bioreactor System (Synthecon, Inc). 
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2.6 Scaffold Material and Architecture 
The utilisation of support matrices that support cells a 3-D growth environment by enhancing 
cell-cell contact, promoting the spatial arrangement of cells, and supporting a high cell 
density due to their high surface area to volume ratio, has been explored (Rosenzweig et al. 
1997; Bagley et al. 1999; Agrawal and Ray 2001; Banu et al. 2001; Li et al. 2001; Tun et al. 
2002). Scaffolds such as CellfoamTm (Banu et al. 2001), tantalum coated porous biomaterial 
(TCPB) (Rosenzweig et al. 1997; Bagley et al. 1999), porous cellulose microspheres 
(Mantalaris et al. 1998), macroporous collagen carriers (Jelinek et al. 2002) and non-woven 
polyethylene terephthalate (PET) matrix (Li et al. 2001) have been used to facilitate a 3-D 
environment that resembles the BM microstructure and promotes expansion of 
haernatopoietic cells, albeit under static conditions. 
3-D scaffold architecture can enhance cell proliferation (Li et al. 2001; Tun et al. 2002) 
because of the highly porous structure which can provide large surface areas to support high- 
density culture growth (Tun et al. 2002). It can also affect the homogeneity of formed tissue 
(Gomes et al. 2003) because the scaffold's interconnecting pores can facilitate the 
rearrangement of dispersed cells (Tun et al. 2002). Tomimori et al. (2000) have observed that 
stromal. cells have different morphology on different porous carriers, affecting their 
haernatopoiesis-supporting activity (Tomimori et al. 2000). 
Therefore, scaffold should possess adequate porosity, interconnectivity, pore size and 
permeability to allow the ingress of cells, growth, and mass transfer (Bagley et al. 1999; 
Agrawal and Ray 2001; Tun et al. 2002). An appropriate surface chemistry is also important 
for cell attachment and proliferation similar to the 3-D haernatopoietic microenvironment 
(Tomimori et al. 2000). A summary of different scaffold used for haernatopoietic cell cultures 
is shown in Table 2.3. 
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Scaffold material 
__7 Porosity/Pore Size References 
Natural material 
Porous cellulose microspheres 95%, 300ýLrn (Mantalaris et al. 1998) 
Macroporous collagen carriers 85%, 100-200ýtrn (Jelinek et al. 2002) 
Synthetic material 
Porous biomatrix - CellfoamTm 90%, Not reported (Banu et al. 2001) 
Tantalum coated porous biornaterial 
(TCPB) 
90%, Not reported 
(Rosenzweig et al. 1997; Bagley 
et al. 1999) 




(Li et al. 2001) 
I 
Table 2.3: Summary of 3-D scaffold used for the growth and expansion of haernatopoietic 
cells 
2.7 Summary 
The development of a stable ex vivo system for the growth of haematopoietic cells would be 
valuable for the study of the mechanisms controlling haernatopoiesis in BM. The successful 
operation of the system lies between the optimisation of bioreactor design and operational 
parameters. Among the various culture systems, the Rotating Wall Perfused Bioreactor 
(RWPB-Synthecon, Inc) is able to provide a low shear stress and high mass transfer culture 
environment to the cellular components with promising results. However, the complex 
kinetics and transient nature of the cells and intricate interactions between culture parameters 
make it difficult to define the optimum factors and culture conditions to enhance production 
of haernatopoietic cells. An optimisation methodology using experimental techniques would 
be impractical due to cost issues. Thus, a modelling approach is utilized to obtain detailed 
knowledge of the momentum and mass transport characteristics of the bioreactor and to assist 
in designing culture vessel and optimising experiment condition (Williams et al. 2002). 
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Chapter 3 
Simulations and Mathematical 
Models 
In this chapter, computational fluid dynamics modelling strategies and techniques for the 
implementation of the various mathematical models (Chapters 4,5 and 6) developed for this 
work are detailed. In addition, fundamental aspects of porous media, mass transport and 
reaction kinetics (for both normal and CML BM) are emphasised. Furthermore, 
computational models developed by several groups are reviewed and their applicability to 
bone marrow tissue is discussed. 
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3.1 Simulation Environment 
A true understanding of haernatopoietic cultures necessitates amalgamating in vivo 
characteristics of the bone marrow and contributory transport phenomena. The BM 
characteristics were detailed in earlier sections; in the present section, fundamental 
description of Computational Fluid Dynamics (CFD) is offered. As the focus of the present 
work is on determining and highlighting key parameters for ex vivo haernatopoiesis, the use 
of 'ready made' CFD packages is deemed 'fit for purpose'. A plethora of 'ready made' 
packages are available, CFX, Fluent, Numeca, Phoenics, Star-CD to name but a few. The 
basis of CFD is the Navier-Stokes equation, and the main consideration is treatment of 
continuous fluid in a discretised fashion computationally. The CFD solution procedures 
described in the sections below focus on the discretisation method utilises by the CFD 
software used, CFX 4.4 (AnsysID). 
3.2 Discretisation Method 
Discretisation is a class of numerical methods of approximating differential equations using a 
system of algebraic equations set at different discrete locations in space and time. These 
discrete equations give information at each spatial point in the domain, termed a grid. There 
are different techniques for discretisation, including finite difference (FD), finite volume 
(FV) and finite element (FE) methods. The main differences between these approaches lie in 
the way the flow variables are approximated; the method of approximation varies with the 
problem type. Of the methods highlighted, only the finite volume method will be discussed as 
the CFX 4.4 (Ansys&) code has adopted this method. 
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3.2.1 Finite Volume Method 
The finite volume method uses the integral form of the conservation equations as the starting 
point: 
6 fpodV + fpov-ndS = 




where t is the time, p is the density, 0 is any conserved intensive property (for mass 
conservation, 0=1; for momentum conservation, 0=v; for conservation of a scalar, 0 
represents the conserved property per unit mass) ,V is the control volume (CV), S is the 
surface enclosing CV, n is the unit vector normal to S, v is the velocity, r is the diffusivity 
of the quantity 0, and k0 is the sink/source of 0. 
The solution domain is subdivided into a finite number of small control volumes (or cells) by 
a grid (or mesh). The usual approach is to define CVs by a suitable grid and assign the 
computational node to the CV centre (Figure 3.1). 
The integral conservation equation applies to each CV, as well as to the solution domain as a 
whole. The global conservation equation is obtained on 
ýumming the equations for all CVs, 
the surface integrals over inner CV faces balance each other. Typical 2-D Cartesian control 
volumes are shown in Figure 3.1 together with the notation. The CV surface consists of four 
(in 2-D) or six (in 3-D) plane faces, denoted by lower-case letters corresponding to their 
direction (For a 2-D system this equates to East (e), West (w), North (n), South (s)) with 
respect to the central node (P) (Figure 3.1). 
The net flux through the CV boundary is the sum of integrals over the four (in 2-D) or six (in 
3-D) CV faces: 
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f fdS Yf fdS 
sks, 
(3.2) 
where f is the component of the convective or diffusive flux vector in the direction normal 
to the CV face. To calculate the surface integral, one would need to know the integrand f 
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Figure 3.1: Control volume for the two dimensional situation 
points are known. Therefore, this integral is approximated as a product of the integrand at the 
cell-face centre and the cell-face area using the midpoint rule: 
ffdS 




f represents the product of several variables and or variable gradients at those locations: 
fc = pov-n for the convective flux and fd =Fgrado-n for the diffusive flux. This 
approximation to the integral requires that the value of f at location 'e' is known. The value 
of f, is obtained by interpolation. For volume integrals, the equation becomes the product of 




-qAV; tý qpAV (3.4) 
v 
where q. stands for the value of q at the CV centre. 
The approximations to the integrals require the values of variables at locations other than 
computational nodes (CV centres). To calculate the convective or diffusive fluxes, the value 
of 0 and its gradient normal to the cell face at one more locations on the CV surface are 
needed. Volume integrals of the source terms may also require these values. 
Upwind Interpolation Scheme (UDS) and linear interpolation or central-difference 
approximation (CDS) are the commonly used schemes for discretising the convection- 
diffusion equations. Other discretising methods have been proposed and can be found in the 
book by Ferziger and Peric 2001. UDS is a first-order scheme, approximating 4 by its value 
at the node upstream of 'e' is equivalent to using a backward or forward difference 
approximation for the first derivative. 
loj, if (v-n), > 0; 1 
0, E if (v-n) < 0. 
(3.5) 
Another straightforward approximation for the value at CV-face centre is linear interpolation 
between the two nearest nodes. At location 'e' on a Cartesian grid, 
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Oe = OEAe + OP (1 - /le) (3.6) 
Xe -Xp 





Examples of approximating the volume integrals of convective, diffusive and source term of 
Equation 3.1 are presented below, only the details of discretisation for the 'e' face of a 2-D 
CV are considered (see Fig 3.1). 
APPROXIMATION OF DIFFUSIVE FLUXES: Midpoint rule and linear interpolation (CDS) 
approximation is applied to the integrated diffusive flux integral: 
d= 
0 rAy 
f. fFgradoondS; e(FL! ), Ay=-(0. -0. ) (3.7) ox XE -xp 
where XE =I (X,., + xi) and xp =I (X, + XI-1) 22 
APPROXIMATION OF CONVECTIVE FLUXES: Convective flux is can be evaluated using 
midpoint rule and either upwind interpolation (UDS) or linear interpolation (CDS): 
c e= 
f pov 9 ndS,, z: ý Aý, Oe (3.8) 
S, 
where M, is the mass flux through the 'e' face AY, = 




fmax(AY,, 0. )Op + min(14,, 0. )OE for UDS; j 
(3.9) ife (I - A,, ) op + 
ife A,, OE for CDS. i 
APPROXIMATION OF SOURCE TERMS: For a given control volume V, source term is 
represented by means of a linear form k, = Su + Spo . Approximation of the volume integral 





(Su + Spop)AV (3.10) 
v 
where Su is the constant part of the source term, Sp is the proportional part of source tenn 
and it denotes the coefficient of Op. 
3.2.2 Numerical Grid 
Depending on the coordinate systems and the basis vectors used, the conservation equations 
can be written in Cartesian, cylindrical, spherical, curvilinear orthogonal or non-orthogonal - 
coordinate systems. 
As mentioned above, calculations for a set of algebraic equations can be made over a 
collection of discrete grid points. The arrangement of the discrete points throughout the flow 
field is termed the 'grid' through the process of mesh or grid generation. Two of the most 
commonly used meshes/grids in FV calculation are structured mesh/grid and unstructured 
mesh/grid. 
A structured regular grid is relatively a more simplified grid structure, and it has consistent 
geometrical regularity. Such grid types are generally restricted to amenable geometries with 
the limited control over the grid distribution. A multi-block grid is a collection of structured 
grids that together fill the domain. In these grids, there are two or more levels of subdivisions 
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of the solution domain. On the coarse level, there are blocks which are relatively large 
segments of the domains, on the finer level (within each block), a structure grid is defined. It 
is easier to grid a complex geometry with a multi-block than a structured grid and allows 
finer grids in the regions which required greater resolutions. Unstructured grid is another 
meshing method where grid points are placed in the flow field in an irregular fashion. 
Unstructured methods are very flexible and can be used in complex geometries. Most often, 
the 2-D grids are made of triangles or quadrilaterals, while 3-D grids are tetrahedral and 
hexahedra. Due to its irregular nature, node point location and neighbours connection need to 
be defined explicitly, however, unstructured meshing requires longer solution time. 
3.2.3 Finite Approximations 
Several methods for discretising a generic conservation equation (for a diffusion and 
convection problem) in FV scheme are available, such as central differencing, upwind 
differencing, hybrid differencing, and quadratic upwind interpolation (QUICK). For the 
Navier-Stokes equations (for momentum and continuity equations, the pressure-velocity 
coupling), Semi-Implicit Method for Pressure-Linked Equation (SIMPLE) and SIMPLE 
Revised (SIMPLER) are the commonly used schemes. Details of the specific schemes given 
above are covered in depth in books by (Patankar 1980; Versteeg and Malalasekera 1995)) 
and Ferziger and Peric (2001). 
3.2.4 Solution Method 
Discretisation yields a large system of non-linear algebraic equations. The method of solution 
depends on the problem. For steady flow problems, pseudo-time marching or an equivalent 
iteration scheme are usually employed. These methods use successive linearization of the 
equations and the resulting linear systems are solved by iterative techniques. In general, the 
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solution involves two levels of iterations: an inner level, where the linear equations are 
solved, and an outer level that deals with the non-linear equations. 
Due to the nature of the iterative procedure, exact solutions to CFD problem are not known, 
and consequently a 'convergence' criterion is normally supplied. Convergence can be the 
proximity of the final numerical outcome to a known solution, however, in CFD software the 
convergence is generally set by specifying a 'minimum residual tolerance' (like mass 
residual) expected or by just fixing the maximum number of iterations or both. The iteration 
scheme stops when the specified conditions have been met. 
3.3 Modelling Environment 
CFX 4 (Ansys@), formerly known as Flow3D, was commercialised in the late eighties based 
on an 'in-house' code developed by the Atomic Energy Authority (AEA). The code is a 
multi-block structured solver based on the staggered SIMPLE technique. Although this 
version of this code is no longer available to developers, the code does permit the end-user to 
modify the equations solved. 
There are several physical models available within the CFX 4 environment, including 
multiphase, heat transfer, moving mesh, etc. The model properties within CFX 4 used in this 
work are outlined below, and these are consistent with the physical model detailed in 
Chapters 4 and 6. 
3.3.1 CFX 4 Model Properties 
LAMINAR FLOW: Biological cellular components are very sensitive to the surrounding 
environment and, therefore, it is important to maintain laminar flow within the scaffold to 
avoid damage to the cells. To provide a criterion to distinguish between laminar and turbulent 
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flow, the Reynolds number (Re), a dimensionless number, is used to quantify the flow 





where v is the fluid velocity, u the viscosity of the fluid, dp is the pore diameter and p is 
the fluid density. Flow within the scaffold that has a value of Re<10 is consider larninar (Bear 
1972). 
ISOTHERMAL AND INCOMPRESSIBLE FLOW: The circulating medium within the bioreactor is 
normally assumed to have the properties of water; an incompressible Newtonian fluid. 
Additionally, the standard experimental condition for culturing HSCs is maintenance at 37*C, 
thus isothermal properties are invoked. 
SCALAR TRANSPORT MODELS: These are used to describe nutrient transport as well as multi- 
cellular growth. To simulate such features, CFX 4 allows the use of scalar transport equations 
to represent the specific entity under consideration. In addition, source terms are incorporated 
into the scalar equations that describe the nutrient consumption and growth kinetics. 
POROUS MODEL: As mentioned in Chapter 2, scaffolds are used to mimic the 3-13 
architecture of the bone marrow. To model the fluid flow through the scaffold, the porous 
property utilises a Navier-Stokes equation and Darcy's law. Specific simplifying assumptions 
have been adopted with respect to the volume porosity; it is assumed to be isotropic and 
homogenous. Furthermore, an additional body force term can be implemented to represent 
the resistance to flow in the porous media as a function of the scaffold pore size and porosity. 
TRANSIENT FLOW: To simulate the time dependent cellular growth within the vessel, transient 
conditions are employed. 
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CONVERGENCE CRITERIA: By testing the effect of converging to different levels of residual 
on the parameters of interest, a criterion of 10-" for mass source tolerance is assumed to be 
sufficient to determine solution convergence. 
3.3.2 Geometries and Meshes Generation 
The 3-D geometries and the dimensions of the bioreactor were defined and the physical 
domains were discretised using the ANSYS ICEM CFD and AI*Environment Version 5.0 
(Ansys@). All model geometries used within the work were created with body-fitted 





Outlet mass flow 
boundaries 
(OUTLET1,2,3,4) 
Figure 3.1: Typical grid and boundary conditions of the domain of interest. 
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3.3.3 Boundary Conditions 
INLET (DIRICHLET BOUNDARY CONDITIONS): All variables such as velocities and scalars are 
specified values at this boundary condition. 
OUTLET (NEUMANN BOUNDARY CONDITIONS): The mass flow boundaries correspond to the 
exit which has been placed sufficiently far from the entrance. All variables, such as velocities 
and scalars, are extrapolated from upstream. 
WALL: No-slip boundary condition is assumed at all solid walls. A common boundary 
conditions applied in fluid flow, and it applies to the velocity components. For scalars 
variables, no flux boundary condition is applied. 
INITIALISATION: Good convergence to a problem can be achieved if the starting point or 
'initial guess', is considered to be suitable. In the present work, experimental knowledge is to 
be used to estimate a reasonable initial guess for all problems that are considered. For 
example, initial nutrient concentration and cellular loading are known at the start of the 
culture, thus such values will used with the simulation set-up. In cases where non-simplified 
initial guesses are required, CFX 4 allows the use of external subroutines (e. g. USRINT) to 
implement the necessary function(s). 
PERIODIC: An important feature of the work presented in this thesis is the use of re- 
circulating media in perfused bioreactors. To represent such features, periodic boundary 
conditions are utilised. This essentially allows for all variables and coefficients from both 
ends of the computational or physical domain to assume the same value. The implementation 
of this boundary condition in CFX 4 requires two steps. These steps have been validated by 
others (Valluri 2003). A similar strategy has also been adopted in this work (See Figure 3.2). 
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Step 1 





Modify geometry to 
replace the Inlet/Outlet 
BCs with PBCs 
I 
Step 3 
Use output files (*. dmp) 
from Step 1 as the initial 
guess for Step 4 
1 
Step 4 
Simulate using the 
modified geometry with 
Step 1 *. dmp 
I 
Step 5 
Output file with PBCs 
Figure 3.2: Periodic Boundary Conditions (PBCs) implementation procedure in CFX 4 (AEA 
Technology plc 1999; Valluri 2003). 
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3.3.4 Solution Quality 
MODELLING ERRORs. All simulations involve simplifying assumptions with regards to the 
domain of interest, geometry, fluid properties and boundary conditions. Consequently errors 
can be introduced at each step in the process and eventually impact on the overall solution. 
However, careful analysis of all of these variables, such as suitable boundary conditions and 
reasonable representation of the cellular growth kinetics, can minimize introduction of 
avoidable errors. 
DISCRETISATION ERRORS. Discretisation allows approximations of the governing equations 
(such as approximation of volume and time integrals) using an algebraic system of equations. 
Reducing the size of the discrete element (grids) can increase the accuracy, but at the same 
time, this increases the computational time and storage. Grid dependency on the solution of 
the flow field is a common procedure to investigate the influence of the grid quality on the 
numerical solution. 
PROGRAMMING AND USER ERRORS. To ensure user errors are eliminated and any software 
"bugs" identified, numerical validation via analytical method is often employed. As an initial 
form of validation, the numerical output is compared with a known analytical solution of 
fluid flow in an annular cylinder (see Appendix BI for details). Additionally, the solution 
from the CFX 4 numerical scheme has been cross checked with an alternative popular 
commercial software-gPROMS (by Process Systems Enterprise); see Appendix B4. 
However, a more thorough form of validation arises from experimental comparison with the 
$real' numerical simulation. Such forms of validation are presented in Chapters 5. 
60 
3.4 Mathematical Models 
3.4.1 Fluid Flow Model 
The governing equations of the fluid motion comprise equations for conservation of mass and 
momentum. The continuity equation is given by: 
ap 
+Vo(pv) =0 (3.12) at 
and the momentum equation is as follows: 
a 
pv +v0 (pv (9 v- pvv) =B- VP'+ V0 
(JU(VV)T) 
at 






Here p is the fluid density, v is the fluid velocity, P is the pressure, T is the transpose 
notation and t is the time. Further, B is body force (such as buoyancy, rotational and 
resistance forces), u is the molecular viscosity and q is the bulk viscosity. If the flow is 
incompressible, the modified pressure, IP', is equal to the pressure. Additionally, the 
molecular viscosity p is constant, hence the contribution from the stress divergence to the 
right hand side vanishes. Assuming incompressible flow and constant viscosity for a 





which also known as the Navier-Stokes equation. 
3.4.2 Porous Model 
Scaffolds have been used to support the growth of haematopoietic cells cultures. Scaffolds 
are solid materials containing either connected or non-connected voids inter-dispersed in 
regular or random manner. Due to the random character of the porous material, the velocity 
of a fluid changes rapidly from point to point along the tortuous path. The model describing 
the flow in the porous regions in CFX 4 is the Navier-Stokes equation and Darcy's law (AEA 
Technology plc 1999): 
a 
(rpv) +V* (p(K 41 v) o v) -Vo(, uK-(Vv + (Vv)r)) = -r9l 9v- yVP (3.16) Tt 
where u, is the effective viscosity, K is the area porosity tensor, v is the velocity, 91 is the 
resistance to flow in the porous medium and y is the porosity. In case of large resistance to 
flow through the porous medium, a large pressure gradient is needed to counterbalance the 
resistance, thus the convective and diffusive terms on the left hand side are negligible, and 
Equation 3.16 reduces to Darcy's Law: 
VI? (3.17) 
Darcy's Law describes the flow within a porous medium by defining the relationship of 




where q is the flow rate, K is the penneability coefficient which contains all the inforination 
about the "architecture" of the consolidated porous medium, AP is the pressure drop within T 
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sample length L and p is the viscosity of the fluid. Darcy's Law can also be extended to 




In porous flow, permeability is an important parameter because the flow patterns and the 
transport phenomena depend on the geometrical arrangement of the pores, internal surface 
area, etc. Many attempts have been made to describe the realistic phenomena inside the 
porous medium using empirical correlations between permeability and other properties, such 
as porosity, capillary pressure curve and internal surface area. One of the most widely used 
models is the Kozeny theory, which describes the relationship of permeability and porosity. 
The model assumes that the bundles of capillary tubes of equal lengths but the cross-sections 
of these tubes have varied radii distribution. Therefore, this model is sometimes treated as a 




where K is the permeability, y is the porosity, C is a numerical coefficient called the 
'Kozeny's constant' and SA is the surface area per unit bulk volume/porous medium. 
The basic Kozeny equation has been modified to suit different applications. Carman used 
Kozeny's equations and replaced 'C' with 115, which gives the best agreement with the 





where SA. is the surface area per unit volume of solid (not porous) material. 
3.4.3 Mass Transfer Model 
As mentioned previously, oxygen, glucose and growth factor concentration play important 
roles in the growth of haernatopoietic cells. Due to the multi-cellular nature of the 
haernatopoietic environment knowledge of the varying concentration of the aforementioned 
nutrients is critical, as it will assist in the true design of the ex vivo haernatopoietic cultures. 
To investigate the spatial and the temporal changes in concentration of these nutrients, the 
general form of mass transport equation is used (Bird et al. 1960): 
a -FPC+VpvC=V-DVC-k (3.22) t 
where p is the density, C is the mass concentration, D is diffusivity of the species, and k 
is the sink/source term which corresponds to the reaction rate. 
The nutrient consumption (the reaction term k) such as Monod-type can be either be zero- 
order, first-order or non-linear order kinetics. However, based on the assumption that the cell 
density is constant throughout the culture, the reaction term can be of zero-order. In the 
majority of cases such assumptions are oversimplified and the representation of the dynamic 
pattern of nutrient consumption and cellular growth is inadequate. Consequently, the reaction 
term can be represented by either the single Monod (Equation 3.23) or double Monod 
(Equation 3.24) kinetics. Monod-type kinetics has been used in computational models to 
describe the cytokine-dependency of haematopoietic cells lines (Chaudhry et al. 2004), 
oxygen consumption by cells in bone marrow (Chow et al. 2001) and oxygen distribution in 
perfusion bioreactors (Pathi et al. 2005; Coletti et al. 2006). 
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v k= "'C (3.23) 
(K,,, + C) 
where V.. is the rate constant describing the maximal cell-specific nutrient uptake, and K. 
is the Monod constant. The double Monod kinetics (DMM) is applied to multi-components 
reactions, such as couple reaction between two substrates. 





CLs)(K.,, + CS) 
where V., Ls is the rate constant for the limiting substrate in the reaction. CLs and Cs are 
the concentration of limiting substrate and secondary substrate, K,,,,.., and K. 
', 
are the Monod 
constant for limiting substrate and secondary substrate, respectively. Double Monod kinetics 
has particular applicability in nutrient transport models for tissue cultures where the 
metabolism of two (or more) metabolites are co-dependent (Howell and Atkinson 1976; 
Kirkpatrick et al. 2003). 
3.4.4 Normal BM Cells Models 
Haernatopoiesis through the development of mathematical models has been studied over the 
last three-four decades. During this period, the various mathematical models have aided 
further understanding of the underlying mechanisms for blood cell formation. Most 
importantly, these models have offered a tool to elucidate the cell renewal, proliferation, 
differentiation, maturation and maintenance of haernatopoiesis. 
The total cell production in an ex vivo BM system can be modelled as an 'unilineage kinetic' 
model (Peng et al. 1996), which allows the study of cell expansion at each subpopulation 
(compartment) as a function of self-renewal probability, specific growth rate and mature cell 
death rate over time. The model is represented by the following set of equations: 
65 
d[Cl 
(217r - ')? 7g 
ICI 1 (3.25) 
dt 
dEc 23= 2(l - i7, )i7g [Cl i7g EC2 (3.26) dt 
d[Cb] 
= 2qg ICb-I I- 77g 1Cb I where b=3,4 ..... B-1 (3.27) dt 
d[CB] 
= 217g 
ICB-1 I- 61CB 1 (3.28) 
dt 
where C is the cell density, q, is the self renewal probability, i7g is the cell specific growth 
rate, 5 is the death rate, b is the number of stages and B is the total number of stages. 
In this model, the process of blood cell formation is represented by a series of compartments 
as shown in Figure 3.3. The first compartment contains the stem cells which undergo either 
self-renewal or differentiation. The committed cells further proliferate or differentiate to 
generate mature cells; represented by the subsequent compartments. There are specific model 
assumptions that include: 1) Cell specific growth rate is obtained from in vitro experiments; 
2) Haematopoiesis is a series of discrete states of expansion; 3) The stem cell undergoes 
either self-renewal or differentiation and the rate is represented by probability; 4) The cell 
division and growth rates are constant; 5) Death rate only occurs in the final phase, random 
loss during the process is ignored. 
There are a number of limitations to the model. Firstly, it restricts the study to only a single 
lineage. Secondly, the assumptions about constant growth rate, death rate and discrete stages 
of differentiation oversimplify the process of haernatopoiesis, since each lineage has its 
distinct growth and death kinetics, as well as number of cell division stages. Thus this model 
is insufficient to capture the true kinetics of haernatopoietic cells. 
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lig I 
Figure 3.3: Modelling of haernatopoiesis. Adapted from Peng et al. (Peng et al. 1996). 
Unilineage modelling has been taken further to incorporate the complex dynamics in a single 
lineage at different stages of differentiation (Nielsen et al. 1998). The population of 
individual lineages is described as a continuous and deterministic process instead of 
compartmentalized cells in discrete states. The model assumes the members of active cells, 
quiescent and mature cells are controlled by four processes: the growth, differentiation, 
death and cell cycle. 
The active cell population: 
aleJ -a('7dcn) 
+[a + (17g 15 _ , a)_,,, (3.29) ý-t ap, 
The quiescent cell population: 
'ale,,, Ol = , a,,, _, 7q at 
I 




at "M MI 
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where e,, is the number of active cells, t is time, CID is the extent of differentiation ranging 
between 0 and 1, ? 7d is the differentiation rate, c,,, o is the number of quiescent cells, 17q is 
the quiescent to active transition rate, ; 7g is the specific growth rate, 8 is the specific death 
rate, 71' is the active to quiescent transition rate, c. is the number of mature cells and 8. 
is the specific death rate of mature cells in the terminal stage. The framework of the above 
model has been applied to investigate the effects of a negative acting growth factor (TGF- 
pl) on erythropoiesis and on the study of granulopoiesis under different culture 
environments (Nielsen et al. 1998; Hevehan et al. 2000). 
The above unilineage models focus on a single population or single lineage expansion, and as 
an improvement on these earlier models, more recent work has been proposed which 
describes the kinetics of different lineages of human haematopoietic stem cells in an ex vivo 
BM culture system (da Silva et al. 2003): 
d[Cl 
]+ xr ]_,: yI XE ] 
-k' - k; (3.32) dt 
kf aL Cl kd Co 
yd 
[cl cl 
where, CO and C, are the cell concentrations for the previous and present stages of the 
differentiation process, respectively. The rate constants kf . 
kx ky and kx represent the d0d9k 
self-expansion, generation, differentiation and death terms, respectively. o-L is the limiting 
coefficient and is dependent on nutrient and space availability: 
CAMX c 
CL all 
types ofcells (3.33) CM4X 
This kinetic model describes the kinetics of major haernatopoietic cells: haematopoietic stem 
cells (HSCs), committed stem cells (SCs), myeloid stem cells (MySCs), lymphoid stem cells 
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(LySCs), colony forming unit-granulocyte, macrophage (CFU-GM), colony forming unit- 
megakaryocyte (CFU-MEG), burst forming unit-erythroid (BFU-E) and colony forming 
unit-eosinophils (CFU-Eo). Concentration of each type of cells as a function of time depends 
on cell expansion, differentiation and death rate. All the rate constants for cell expansion, 
differentiation and death were obtained from experimental results using a primitive type of 
haematopoietic stem cell, CD34+, as a starting population. 
For example, the balance for MySCs is: 
d[MyScl 
= k: 6& EM M dt aL 
ýSCI+kdY&ISCI 
(3.34) 
C, FV-M, g[MYSC] 
dd 
+kdBFu -E[ MYSC I+ kdcFu - E*[MyScl)-kmyk[MySc] (kcFv-G" [MyScl + k' k 
The concentration of MySc as a function of time depends on its own self expansion, 
differentiation from SC, differentiation into CFU-GM, CFU-MEG, BFU-E, CFU-Eo and self- 
destruction. 
Despite the usefulness of the above model, it does not, however, explicitly account for other 
parameters, such as glucose concentration, oxygen tension, and growth factor levels. 
Furthermore, the kinetics parameters were obtained from only one single experiment, thus, 
the rate constant may not be sufficient or truthfully represent the actual kinetics. Moreover, 
this type of model is limited to the study of in vitro cell expansion only. 
3.4.5 Periodic Haematological Disease - CML Cells Model 
The advancement of mathematical models has contributed to the enhanced understanding of 
regulatory mechanisms of normal haernatopoiesis. Using such models, and with further 
modifications, it is also possible to extend the applicability to haematopoiesis under 
pathological conditions. A particular group of haematological conditions are known as 
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periodic, such as chronic myeloid leukaernia. This condition is of particular interest due to 
the unique genetic abnormality and the periodic oscillation in cell numbers. 
A number of mathematical models available in the literature have accounted for the complex 
kinetics oscillation behaviour of CML cells and elucidate the haernatopoietic process under 
CML. The main assumptions for these models typically fall into two categories: 1) oscillation 
originated from the stem cell compartment and 2) oscillation is due to the destabilisation of 
the feedback control. 
In earlier studies, models of periodic haernatological disease focused on the oscillation in a 
single lineage system. An age-structured model for erythropoiesis in autoimmune haemolytic 
anaemia has been developed (Mahaffy et al. 1998), which incorporated the effect of EPO on 
the production of erythrocytes. Following on from this work, the age-structure model for 
cyclical thrombocytopenia was developed (Santillan et al. 2000), which incorporated a 
negative feedback loop to examine the production of platelets under the effects of TPO. 
Feedback mechanisms of different lineages can contribute to the oscillation of blood cells, 
but it is also known that the destabilisation of HSC regulation mechanism can be another 
source of blood cell oscillation. A two compartment model developed by Bernard and co 
workers investigated the production and regulation of neutrophils in cyclical neutropenia 
(Bernard et al. 2003). In addition to the feedback mechanism between G-CSF and neutrophil 
numbers, the model also incorporated the Go cell cycle in the stem cell compartment; 
representing the feedback mechanism between stem cell recycling and stem cell 
proliferation/differentiation. 
A more comprehensive model has been proposed recently to study the dynamics of CML, 
taking into account the Go cell cycle of stem cells, along with leukocytes, platelets and 
erythrocytes lineages (see Figure 3.4) (Colijn and Mackey 2005). This model takes the form 
of delay differential equations based on the previous Go stem cell model, age-structured 
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model of erythropoiesis, model of leukopoiesis in cyclical neutropenia and age-structured 
model of cyclical platelet disease (Mahaffy et al. 1998; Santillan et al. 2000; Bernard et al. 
2003). Furthermore, this model incorporates implicitly the feedback mechanisms between the 
different lineages and growth factors. 
3.4.5.1. Stem Cell Compartment 
The Go stem cell model describes the proliferating and resting state of the stem cells that 
occurs in the cell cycle. Stem cells either stay in the resting phase or undergo mitosis and 
proliferate into another daughter cell. During this process, stem cells can be destroyed by 
apoptosis. The Go stem cell model is used for CML application: 
dQ 
= _ß(Q)Q - 
(KN + KR + Kp)Q + 2J8 Qr'ß(Q(t - r, »Q(t - r, ) (3.35) dt 
where Q is the CML stem cells population, t is the time, 8Q is the death rate of stem cell, 'r, 
is the time delay for stem cell proliferation, icN , icR, icp are the differentiation rates of stem 
cells into leukocytes, erythrocytes and platelets, respectively. 8(Q) is the recycle phase of 
resting CML stem cells into proliferating phase and can be represented by the Hill function 
(see Bernard et al. 2003): 





where k,, is the maximum recruitment rate from non-proliferative phase, 02 and e are the 
Hill coefficients. The coefficient is estimated based on the experimental data of re-entry rate 
of cells into the cell cycle, cytokines involved in the division signalling and the proliferation 




Figure 3.4: Haernatopoiesis model of CML cells including Go stem cells (Q), leukocytes (L), 
erythrocytes (R) and platelets (P) lineages. Stem cell is either in resting phase or entering 
(P) into proliferating phase (Qp) and differentiation into erythrocytes, leukocytes and 
platelets with the differentiation rate of R( K'R ), N( icN ) and P( icp ). A'R , AN and Ap are the 
amplification factors of R, N and P, respectively. r,, rN, -rRm, -r.. and rp, are the time 
delay for stem cells, leukocyte, reticulocyte, erythrocyte and platelet maturation, respectively. 
rps is the time delay for platelet aging due to senescence. 8. , 
8R 
, 
8. and 8p are the death 




3.4.5.2. Leukocyte Compartment 
The daughter cells from stem cells further differentiate into leukocyte, erythrocyte and 
platelet lineages. These cells continue to divide, mature and eventually die. These lineages 
differentiation and expansion processes are represented by another three components in the 
model. The process of leukocytes (N ) production is represented as: 
dN 
= -gNN+ANicN(N,,, )Q,,,, (3.37) dt 
where SN is the death rate of leukocyte, AN is the amplification factor of leukocyte, rN is 
the time delay for leukocyte maturation and KN(N) represents the feedback loop between 
the leukocyte compartment and the rate of stem cell differentiation into the leukocyte lineage. 
It is proposed that G-CSF binds to the receptor on leukocytes and the relationship between 
the activities of leukocytes is proportional to the bounded active site: 
KN (N) = fý 
0, hi 
Olý + Yý 
(3.38) 
where f. , 
0, and k are the Hill function coefficients estimated based on the differentiation 
activity of leukocytes under G-CSF administration and the proliferation rate of leukocytes. 
under steady-state (for specific details see Bernard et al. 2003). 
3.4.5.3. Erythrocyte Compartment 
A delay model replaced the age-structured model for erythropoiesis and this is written as: 
dR 
= -, 6R R+ 




where R is the number of erythrocytes, t5, is the death rate of erythrocyte, AR is the 
amplification factor of erythrocyte, KR(R) is the differentiation rate of stem cells into 
erythrocytes, rRm and r.. are the time delay for immature erythrocyte (reticulocyte) and 
erythrocyte, respectively, Q,. and Q,. are the time delay for the stem cells to mature into 
reticulocyte and erythrocyte, respectively. When stem cells differentiate into reticulocytes, 
these committed cells continue to divide and mature into erythrocytes. Ultimately, 
erythrocytes then enter into the circulation. During this process, the erythrocytes can be lost 
through senescence and random death. 





"2 - SEpOE (3.40) dt I+ KEpo R 
where aEO, k and KEO are the estimated Hill function coefficients from the data 
presented in Erslev et al. (1991), E is the concentration of EPO, R is the erythrocyte 
number and SEpO is the destruction or decaying rate of EPO (Erslev 1991; Mahaffy et al. 
1998). Assuming the number of stem cells differentiating into the erythrocyte lineage is 
proportional to the concentration of EPO under steady state condition, the differentiation rate 
of stem cells into eryffirocytes becomes: 




where W, is the Hill coefficient. The coefficient is estimated based on the steady-state values 
of erythrocyte mortality, stem cell concentration, and erythrocyte concentration (for specific 
details see Mahaffy et al. 1998). 
3.4.5.4. Platelet Compartment 
Similarly, the age-structured model for platelet production and apoptosis can be replaced by 
the differential delay equation: 
")Q" -e 
0= 
_igpp + Ap 
ýK', (p -8PrPs Kp (3.42) 
dt 
where P is the number of platelets, 5. is the death rate of platelet, Ap is the amplification 
factor of platelet, i*p, is the time delay for platelet maturation, -rps is the time delay for 
platelet aging due to senescence and icp(P) is the rate of differentiation into the platelet 
lineage. Similarly, assuming that the number of stem cells differentiating into the platelet 
lineages is proportional to the concentration of TPO under steady state, the differentiation 
rate of stem cells into platelets, icp (P) , becomes: 
Kp(p) I+KTpOP'ý (3.43) 
where KTpO and k are the estimated Hill function coefficients from the data presented in 
Kuter, D. J (1996) and WP is the Hill coefficient obtained using the same approach as W, (for 
specific details see Santillan et al. 2000) (Kuter 1996; Santillan et al. 2000). 
Combining the four cell compartments along with the six delay differential equations, given 
above, forms the basis for the study of CML dynamics. 
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3.5 Delay Differential Equation (DDE) 
Delay differential equations are a special type of functional differential equations similar to 
ordinary differential equations, but their evolution involves past values of the state variable. 
The solution of delay differential equations, therefore, requires knowledge of not only the 
current state, but also of the state a certain time previously. 
In the literature, for such problems the following approach is normally employed and 
implemented (Asachenkov et al. 1994). 
The previous DDE equations have a general form: 
Lo 
=-; VO+V. DVo+kl +k2 (3.44) at 
where 
k, = a, 
[OT I Or, OT 
= O(t) (3.45) 
k2=a2 [OT, I OTs 0 OTs = O(t -Ts ) (3.46) 
The terms a, and a2 are constants, 0 is any conserved intensive property, Do is the 
diffusivity of ý and T, is the time delay. Replace Ojs with y,, and solve the DDE equations 





Equation 3.47 is the form in which it is implemented in CFX. Essentially, the variable y, 
follows the variable 0 with a time lag of Ts. The time lag need not be a fixed constant, but a 
distribution with a mean around Ts. (Asachenkov et al. 1994). 
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Chapter 4 
Bone Marrow Culture Growth 
Model 
4.1 Introduction 
A number of mathematical models have been developed to study the fluid dynamics and 
nutrient distribution in perfusion bioreactors (Homer et al. 1998; Begley and Kleis 2000; 
Begley and Kleis 2002; Williams et al. 2002; Pathi et al. 2005; Coletti et al. 2006), as well as 
haematopoietic cell growth dynamics (Peng et al. 1996; Hevehan et al. 2000; McNiece and 
Briddell 2001; da Silva et al. 2003) (See Chapter 3 for details). These models have served to 
not only enhance our understanding of the hydrodynamic and mass transfer environments in 
various bioreactors under different operating conditions, but also to demonstrate the utility 
and potential of computational models in designing bioreactors for optimal growth of cells 
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and/or tissue-engineered constructs. However, none of these models accounted for the 
cellular growth of different lineages of HSCs in a dynamic flow bioreactor. In the present 
study, a mathematical model has been developed to study the growth characteristics of 
haematopoietic cells under various operating conditions in a low-shear perfused bioreactor, 
embedded with a porous scaffold (Figure 4.1). The model is used to obtain data on the 3-D 
flow field, shear stress patterns and nutrient distribution alongside simulated multi-cellular 
growth and cellular functions. 
4.2 Model Formulation 
The assumptions made in the present model include a laminar flow regime within the vessel, 
Newtonian and incompressible fluid properties, and an isotropic and homogenous porous 
scaffold. In addition, the scaffold is assumed to be free from blockage and deposition. The 
dimensions for the bioreactor (Rotating Wall Perfused Bioreactor-RWPB, Synthecon, USA) 
and the scaffold are given in Appendix A Table Al and the geometry of the bioreactor is 
shown in Figure 4.1 (B). All the model equations, below, are presented in their general forms 
for convenience and expandability. 
4.3 Model Equations 
4.3.1 Fluid Flow 
The continuity and Navier-Stokes equations presented in Chapter 3 are used to describe the 
flow within the RWPB (Bird et al. 1960). 
4.3.2 Porous Flow 
Fluid flow inside the scaffold is described by the general porous flow equations (AEA 
Technology plc 1999), 
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Figure 4.1: (A) 3-13 architecture of the bone marrow showing the intravascular and 
extravascular components (modified from Abbound and Licthman 2001). The intravascular 
space consists of the nutrient arteries, radial arteries, sinuses, central arteries and the central 
sinus. The extravascular component represents the haernatopoietic space. (B) 3-D scaffold 
architecture. The structure of the porous scaffold mimicking the intra and extra-vascular 
region of the BM is incorporated inside the vessel. (C) Rotating wall perfused bioreactor. A 
Couette-Taylor mixing vessel which is able to provide a low shear environment and high 
mass transfer rates required for cellular growth. 
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a (Ypv)+vo(P(K-v)ov)-V*Ka = -y9l. v-yvp at 
where, r is the porosity, K is the permeability, a is the stress tensor and 91 is the 
resistance term. The scaffold is representative of a porous medium whose resistance is given 






where, SA. is the specific surface defined by SI =, vlH,, and H,, is the hydraulic radius, 
defined as H,, 2 with r being the pore radius. The mean shear stress in the scaffold P 
region is given by Begley et al. 2000 (Begley and Kleis 2000), 
I 




where, ý. is the mean shear stress and S., Sý, S, are the shear stresses in the x, y and z- 
direction, respectively. 
4.3.3 Nutrient Transport 
The spatial distribution of nutrients, C, (we focused on oxygen and glucose) within the 
scaffold is described by the general mass transport equation (Bird et al. 1960), 
a 
pC+VpvC=V. DVC-k at 
(4.4) 
where, D is the diffusion coefficient of the substrate (oxygen and glucose) in the medium 
and k is the source term to describe the cellular consumption (k. ) or growth (k, ) kinetics. 
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Metabolic consumption by the cells, k., is described by the Double Monod Kinetic (DMM), 







+ kG CG-) 
(4.5) 
where, 
C02 and C. are the oxygen and glucose concentrations, respectively, 
k. 
2 and k. 
are the kinetic coefficients for oxygen and glucose, respectively, and K.. is the rate 
limiting constant in the expression (Kirkpatrick et al. 2003). 
4.3.4 Cellular Growth Kinetics 
The growth kinetics for the cells is analysed by dividing all cells into two groups: progenitor 
and mature cells. The progenitor cell group consists of 8 cell types: haematopoietic stem cells 
(HSCs), committed stem cells (SCs), myeloid stem cells (MySCs), lymphoid stem cells 
(LySCs), colony forming unit-granulocyte, macrophage (CFU-GM), colony forming unit- 
megakaryocyte (CFU-MEG), burst forming unit-erythroid (BFU-E) and colony forming 
unit-eosinophils (CFU-Eo). Although, this study focuses on the growth of different 
progenitor cells, a mature cell group is included in the model to provide a fuller description of 
the BM cellular hierarchy. To reduce the number of equations to be solved, only a single type 
of mature cells is considered. Specifically, the consumption term used in the mature cell 
group metabolism equations refers to granulocytes since they dominate the extravascular 
compartment (Chow et al. 2001). Cellular growth kinetics (k,, ) of both compartments is 
given by (da Silva et al. 2003), 
ký, = kýuL [CI 1+ kdx [C, 1-E kdy [CI 1- kx [C, 1 (4.6) 
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where, CO and C, are the cell concentrations for the previous and present stages of the 
differentiation process, respectively. The constants k,, k, ky, and kx represent the self- ddk 
expansion, generation, differentiation and death terms, respectively. aL is the limiting 
coefficient defined as, 
CM4X - Y- c 
all types ofcells (4.7) CAUX 
I 
where, the aL range is dependent on nutrient and space availability. 
4.4 Initial and Boundary Conditions 
No slip and no flux conditions are applied at all boundary walls. The inlet perfusion rate is at 
10 mrn/s. The operation parameters were chosen to match the experimental conditions: the 
culture medium was assumed to have aqueous properties at 37 'C and I atm; inlet oxygen 
and glucose concentrations were 20% and 5.5 mM, respectively; inoculum density ranged 
from 0.1_1 X 106 cells/ CM3 ; and the duration of the culture simulation was limited to 14 days. 
In this study, rotation of the vessel is not included. 
4.5 Computational Details and Model Parameters 
Structure and hexahedral grids were used to discretise the physical domain using ICEM CFD 
5.0 meshing software developed by ANSYS, Inc. Sensitivity analysis was performed to 
optimise the computational mesh with approximately 220,000 cell nodes being chosen as an 
acceptable compromise between accuracy and computational time. The mathematical models 
for the 3-D flow/reaction/transport problem were developed and implemented within a 
computational fluid dynamics environment (CFX4.4, ANSYSID). The biophysical parameters 
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are given in Appendix A Table A2 and the cellular growth kinetics of progenitors and mature 
cells are given in Appendix A Tables A3 and A4, respectively. 
4.6 Results and Analysis 
4.6.1 Velocity & Shear Stress Profiles 
The flow field and shear stress in a bioreactor affect nutrient distribution and cellular growth. 
Furthermore, the velocity field can be optimised to control the extent to which seeded cells 
can penetrate the scaffold core. It is pertinent, therefore, that these properties are analysed. 
Figure 4.2 shows the velocity contours within the RWPB embedded with a scaffold for 
varying scaffold porosities. In general, the fluid velocity was found to be low, which is 
consistent with the hydrodynamic conditions in the bone marrow in vivo and also justifies the 
laminar flow assumption. The average flow velocity in the scaffold is 0.1 mm/s, which is 
within the range of sinusoidal blood flow (0.0 1 -0.3 mm. /s) found in the BM (Wickramasinghe 
1975). The velocity contours show that the flow improves with increasing scaffold porosity, 
with the maximum velocity occurring in the central region of the bioreactor (or scaffold). 
Furthermore, the highest velocity was found in the lowest porosity (80%) scaffold. This is 
due to the fact that low porosity restricts the volume of space available to the fluid, which 
creates a higher pressure drop resulting in an elevated fluid velocity within the scaffold. 
A low shear environment can induce and facilitate cell-cell contact and cell aggregation as 
well as cell-matrix associations that may subsequently assist in the tissue formation process. 
Our results show that the shear stress in the RWPB was between 6.6 x 10-8 to 0.086 
dynes/crný. The minimum value corresponds to the low fluid flow near the wall of the 
bioreactor, whereas the maximum value was found at the inlets of the RWPB where the 
highest fluid velocity was observed. Figure 4.3 shows the partial shear stress contour profiles 
(1.6 to 8.0 x 10" dynes/cm2) in the RWPB for various pore sizes (250-450 gm). It can be 
noted that shear stress is relatively high near the centre of the scaffold and gradually 
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decreases towards the vessel wall. The predicted maximum shear stress within the vessel is 
lower than the threshold value (0.92 dynes/cm) that has been reported to be detrimental to 
the animal cells (Goodwin et al. 1993). The low shear stress in the bioreactor is able to 
provide a suitable environment that facilitates the formation of a 3-D microenvironment and 
supports the growth and maintenance of haernatopoietic cell cultures. 
4.6.2 Nutrient Distribution and Cellular Growth Kinetics 
The haematopoietic space in the BM is occupied by various types of blood cells that have 
different metabolic demands, such as oxygen and glucose. In order to develop more realistic 
and complex multi-cellular models, a comparison in the oxygen tension between the single 
and multi-cellular models was performed, as shown in Figure 4.4. In the single cell type 
growth model, it is assumed that the culture consists of only granulocytes, which are the most 
abundant type of cells in the BM (Chow et al. 2001). Rapid proliferation and the high nutrient 
consumption rate of granulocytes result in a low gas phase oxygen concentration throughout 
the scaffold. Furthermore, these simulations show that some regions of the scaffold 
experience less than the optimum oxygen tension (4-20%) required for BM cellular growth; 
therefore it is likely that a certain proportion of growing cells encountered hypoxic and 
anoxic conditions, which in turn influences their growth profiles (Ishikawa and Ito 1988; 
Cipolleschi et al. 1993; Palsson et al. 1993). In contrast, the multi-cellular growth model, 
which includes the 8 different cell types, confirmed that the oxygen tension levels are 
maintained above the known hypoxic conditions throughout the scaffold. These results 
demonstrate that single cell lineage development is not appropriate for the ex vivo 
reconstruction of the BM and therefore it is insufficient to represent the complex nature of 
haematopoiesis in BM. Thus, the multi-lineage growth model has been adopted in this work. 
Nutrient mass transfer to metabolically active cells is controlled by convection and diffusion; 
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Figure 4.2: Velocity contours (mm/s) in the mid-plane of the bioreactor for different scaffold 
porosities: (A) 80%, (B) 85%, (C) 90%, and (D) 95%. The operating conditions are: 80- 
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Figure 4.3: Shear stress contours (10" dynes/cM2) in the mid-plane of the bioreactor for 
different pore sizes: (A) 250pm, (B) -)50pm, and (C) 450prn. The operating conditions 
are: ;/= 90%, dl, = 250-450 pm and v= 10 mm/s. 
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Cellular growth and oxygen concentration profiles are illustrated in Figure 4.5 for different 
inoculum densities and porosities. These results highlight the expansion patterns of the 
haernatopoietic cell lineages and their oxygen demand during a 14 day culture period. It is 
shown that a reduction in the oxygen concentration is accompanied by an increase in the cell 
numbers for all inoculuin densities and porosities. While such results are expected, 
interestingly, the rate of expansion of the haernatopoietic cell lineages under the simulated 
environmental conditions is a function of both the inoculum density and porosity. Oxygen is 
regarded as the limiting substrate in cell growth process due to its low solubility in the culture 
media. In contrast, glucose has a higher solubility than that of oxygen and therefore glucose 
depletion is less likely to occur. 
Inoculurn densities of 0.1,0.2, and I (X 106 celIS/CM3) showed a 42,38 and 24 fold increase 
in total cell numbers at 95% porosity, respectively. These results are consistent with the 
experimental data available in the literature for HSC (stirred) cultures; for a 14 day culture 
period, a 40-50 fold total expansion has been achieved (Collins et al. 1998a). In the present 
case, the higher the inoculurn density the lower the rate of expansion. This can be attributed 
to the limited space available within the scaffold to accommodate the increased number of 
cells, as reported previously by other researchers (Palsson et al. 1993; Poloni et al. 1997). 
Consequently, when selecting scaffold properties, it is important to choose a suitable porosity 
factor, as this is critical to the proliferation rate for the cells. An increased porosity factor 
provides a larger surface area for cell growth and thus it is able to support higher cell density 
growth (Palsson et al. 1993; Oh et al. 1994; Poloni et al. 1997). As demonstrated in Figure 
4.5A, the 95% porosity scaffold supported a total cell number of 4.1 X 106 cellS/CM3 
compared to a total cell number of 3.5 x 106 celIS/CM3 for an 80% porosity scaffold. These 
results highlight the importance of the porosity factor in the oxygen transport process. High 
porosity scaffolds facilitate higher average oxygen concentration in the bioreactor than low 
porosity scaffolds for the same inoculurn density. Therefore, the greater the area available for 
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Figure 4.4: Average oxygen concentration for various axial positions of the scaffold. Oxygen 
consumption of single and multiple cell types were compared at day 14. The operating 
conditions are: v= 10 mm/s. C, = 20%, d, = 250 p rn, inoculum density =Ix 105 cells/cm' 
and y= 80%. (Open Circle: Single cell type, Square: Multiple cell types). 
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4.6.3 Multi-lineage Cell Distribution 
To incorporate the dynamic nature of the haernatopoietic process, a multi-lineage growth 
model for HSC cultures was formulated that provided a transient distribution of the different 
cell types, as shown in Figure 4.6. With an initial CD34+ cell concentration of 2x 105 cells/ 
cm 3, the 14 day culture simulation shows that CFU-GM and CFU-Eo dominate the primitive 
cell compartment corresponding to 3.5% and 3% (on average) of the total population, 
respectively. Furthermore, the total number of CFU-GM (1.5 X 107 cells) represents a 16-fold 
increase. These simulation results are consistent with the work of Sandstrom et al. 
(Sandstrom et al. 1995), who showed in their experimental study that CFU-GM increased 18 
folds after a 15 day culture period. Our results are significant as they indicate the minimum 
number of CFU-GM required for transplantation for an average patient. CFU-GM number is 
a customary indicator of assessing the adequacy for transplantation (McAdams et al. 1996). 
The spatial distribution of oxygen tension within the bioreactor is important for in the 
development and production of the haematopoietic cellular components. The oxygen tension 
within the bioreactor (gas phase oxygen) is presented as frequency plots in Figure 4.7. At the 
start of the culture, the oxygen tension distribution within the bioreactor is homogeneous at 
20% (v/v), which corresponds to the inlet condition (Figure 4.7A). As the culture progresses, 
the gas phase oxygen concentration in the bioreactor varies to values between 3% to 20% 
(v/v), which is consistent with the oxygen requirements by the distributed cell types. By the 
end of culture at day 14, the simulation results show a heterogeneous oxygen tension 
distribution in the vessel (as a percentage of scaffold volume), where about 53% of the 
scaffold volume is at higher than 14% (v/v) oxygen tension, 19% of the scaffold volume is 
between 7-14% (v/v) oxygen tension, and 28% of the scaffold volume is at lower than 7% 
(v/v) oxygen tension for the 90% porosity case. 
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Ishikawa and Ito have indicated that a spatial variation of oxygen tension within the 
microenvironment of the BM does indeed exist, ranging between 4-21% (v/v) (Ishikawa and 
Ito 1988), corresponding to the different oxygen tension requirements by the varying cell 
types, which is in agreement with the present study. High oxygen tension (20%) supports the 
growth of mature cells, while low oxygen tension (5%) enhances the growth of primitive 
cells and favour the differentiation of particular progenitor cells (Ishikawa and Ito 1988; 
Koller et al. 1992b; Palsson et al. 1993). From our simulations, it is evident that the 
distribution of oxygen tension obtained during the 2-week culture period should support self- 
renewal, differentiation and proliferation of all types of haematopoietic cells in a manner that 
resembles the in vivo BM. As highlighted earlier, porosity affects the oxygen tension within 
the scaffold. Our results confirm the effect of porosity on the gas phase oxygen concentration 
distribution in the vessel (Figure 4.7). By the end of the culture at day 14, the highest porosity 
(95%) scaffold maintains 26% of its volume at 20% (v/v) oxygen concentration. Whereas, for 
the lowest porosity (80%) scaffold, a larger proportion (32%) of its volume is maintained at 
an oxygen level of 20%. This is consistent with the view that higher porosity scaffolds 
support higher cellular densities and therefore higher levels of oxygen consumption for 
cellular metabolism. In contrast, lower porosities provide less space for cellular growth and 
thus a lower oxygen tension requirement. 
4.7 Summary 
Haematopoietic stem cell cultures have generated intense interest due to their potential 
applications in c6ll-based therapies (Nielsen 1999). However, achieving controllable and 
consistent production of clinically relevant numbers of haematopoietic cells requires the 
optimisation of several important bioprocess culture parameters and bioreactor specification 
factors. The work presented in this chapter aimed at developing a model that is able to 
simulate the growth of HSCs in a low-shear, perfused, 3-D bioreactor system embedded with 
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Figure 4.5: Cellular growth (solid symbol) and oxygen consumption (open symbol) for 
different inoculum densities: (A) Ix 105 celIS/CM3 (B) 2x 10' cells/ cm3, (C) IX 106 cells/ 
cm 3, and porosities (square: y= 80%, circle: r= 85%, triangle: y= 90%, inverse triangle: 
r= 95%). The operating conditions are, v= 10 mm/s, C0, = 20% (v/v), d, = 250 PM. G: 
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Figure 4.6: Cell population distribution at various time points. The operating conditions are: v 
= 10 mm/s, 20% (v/v), y= 95%, d 1, = 
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Figure 4.7: Oxygen concentration frequency for different porosities 80-95%) during tile 
culture at various culture points: (A) Day 3, (B) Day 6, (C) Day 9, (D) Day 12 and (E) Day 
14. The operating conditions are: v= 10 rnm/s, C, = 20% (v/v), d, = 250 pin, inoculum 
density of 2x 105 cells/cm'. 
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model for different cell lineages that attempts to account for the complexity of the BM 
functionality. This particular characteristic is crucial given the mass production ability of the 
BM, which has been absent from other studies involving bioreactor design for BM 
reconstruction. Although experimental validation of this work is yet to be carried out, the 
model presented here is able to demonstrate a number of key points: (1) the fluid dynamics 
environment inside porous scaffolds offers a low shear stress environment for cellular growth 
and velocity that resemble the known sinus blood velocities within the in vivo BM 
environment; (2) within the range of practical initial seeding densities, the present reactor 
design and configuration can accommodate HSC expansion that is normally required for 
clinical applications; (3) the spatial average oxygen concentration in the vessel ranges from 
4-21%, which is close to known physiological BM conditions in vivo. This result further 
substantiates the importance of local oxygen concentration experienced by the cells over the 
widely used gas-phase concentration; spatial oxygen distribution is also more informative. 
Our data highlight the close relationship between flow characteristics, inoculum. density, 
perfusion rate, pore size, porosity, and nutrient concentration, enabling their a prior! 
optimisation that could lead to a more favourable environment for cell growth and 
maintenance. Furthermore, the simulation results are substantiated by the available literature 
data. The computational model developed is sufficiently general for further model expansion 
and incorporation of an even more realistic haematopoietic process and parameters, such as 
inclusion of growth factors and metabolites. In addition, the model can also be expanded to 
study other types of cultures important for clinical investigations, such as leukaemia (Colijn 
and Mackey 2005). 
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Chapter 5 
Model Testing - Part I 
To assess the validity of the model, numerical solutions for nutrients transport and cell 
growth in the bioreactor are compared with experimental results obtained by Liu et al. 
(2006). Their work demonstrated the expansion of umbilical cord blood cells in a RWPV 
using combinations of low level cytokines and cell-dilution feeding protocol. Quantitative 
analysis of the differences between the experimental and computational results was carried 
out. 
5.1 Model Formulation and Parameter Values 
As the experimental work of Liu and others does not correspond to the work presented in 
Chapter 4 directly, some minor modifications were implemented in the model to capture the 
experimental work for the expansion of haematopoietic stem cells in a perfusion vessel using 
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a cell-dilution feeding protocol (Liu et al. 2006). Due to the high prolific rate of HSC, Liu et 
al. (2006) utilised the cell-dilution feeding protocol in order to provide sufficient space for 
cell expansion, avoid depletion of nutrients and accumulation of metabolites in the culture. 
Cells are diluted on day 3,5, and 7 to maintain the cell density below 1.5XI06 cells/ml by 
partial removal of excess cell suspension and replenish the vessel with fresh medium. To 
simulate this feeding schedule, the simulation is re-started on day 3,5, and 7 with an initial 
cell density at 2xlO' cells/ml. Furthermore, in contrast to the previous case, where a scaffold 
was utilised in the bioreactor, the work of Liu and others dealt with suspension cultures, thus, 
porous flow parameters are redundant and set the porosity to 1.0. 
Other biophysical parameters and growth kinetic parameters are as in the case of Chapter 4, 
see Appendix A, Table A2-4. All experimental results reported in the following section are 
shown as the mean ± standard deviation. The coefficient of determination, R2, was used to 
assess the variability between the model and experimental values of total cells and G-CSF. 
5.2 Results and Discussign 
5.2.1 Total Cell Number 
Figure MA compares the total cell density for 8 days with an inoculum, density of 
2xlO5cells/ml. The results showed that the predicted total cell density is within the range of 
all experimental values, at first glance, it does appear that the experimental and numerical 
results agree well. 
In the work of Liu et al. (2006), the cells removed from the experimentation are assumed to 
have the same expansion capability as the cells in the vessels, and therefore, the total 
expansion also accounts for these cells. For a suitable comparison of cell expansion pattern, 
the results obtained from this work capture such features and are presented in Figure 5.1 B. It 
can be seen that the simulation results are very close to experimental results until day 7, after 
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Figure 5.1: Comparison of (A) total cell density and (B) cumulative total cell expansion 
between published experimental results (0) and numerical predictions (m). 
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which the difference become larger. This is mainly due to the value obtained from simulation 
on day 3 is considerably lower than the mean experimental values (Figure SAA), thus when 
calculating the cumulative expansion of cells, this effect become noticeable after day 7. 
However, in general, the simulation results do capture the trend of the cell expansion 
obtained from the experimentation. 
5.2.2 CFU-GM expansions 
As mentioned previously, the number of CFU-GM is an important indicator for assessing the 
BMT possibilities. Figure 5.2 compares the simulations and experimental results (Liu et al. 
2006) of the CFU-GM expansion. The simulations results predict that there is a9 fold 
increase in CFU-GM, whereas the results of Liu and others (Liu et al. 2006) report a 23 fold 
increases. As the work within Chapter 4 does not take into account specific cytokines for the 
growth of the CFU-GM, it is possible that this is the reason for the large difference in the 
growth between the experimental and the simulation results. It is well understood that G-CSF 
and GM-CSF stimulate the production of CFU-GM, additions of these cytokines in ex vivo 
environment has been shown to increase the CFU-GM output by 2-3 folds in 10 days (Koller 
et al. 1995b; Poloni et al. 1997). The cellular growth kinetics parameters used within the 
simulation work were obtained from the work of da Silva et al. (2003), where neither G-CSF 
or GM-CSF were utilised, thus the differences between the simulation work and the 
experimental work of Liu et al (2006) are considered reasonable. 
The sum of square errors between the experimental data and model predictions can be shown 
to be less than 10%; signifying a good level of predictability from the model. However, 
further improvements to the model are clearly necessary in order to capture the effects of 













Figure 5.2: Comparison of CFU-GM expansion between published results (Liu et al. (2006)) 
and numerical predictions (Present Work). 
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Model Testing - Part 11 
In the earlier part of this chapter, normal haernatopoietic cell growth model has been tested 
against the experiment data from Liu et al. (2006). To further assess the validity of the BM 
model, specific experiments were carried out using a human myeloid leukaemia cell line to 
obtain growth and metabolism data. The purpose of this section is to compare data generated 
from the model to the experimental data. 
5.3 Material and Method 
5.3.1 Cell Line Culture 
K562 human leukaemia cells (ATCC) were gown _and 
maintained in Iscove's modified 
Dulbecco's medium (IMDM, Invitrogen) in the presence of 10% fetal bovine serum (FBS, 
Invitrogen) at 37*C in a humidified atmosphere with 5% C02 in air, supplemented with 50 
units/ml penicillin, and 50 mg/ml streptomycin (1% Pen/Strep, Invitrogen). Inoculurn density 
of the cell cultures were IX104 cell/ml in a T-75 flask. Due to the high proliferative nature of 
the cell, a cell-dilution protocol was adopted to reduce the cell concentration. At day 2,4,6 
and 8, half of the medium (including cells) were removed and discarded and replaced with 
the same volume of fresh media. 
Cell growth was studied by determining the cell number/ml at different days of in vitro cell 
culture. Cell number was counted every other day. The viable and non-viable cells in the 
culture were distinguished with the use of trypan blue dye (Sigma) and a bright-line 
haernocytometer (Assistant, Germany). 
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5.3.2 Glucose Consumption 
The glucose concentration in the culture medium was measured every other day by using a 
BioProfile 400 (Nova Biomedical, U. S. A. ). Medium was removed from the culture and 
centrifuged at 120g for 7 minutes at 25*C. 1.5ml of sample in supernatant was collected for 
analysis. 
5.3.3 Statistical Analysis 
All experimental data are reported as means ± standard deviation (SD). Statistical analysis for 
comparing the variability of total cells and glucose level between the computational and 
experimental results are performed using the coefficient of determination, R2. 
5.3.4 Mathematical Model and Equations Development 
The underlying mathematical model presented in Chapter 4 has been adapted used to 
simulate the expansion of K562, a human myeloid leukaemia cell line, in the bioreactor. 
Generally speaking, the use of primary cells is a standard practice for accessing cell 
properties in vitro, however, primary cells activities vary greatly, thus it is not realistic to use 
primary cell to validate the existing model. Furthermore, no human haernatopoietic cells have 
been successfully derived into a cell line, for this reason, we have employed K562, a cell line 
derived from the human leukaemic haematopoietic cells for the experiment. 
Cellular growth kinetics equations are given in section 4.3.3 (Equations 4.6); these are in 
general form and can be used to study either multi-cellular growth or single cell type growth. 
To model this cell dilution protocol, the simulation is re-started on day 2,4,6, and 8 with half 
of the cell population and medium (from the previous simulation). The various parameters 
and constants within the model are similar to the values given for Section 5.1 (See Appendix 
A Table A24), with suitable adjustments made where necessary (see Appendix A Table A7). 
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5.4 Results and Discussions 
Comparisons between simulation and experimental results for K562 cells are presented in 
Figures 5.3 and 5.4 In Figure 5.3A, there are observable differences between the model and 
the experimental data, however, statistical analysis (based on R-squares) shows that the sum 
of square error was less than 3% between the two sets of data. Although, overall the model is 
able to predict the experimental with a good level of accuracy, the relatively large difference 
between the two types of data during the initial culture periods can be attributed to the model 
not being able to capture and account for the ability of the K562 cells to 'handle' shocks in 
the system where there is a sudden change in environmental conditions. Therefore, while the 
cells within the experimental set-up are adjusting and acclimatising accordingly to the 'new' 
conditions, the model is not yet designed for such features. However, with the increase in the 
culture time, the cell density approaches to that of the experimental value (day 6 and beyond), 
which is possibly due to the culture conditions not affecting the growth characteristics as 
greatly as observed during the early stages of the culture. In Figure 5.3B, the total cell 
number between the numerical results and the experimental data are compared. Similar 
strategy is adopted by Liu et al. (2006) to obtain total cell expansion as mentioned previously. 
It is evident that the observable differences are minimal (R2 = 0.97 1). 
Glucose consumption is an indication of cell metabolism and growth. In Figure 5.4, the 
glucose consumption of K562 in the experiment is comparable to the model predictions. The 
sum of square errors between the experimental data and model predictions was less than 
10%. 
5.5 Summary 
The validity of growth and metabolic model of haernatopoietic stem cells was investigated. In 
summary, the model predictions are in good overall agreement with the published work and 
106 
experimental data (R2>0.9). These results demonstrate that the model is capable of describing 
the growth of the progenitor cells (CFU-GM), total cell growth and metabolic behaviour of 
K562 cells with a good level of accuracy. This work herein formed the basis for the model 
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Figure 5.3: Comparison of (A) cell density and (B) cumulative total cell number for K562 
between experimental results (m) and simulations predictions (0) under cell-dilution feeding 
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Figure 5.4: Comparison of total glucose consumption between experimental results (m) and 
simulation predictions (o). 
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Chapter 6 
Simulation of ex vivo Bone 
Marrow Culture: Application to 
Chronic Myeloid Leukaemia 
Growth Model 
Abnormalities in the feedback mechanisms for the haernatopoietic process lead to bone 
marrow diseases, such as chronic myeloid leukaemia. There are many variants of CML, 
including the periodic form, as characterized by oscillating cell numbers. Studies suggest that 
the destabilization of the feedback loop between blood cells and growth factors (GF) 
contributes to periodic haernatological diseases (Adimy et al. 2006a). 
Considerable work has been carried out in the 2-D (flask) CML cultures attempting to 
explicate the cell functionalities within an ex vivo environment. However, CML cells are 
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unable to sustain growth in 2-D (flask) cultures for lengthy periods, normal cells have the 
selective growth advantage and outgrow the CML cells in vitro (Udomsakdi et al. 1992; 
Petzer et al. 1997; Luna-Bautista et al. 2003; Chavez-Gonzalez et al. 2004). Recently, Wu et 
al. (2006) developed a 3-D bioreactor and successfully generated functional leukaemia cells 
for at least four weeks (Wu et al. 2006). As in the case for normal haematopoiesis, it is 
plausible that the lack of a three-dimensional (3-D) microenvironment, a key contributor to 
the growth patterns, results in the varying properties of the BM cells. More specifically, the 
cell-cell and cell-matrix interactions are known to be crucial in sustaining long term 
haernatopoietic cell cultures. 
A number of mathematical models developed to study the mechanisms involved in CML 
growth were highlighted in Chapter 3. The work of Colijn and Mackey (2005) was 
particularly emphasised. Colijn and Mackey's model failed to explicitly include the G-CSF 
feedback control; therefore, how G-CSF affects granulopoiesis in CML could not be 
investigated. The recent work of Admiy et al. (2006) studied the effects of growth factors, G- 
CSF on the dynamics of neutrophil production (Adimy et al. 2006a). Though the G-CSF is 
explicitly accounted for in the model, other important cell lineages such as erythrocytes and 
platelets were not included, and therefore limited the study to certain lineages, affecting the 
stability of the system. 
The present work deals with the development of a mathematical model for the study of CML 
cellular growth patterns in an ex vivo culture system using a 3-D perfusion bioreactor. This 
work is an extension of the work presented by Colijn et al. (2005), with the inclusion of 
specific growth factors, such as G-CSF, TPO and EPO, to account for the feedback 
mechanisms of different lineages. Furthermore, the effect of different cytokine combinations 
and concentrations on CML growth is investigated, along with different operating conditions 
(re-circulating and non-re-circulating media). 
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6.1 Geometry 
The vessel comprises of two main regions: non-scaffold and scaffold, see Chapter 4, Figure 
4.1. The non-scaffold region consists of inlet/outlet, central canal and radial branches. The 
scaffold is the region where the cells are localised and is assumed to have a 80-90% porosity 
with a pore size of 250-350 ýLrn as well as isotropic and homogenous pore structure. In 
addition, the scaffold is assumed to be free from blockage and deposition. 
6.2 Model Formulation 
The basic model equations were presented in Chapter 3; in this chapter specific model 
equations pertaining to the work described herein are offered. 
6.2.1 Model Equations 
6.2.1.1. Fluid Flow and Mass Transport 
As in the case of Chapter 4, the continuity, Navier-Stokes and porous flow equations are used 
to describe the flow within the Rotating Wall Perfused Bioreactor (RWPB). The spatial 
distribution of nutrients within the scaffold is described by the general mass transport 
equation and the growth factors consumption is described by Monod-type kinetics. 
6.2.1.2. Growth Kinetics 
Four compartments (stem cells, leukocytes, platelets and erythrocytes) and the relative 

































Figure 6.1: CML haernatopoiesis model. Stem cell (Q) is either in resting phase or entering 
8) into proliferating phase ( Q1, ) and differentiation into erythrocytes (R), leukocytes (N) 
and platelets (P). The differentiation rate of R( icR ), N( K'ý, ) and P( Icl, ) are regulated by the 
amount of EPO, G-CSF and TPO, respectively. A R, 
A, 
v and A,, are the amplification factors 
of R, N and P, respectively. '5C) 1(5R 1(5N and 15,, are the death rate of Q, R, N and P, 
respectively. t5,,. 05 and (5,,,,, are the degradation rate of EPO, G-CSF and TPO, , 110 1 (; CSF 
respectively. 
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i) Stem Cell compartment 
Under normal conditions, the majority of HSCs and progenitor cells are quiescent in the Q, 
phase of the cell cycle. Colijn et al. (2005) employed a G,, model to illustrate the proliferating 
and resting phase of stem cells (Colijn and Mackey 2005). It is a typical delay model to 
accounts for the time that the cells spend in completing the proliferative phase of the cell 
cycle. 
dQ 
= -, 8(Q)Q - (icN + icR+ icp)Q + 2e-8'Lr, P(Q(t - r, ))Q(t - TO dt 
where Q is the CML stem cell population, t is the time, 6(Q) is the re-entry rate of resting 
CML stem cells into proliferating phase and is represented by the Hill function described in 
equations 3.36, JQ is the death rate of stem cells, r, is the time delay for stem cell 
proliferation, xN, icR and icp are the differentiation rates into the leukocyte, erythrocyte and 
platelet compartment, respectively and are describe by the following Hill function 
expression: 
icN (G) = f. 
Gý 
(6.2) 
Ghý + kGCSF 




KR (E) Z. 21 + kEpo'ý 
(6.4) 
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where G, T, E are the concentrations of G-CSF, TPO and EPO, respectively. f, ', 
W, W, 
A, k, and k are the Hill function coefficients. Estimation of these values are described in 
Chapter 3. k,,,, k,, O, kTpO , are Hill constants calculated from the differentiate rate of 
leukocyte, erythrocyte and platelet compartment respectively (Appendix A, Table A5). 
ii) Leukocyte, erythrocyte and platelet compartment 
Similarly, leukocyte (N), erythrocyte (R) and platelet (P) cellular components are represented 
by the following equations. 
dN 
= -gNN+ANKN (Nr,, )Qr, (6.5) 
dt 
dR 




= -. 3pP + Ap 
ficp (Pm)QP,, - e-"PTIs Kp (P,, P. 
(6.7) 
dt 
where 45N 8R, 8p are the death rates of leukocytes, erythrocytes and platelets, respectively. 
Q,. 
" , _0,. 
Q,.. , a,. , Q,. P, +,,, are 
the delay time for stem cells to mature into leukocytes, 
reticulocytes, erythrocytes, platelets and senescence platelets respectively. Av, AR, Ap are 
the amplification factors of leukocytes, erythrocytes and platelets, respectively. r. , 'rRM , 
-r,. and rpm are the time delay for leukocyte, reticulocyte, erythrocyte and platelet 
maturation, respectively. rps is the time delay for platelet aging due to senescence. 
Additional complexity lies in the modelling of erythrocyte and platelet lineages in 
comparison to the leukocyte lineage. The leukocyte lineage matures and dies at a constant 
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rate, while the erythrocytes and platelets mature and go into senescence. Therefore, an extra 
delay term has been incorporated into the respective equation to account for the loss via 
senescence in blood (Colijn and Mackey 2005). 
iii) G-CSF 
Change in the G-CSF concentration represents the difference between the production and 







dt kN+N kN+N 
where G is the concentration of G-CSF, VG"' is the maximum production rate of G-CSF, kN 
is the dissociation constant of neutrophils and i5GcsF the elimination of G-CSF by neutrophils 
iv) TPO 
In a similar fashion to G-CSF, the changes in the TPO concentration represent the difference 




- (5Tpo [T] (6.9) 
dt I+KTpo P" 
where TPO is the concentration of TPO, arpo, KTpO and k are the parameters in the Hill 
function and STpo is the half-life of TPO. 
EPO 







dt 1+ KEpoRhl 
where EPO is the concentration of EPO, aEpO, KEpO and k are the parameters in the Hill 
function and SEpO is the half-life of TPO. 
6.3 Initial and Boundary Conditions 
The initial conditions were: the inlet perfasion rate is at 15 mm/s; the inoculum density is set 
at IxIO' celIS/CM3 with the duration of the culture simulation set at 10 days; and the inlet 
growth factor concentrations and combinations being: 1) G-CSF (10 ng/ml), 2) TPO (10 
ng/ml) 3) EPO (3 U/ml) 4) G-CSF (10 ngIml) + TPO (10 ng/ml), 5) G-CSF (10 ng/ml) + 
EPO (3 U/ml) 6) G-CSF (10 ng/ml) + TPO (10 ng/ml) + EPO (3 U/ml) 7) G-CSF (30 pgIml) 
+ TPO (5 mU/ml) + EPO (10 mU/ml). The kinetics of CML lineages and growth factors are 
given in Appendix A Table A5 and the biophysical parameters are given in Appendix A 
Tables A6. 
As indicated previously, this chapter is divided into two parts: with and without re- 
circulation. In simulations without re-circulation, the inlet and outlet boundary conditions are 
declared as Dirichlet boundary and outlet mass flow boundary conditions, respectively. While 
for the simulations with the re-circulation, the boundary conditions are set as periodic 
boundaries conditions (PBC). The standard velocity condition of 'no slip' is applied at the 
wall boundaries, with no-flux condition across the walls. The flow assumptions applied in 
Chapter 4 are carried forward here. 
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6.4 Re-circulation Medium - Periodic Boundary Conditions 
(PBCs) 
In a perfusion culture system, fresh medium are introduced into the vessel continuously while 
the metabolic waste is removed to prevent waste 'build-up'. However, for effective use of 
cytokines, as they are costly materials, the medium is usually recycled back into the vessel; 
fresh medium is only replaced at various time points during the culture. To simulate medium 
re-circulation, periodic boundary conditions are applied. The approach for the 
implementation procedure was described in Chapter 3. 
6.5 Results and Discussion 
6.5.1 Perfusion Without Re-circulation 
CASE 1: NORMAL BM CELLS VS. CML CELLS 
In the previous chapter, the growth characteristics of normal haernatopoietic cells were 
investigated under varying operating conditions in a low-shear perfused bioreactor embedded 
with a porous scaffold. As a further advancement of this previous work, in this chapter the 
former model is utilised, which further incorporates the effects of cytokines on cellular 
growth. This model is then applied to CML cells in pathological BM. Growth rates of 
specific lineages of normal and CML cells are provided in Table A5 (Appendix A). 
Comparison of normal BM and CML cell growth in a 3-D perfasion culture system are 
shown in Figure 6.2. At the stem cell level, CML cells rapidly decline to an undetectable 
level, whereas normal BM cells decrease more slowly (Figure 6.2A). This observation is in 
line with the work carried out by Udomsakdi et al. (1992), who showed that the long-term 
culture initiating cells of CML cells decline more rapidly than the normal BM cells due to a 
defect at the CML stem cell level (Udomsakdi et al. 1992). 
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At higher levels of maturity, CML cells demonstrate a significant increase in leukocytes as 
compared to normal BM culture cells (Figure 6.2B). Throughout the simulation period, CML 
cultures have three times more leukocytes than the normal BM cells culture. Platelets in the 
CML cultures show a higher expansion rate than in normal haematopoiesis, whereas, almost 
no difference (<I%) is observed between the number of erythrocytes CML and normal BM 
cultures (Figure 6.2C, D). At the end of the 10 days simulation period, CML cultures have 
approximately 5% more cells than the normal BM cultures (Figure 6.2E). These cell 
proliferation patterns of CML are also observed in clinical BM: amplification in granulocytes 
lineages, decrease in erythropoiesis, steady or an increased in the number of platelets. Some 
patients also display hyper-cellular bone marrow; correlated with increasing number of cells 
in the marrow (Lichtman and Liesveld 2000). These results also agree with the previous ex 
vivo findings of other investigators, who compare the expansion of normal and CML cell and 
demonstrate that the primitive CML cells (LTC-IC) lost the ability to expand regardless of 
the addition of cytokines; while the relatively more mature cells showed amplification in their 
population (Petzer et al. 1997). 
CASE 2: EFFECT OF SINGLE VS. MULTIPLE GROWTH FACTORS ON CELL EXPANSION 
pATrERNS 
Cytokines can be specific or non-specific, as they can act on different types of cells such as 
primitive cells, progenitor cells, or committed cells and on different lineages. Some growth 
factors also have synergistic or additive effects when used with other growth factors (Metcalf 
and Nicola 1995). In this study, the individual effects of single cytokines (G-CSF, TPO or 
EPO) as well as their combined effects (G-CSF+TPO, G-CSF+EPO, TPO+EPO, G- 
CSF+EPO+TPO) on the expansion of different lineages are examined. 
In all cases, stem cell numbers show a continuous decline throughout the 10 day cultures, 
especially in the case of cytokine cocktails (Figure 6.3A). Previous studies showed that G- 



















































Figure 6.2: Expansion of different lineages in normal and CML cells. Both cases have the 
same conditions: 90% porosity, pore size at 250 gm, perfusion rate Of I. SX10-3 m/s, G-CSF, 
TPO and EPO concentration at 10 ng/ml, 10 ng/ml, and 3 U/ml, respectively. 
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respectively (Metcalf and Nicola 1995). As expected, in the single cytokine studies, G-CSF 
amplified and maintained the number of leukocytes while platelet and erythrocyte expansion 
was dependent on the addition of TPO and EPO respectively (Figure 6.3B, C, D). 
interestingly, in the cytokine cocktail studies, combining G-CSF with TPO, EPO or 
TPO+EPO did not indicate better expansion in leukocytes than by using G-CSF alone; the 
GF combinations indeed decrease leukocyte expansion to some extent (Figure 6.3E). This 
observation is also found in the erythrocytes lineages (Figure 6.3D). Whether this effect is 
cell lineage specific or due to growth factor competition is unclear and needs further analysis. 
The effects of either single or combinations of growth factors on cell dynamics of different 
lineages varied. Though adding TPO+EPO gives similar total number of cells as G- 
CSF+EPO+TPO, there is no expansion in the leukocytes lineages (Figure 63B). The growth 
factors combination of G-CSF, TPO and EPO seems to be the more effective in increasing 
the total numbers of each cell types (Figure 6.3A-E). These results are in line with a previous 
study by Bhatia's group demonstrated total CML cells expansion is significantly higher under 
the combinations of cytokines than using single cytokines (Bhatia et al. 2000). 
The addition of cytokines promotes the proliferation, differentiation and maturation of early 
pre-progenitors through terminal differentiation, thereby amplifying the total cell population. 
However, at the same time, this process increased GF-induced maturation and decreased self- 
renewing divisions of primitive progenitors. This has also been demonstrated in other studies, 
where the combination of growth factors within the culture significantly reduced the 
primitive population that has multilineages colony formation ability (Brugger et al. 1993; 
Bhatia et al. 2000). 
CASE 3. EFFECT OF GROWTH FACTOR CONCENTRATION ON CML CELL EXPANSION 
Previous studies have demonstrated that high concentration of cytokines can enhance the 
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Figure 6.3: Expansion of stem cells, leukocytes, platelets and erythrocytes under single and 
combined cytokines (G-CSF, TPO, EPO). The culture conditions: I. D. = IxIW cells/cm, 
= 90%, d, = 250[im, v=1.5 mm/s, G-CSF = 10 ng/ml, TPO = 10 ng/mi and EPO = -3 ) U/ml. 
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(Luna-Bautista et al. 2003; Chavez-Gonzalez et al. 2004). However, Bhatia et al. (2000) 
demonstrated that using high doses of cytokines does not further increase CML cells 
expansion. To further investigate the effect of varying growth factor levels on the growth of 
CML cells, two different concentrations of cytokines cocktails were chosen. The first 
concentration (normal level: G-CSF = 10 ng/ml, TPO = 10 ng/mI, EPO =3 U/ml) typically 
represents the values used in in vitro cultures, whereas the second concentration '(low level: 
G-CSF = 30 pg/ml, TPO =5 mU/ml, EPO = 10 mU/ml) corresponds to the in vivo levels of 
cytokines. 
Figure 6.4 compares the growth kinetics of stem cells, leukocytes, platelets and erythrocytes 
under normal (in vitro level) and low (in vivo level) growth factor concentrations. Under 
normal GF concentration, stem cell numbers declined to an undetectable level after the first 
day, whereas, in the low GF concentration culture, the stem cells is able to maintained higher 
numbers for a longer period (Figure 6.4A). A previous study by Bhatia et al. (2000) has also 
demonstrated that increasing cytokines concentration fail to expand the primitive CML LTC- 
IC (Bhatia et al. 2000). 
At normal GF concentrations, leukocytes show a marked increase in numbers followed by a 
decline (Figure 6.413), whereas, under low GF conditions, leukocytes show a continuous 
decrease in cell numbers. Platelet numbers show similar expansion patterns under both 
conditions, though platelet numbers under normal conditions has about 22% more cell 
numbers than the low conditions (Figure 6.4C). Erythrocyte numbers under normal growth 
factor concentration showed a continuous increase throughout the culture as compared to low 
GF conditions (Figure 6.41)). Under normal GF concentration, there are four times more total 
cell number than the low GF concentration at the end of 10 days culture simulation (Figure 
6.4E). Interestingly, among these lineages, leukocytes and erythrocytes are relatively more 
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Figure 6A Expansion of stem cells, leukocytes, platelets, erythrocytes and total cell number 
under normal and low growth factors concentration. The operational conditions are y= 90%, 
dp = 250 um, v=1.5 mm/s, ID = IxIO'celIS/CM3 . Normal GF: G-CSF = 10 ng/ml, TPO = 











Figure 6.5: CML cells population distribution at various time points. Tile operational 
conditions arey= 90%, dl, = 250 ýtm, v=1.5 rnm/s, 11) = IxIW cells/cin Normal GF: G- 
CSF = 10 ng/ml, TPO = 10 ng/rnl and EPO 3) U/mI, Low GF: G-CSF =I Oup/ml, T110 =5 In 
1-nU/ml and EPO = 10 mU/mI. 
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leukocytes and erythrocytes numbers were found between two different GF conditions, 
whereas, only 1.3 times difference is shown in platelet numbers. The expansion patterns of 
individual lineages under normal and low GF concentrations are shown in Figure 6.5. From 
the distribution pattern of the lineages, it is demonstrated that under normal GF 
concentrations, erythrocytes dominate the cellular composition with over 80% occurrence 
whereas under the low GF concentrations, platelets are the most abundant cell type, which 
contribute to 60% of the total cell population (Figure 6.5). This further demonstrates that 
platelet expansion is less responsive to GF level and showed better expansion among the 
lineages in the low GF condition. 
Different levels of cytokine have drastic effects on the stem cell dynamics, which in turn, 
influences the distribution of cells types. Based on this observation, optimising the cytokine 
level could be an effective strategy to maintain cell numbers and cell types distribution, thus, 
to re-create an environment similar to in vivo steady state for expansion and maintenance. 
6.5.2 Perfusion With Re-circulation 
CASE 4: EFFECT OF RE-CIRCULATION MEDIUM ON CELL EXPANSION PATTERN 
Without re-circulation of the medium in the perfusion bioreactor, the average cytokine 
concentration in the vessel remains the same throughout the 10 days culture (Figure 6.6A-C); 
signifying that cytokines are not utilized in an efficient manner. Consequently, the use of 
medium re-circulation avoids unnecessary disposal of cytokines. Results from this study 
demonstrate that the total amount of growth factor utilised in the re-circulation culture 
simulation was limited to 1500 ng of G-CSF, 1500 ng of TPO and 450 U of EPO, while in 
the culture without any re-circulation, approximately 100 times greater concentration of 
growth factors was required. Additional effects of re-circulation and non re-circulation on 
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Figure 6.6: Concentration of G-CSF (A), TPO (B) and EPO (C) in the perfusion bioreactor 
with re-circulation and without re-circulation. The operational conditions are I. D. = IxIOI 
cells/cm', y= 90%, dp = 250 wn, v=1.5 mm/s, G-CSF = 10 ng/ml, TPO = 10 ng/ml and 











































Figure 6.7: Kinetics of different lineages in the perfusion bioreactor with re-circulation and 
without circulation. The operational conditions are I. D. = lxlO5 cells/cm3, y= 90%, dp 
250 ýtm, v=1.5 mm/s, G-CSF = 10 ng/ml, TPO = 10 ng/ml and EPO =3 U/ml. 
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cell numbers under the two conditions (Figure 6.7A, B, C), it does appear that all cell lineages 
have lower expansion potential under re-circulation mode. At the end of the simulation, the 
total number of cells has 1.3 fold difference between the two operating conditions (Figure 
6.71)). The decline in cell proliferation in all lineages is attributed to the lower levels of 
cytokines being delivered to the cells in the re-circulation operation. Different types of 
operation can influence the expansion pattern of CML cells, by replacing the depending GFs 
more frequently and combined with re-circulation of medium, GFs can be more effectively 
used. 
CASE 5: SPATIAL DISTRIBUTION OF GROWTH FACTORS AND CELLS WITHIN THE 
SCAFFOLD 
The design of scaffold architecture can affect the transport profiles in the bioreactor and 
therefore can affect cellular growth. The spatial distribution of growth factors, EPO, and 
erythrocytes in the 3-D perfusion culture vessel are shown in Figure 6.8. In figure 6.8A, the 
spatial distribution of EPO shows a high level of growth factors around the centre part of the 
bioreactor which corresponds to the highest velocity area, as observed in Chapter 4 (Figure 
4.2). During the transport of growth factors, these are likely to be consumed or degraded 
naturally, but with high flow rate, the growth factors are replenished. Low GF concentration 
were observed around the boundary areas at two ends, it is possible that due to the slow flow 
of the media around these areas, as a result, the consumption and degradation rate is faster 
than the replenishing rate, thus creating this gradient level. In Figure 6.8B, the distribution of 
erythrocytes showed a similar contour as the distribution of EPO. Comparing two contour 
plots, numbers of erythrocytes are relative to the concentration of growth factor, this implies 
that cellular growth is dependent on the growth factor concentration. 
The delivery of GFs for cellular growth is govemed by scaffold porosity and pore size. Thus, 
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Figure 6.8: Contour plot of EPO and Erythrocytes concentrations on axial positions on day 3 
under re-circulation operation. Planes are drawn at the X-Z orientation on the axial direction 
of the RWPB (Figure 4.1 B). The operation conditions are I. D. = I XI 01 CelIS/CM3,7 = 90%, 
d, = 250 ýtrn, v=1.5 mm/s, G-CSF =I 0 ng/ml, TPO = 10 ng/ml and EPO -3 1 U/ml. Arrows 








Time (daý s) 
Figure 6.9: Expansion of total number of cells for different porosities and pore sizes. The 
operation conditions are I. D. = IxIW cells/crn 
3,80 or 90%, d= 250 or 350 pin, v=1.5 
mmls, inlet GF concentration: G-CSF = 10 ng/ml, TPO = 10 ng/rnl"and EPO = 33 U/nil. 
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Figure 6.10: G-CSF (A), TPO (B) and EPO (C) concentrations within different scaffold 
architecture during 10 days with culture under re-circulation operation. Tile operation 
conditions are I. D. = lxlO' cel IS/CM3,7 = 80 or 90%, d, =2 50 or' ) 50 ltrn, v=1.5 mm/s, 
initial GF concentration: G-CSF = 10 ng/ml. TPO = 10 ng/ml and EPO =3 U/ml. 
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demonstrated the largest number of total cell expansion was observed in the high porosity 
(90%) and large pore size (350 grn) case (Figure 6.9). This finding is in agreement with the 
results from Chapter 4 that higher porosity scaffolds provides more space for cellular growth 
thus, resulting in a higher demand for growth factor. For this reason, the least GF 
concentration is observed in the scaffold with 90% porosity 350 gm (Figure 6. IOA, B, C). 
Furthermore, the low flow resistance in the large pore size scaffold facilitate the transport of 
fresh growth factors into the vessel, as a result increase the cell proliferation rate. 
6.6 Summary 
The work presented in Chapter 4 has been extended to investigate the proliferation capability 
of BM cells under pathological conditions. The proposed model is applied to simulate the 
expansion of CML cells in a perfusion vessel using cytokines as the stimulant. The result 
demonstrates the in vivo and in vitro phenomena observed in CML cells. Additionally, this 
study has shown that individual lineages CML cells grow better under single growth factors 
as compared to growth factor cocktails, whereas, for total CML cells expansion, a mixed 
growth factor condition is preferred. CML cells are sensitive to GF concentration, GF 
concentration normally utilised within in vitro cultures showed higher expansion (four times) 
in total CML cell numbers. Furthermore, scaffolds with high porosity (90%) and large pores 
size (350 pm) offers a more efficient way of transporting growth factor for CML 
proliferation. Finally, non re-circulation operation provides a more stable growth factors 
gradient in the vessel for greater cell expansion, nevertheless, by optimising the re-circulation 
condition, GFs can be economically used. The developed model improves the understanding 
of nutrients transport and CML cells expansion pattern in a perfusion culture system, thus, 





In the present work, a mathematical model has been developed for the study of the growth of 
haernatopoietic cells in a 3-D perfused bioreactor system embedded with a scaffold. 
Momentum, mass and porous transport equations were solved simultaneously to obtain the 
shear stress, velocity, nutrients concentration (oxygen and glucose) and cellular growth 
distribution inside the scaffold. The simulation results show that the bioreactor system can 
provide a low shear stress (6.6 x 10-8 to 0.086 dynes/cm2) environment for cellular growth, 
while having an average velocity (0.1 mm/s) that resemble the known sinus blood velocities 
within the in vivo BM environment. The multi-cell-types study showed that oxygen content 
within the bioreactor is sufficient to avoid hypoxic conditions (<4% v/v) which can be 
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detrimental to the cells (Ishikawa and Ito 1988; Cipolleschi et al. 1993). The simulation work 
provided in chapter 4 can be utilised in a number of ways to not only aid the development of 
the most favourable design of haematopoietic culture systems, but also to provide a sound 
basis for the advancement of haematopoietic culture models for its application to diseased 
BM. In particular, the oxygen and nutrient concentration profiles attained offer the starting 
point for culture conditions in the study of pathological BM (see Chapter 6). Thus, this work 
supports further studies presented in the chapter 6 of this thesis. 
With any simulation efforts, it is critical that the outputs are verified so as to provide a degree 
of confidence with the obtained results. Consequently, the simulation results are compared 
with the experimental work by Liu and others, where haematopoietic cells were cultured 
using a similar perfusion system (Liu et al. 2006). Following the methodology given in their 
work, the work was simulated and the results compared to the experimental results provided. 
The simulated results for the CFU-GM numbers and total cell numbers were within an 
acceptable range of error (the sum of square errors between the experimental data and model 
predictions was less than 10%), therefore suggesting that the computational model is able to 
capture the growth kinetics of haernatopoietic cells. To further assess the validity of the 
model, experimental work was carried out using K562, a type of human myeloid leukaemic 
cells. With a pre-defined experimental set-up, total cell density and nutrient (glucose) 
utilisation were obtained. Comparing the experimental output with the simulation output, it is 
evident that the model data are in good agreement with the experimental data (R2>0.9), thus 
further validating the major findings predicted by the computational model. 
The validation of results obtained from the mathematical model described in Chapter 4 
formed the basis to extend the application of this model into diseased BM. A more complete 
picture of haernatopoiesis and feedback regulations by growth factors has been incorporated 
into a known stem cell model (Chapter 6). The proposed model is applied to simulate the 
expansion of CML cells in a perfusion vessel using cytokines as the stimulant. The result 
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demonstrates the in vivo and in vitro phenomena observed in CML cells: CML stem cells 
rapidly decline whereas leukocyte lineages increase significantly, this observation is in line 
with work carried out by Petzer et al. (1997) and Lichtman et al. (2000). Furthermore, the 
self-renewal, differentiation and expansion pattern are affected and altered by the 
concentration and varying combinations of cytokines. By combining non-recycled perfusion 
with the presence of haematopoietic growth factors G-CSF, TPO and EPO, a remarkable 
amplification of the cell number was observed. This model provides a better understanding of 
the combined effects of some important culture parameters such as flow rate, scaffold 
properties, growth factors concentrations and operation mode. Identification of the 
parameters controlling haematopoiesis of CML cells can assist and optimize the design of the 
CIAL culture system for pre-clinical and clinical use. 
Although the usefulness of the models presented in this work cannot be discounted, 
significant amounts of work pertaining to either normal or CML haernatopoietic cultures 
remain to be carried out. These models provide a basis for future developments and 
enhancement of viable haernatopoietic culture models for aiding the reconstitution of healthy 
and pathological BM in an ex vivo environment. 
7.2 Future Work 
In this sections, suggestions for advancing the present models and future implementation in 
the CFD simulation software are offered. 
7.2.1 3-D BM and Scaffold 
The 3-D haernatopoietic inductive microenvironment controls the renewal, differentiation, 
maintenance, maturation and the egress of the blood cells in haernatopoiesis. This intricate 
process involves interactions between proteins, cells and cytokines in this unique 3-D niche. 
In the present study, the growth of blood cells in a bioreactor has been simulated with an 
145 
assumption that the 3-D scaffold is homogeneous and isotropic. However, as cells grow, they 
tend to occupy the void spaces in the scaffold, and consequently, the scaffold can no longer 
be assumed to be isotropic, which in turn is likely to affect the momentum and mass transport 
in the bioreactor. In addition to considering the scaffold properties, it also pertinent that the 
cell-cell and cell-matrix interactions information should be incorporated into the model. 
However, how the cell-cell and cell-matrix interacts is yet to be fully elucidated. 
Nevertheless, the combination of such data should prove to be very useful in design of a 
tissue-specific scaffold for the cells to recreate the necessary HIM. 
7.2.2 Cytokine Interaction 
Three different cytokines, G-CSF, EPO and TPO, have been studied in the production of 
CML cells in a perfused BM culture system. There are many other major growth factors such 
as stem cell factor, Interleukin-3 and 6, etc involved in blood formation process that are 
specific or non-specific on a cell lineage, and/or act on the different maturity levels. In 
addition, these cytokines can be synergistic and/or compete with each others (Koller et al. 
1992b; Brugger et al. 1993; Koller et al. 1995b; Poloni et al. 1997; Chaudhry et al. 2004). It 
has been demonstrated that cytokines can stimulate the rates of cellular glycolysis and show 
different expansion cell patterns under varying oxygen tensions (Koller et al. 1992b; Laluppa 
et al. 1998; Bauer et al. 2004). Thus far, in the present work, such effects have been 
neglected. Further advancements of BM culture models would therefore attempt to 
incorporate the synergistic and/or competitive effects of the different cytokines involved in 
cell growth. 
7.2.3 Rotational Effect 
Although the rotating wall bioreactor has been utilised, the rotational aspect of the reactor has 
yet to be studied in the context of BM cultures, and how it actually affects shear stress levels, 
146 
mass transport and cellular growth. In a previous study, Kohler et al. (1999) found there were 
no significant improvement in the CD34+ and CFU-GM expansion using rotating culture 
vessels (Kohler et al. 1999). However, other studies have shown that rotating the vessel can 
improve fluid flow and mass transport, while maintaining the low shear stress levels (Begley 
and Kleis 2000; Begley and Kleis 2002). Further, simulated microgravity conditions can also 
allow cells to aggregate into a 3-D structure (Goodwin et al. 1993). In regards to this, studies 
have shown that haernatopoietic bone marrow cells produce greater number of cells and 
progenitors in a microgravity environment than 'normal' 2-D flask cultures (Plett et al. 200 1). 
Additionally, under microgravity, human malignant melanoma tissue has similar 
immunohistochemistry to the in vivo situation (Licato et al. 2001). A simplified analytical 
model to study the fluid flow in a rotating tube is offered. (See Appendix BI). For 
completeness and further verify such observations, it is a worthwhile effort to investigate the 
rotational effects of the vessel on cellular growth. 
7.2.4 Fluid Flow Validation 
Despite the fact that the results presented in Chapter 6 demonstrate good overall agreement 
with the published and our own experimental data, one important aspect of future work will 
be the spatial verification of the simulated flow field. For such purposes, it is recommended 
to employ either particle-image velocimetry (PIV) or nuclear magnetic resonance (NMR) 
technique to obtain detailed experimental data around or within the scaffold (Williams et al. 
1997; Sucosky et al. 2004). 
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Appendix A 
Model Parameters and 
Nomenclature 
The following tables contain the configurations of the bioreactor and model parameters used 
in Chapter 4,5 and 6. These include the cell kinetics of normal and CML cells, the uptake 
rate of oxygen, glucose and cytokines. 
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Bioreactor Parameters Value Unit 
Vessel Volume 50.41 cm, 
Vessel Length 3.8 cm 
Central canal radius 0.8 cm 
Vessel radius 2.2 cm 
Scaffold Parameters 
Scaffold Volume 50.06 cmý 
Scaffold Length 3.8 cm 
Outer Tube Radius 2.2 cm 
Inner Tube Radius 0.8 cm 




Table Al: Bioreactor and scaffold parameters 
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Parameter Symbol I Value Reference 
Flow Parameters 
Viscosity lu 6.92xlO'kg/ms (Perry and Green 1997) 
Density P 993.37 kg/M3 (Perry and Green 1997) 
Temperature 37 *C 
Perfusion Rate v 10 mm/s 
Porous Material Parameters 
Volume Porosity 80,85,90,95 ( 
Pore Sizes (Diameter) d, I 250,350,450(, wn) 
Cell Parameters 
Specific Cell Volume (x 10 -9 
(Granulocytes) 
2.8 cell/ cmý (Chow et al. 200 1) 
Inoculurn Cell Density 0.1 -1 x 10' ' celIS/CM3 
ss Transfer Parameters (Glucose) 
Glucose Diffusivity DG 6.6 x 10'10 m2/s 
11 (Gruetter et al. 1998; Botchwey et al. 
2003) 
Initial Concentration C. I 3000mg/l 
Transfer Parameters Wxyzen) 
Oxygen Diffusivity D 02 1,5 X 10-9 M2/S (Chow et al. 200 1) 
Specific oxygen uptake rate ( x10 -14 
(for granulocytes cell) 
V. 2.2-64.9 mol/cell/h (Chow et al. 200 1) 
Initial oxygen tension C02 20% 
Reacdon Parameters 
Rate constant in Monod type kinetics equation K- 
V... 
Rate constant in Monod type kinetics 
expression for glucose 
kr, 1.1 rn/i/kg (Carruthers 1990) 
Rate constant in Monod type kinetics 
expression for oxygen 
k 02 1161 mP/kg 1 
(Chow et al. 200 1) 
Table A2: Model parameters for normal BM cells in a 3-D perfused vessel. 
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Self ký 3.8 1.3 2.8 x 10-2 1.0 x 10,1 2.1 x 10-1 1.7 x 10" 4.2 x 10 4.9 x 10-1 Expansion 
Cell kkx 9.5x10-1 8.2 x 10-4 1.5 x io-" 1.4 x 10 1.0 x 10-, 2.9x 10 3.2 x 10*1 9.1 x 10-1 Death 
Differenti kdX 4.2 1.6 3.3 x 10' 9.1 x 10-' 1.4x 10«1 
] 
1.2 x 10-1 4.4 x 10-2 ation 
Table A3: Growth kinetics of normal BM progenitor cells (per day) (da, Silva et al. 2003) 
Term Symbol CFU-GM Reference 
Rate of Granulocytes Growth x kj 
0.69 day-' 
" 
(Hevehan et al. 2000) 
Rate of Mature Cell Growth 0.35 day (Peng eta]. 1996) 
Rate of Mature Cell Death kk' 0.5 day-' (Peng et al. 1996) 
Table A4: Growth kinetics of normal BM granulocytes and mature cells 
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Parameter Symbol Value Reference 
Cells 
Number of CML stem cells Q UxlChells/kg (Bernard et al. 2003) 
Death rate of proliferation 
normal BM stem cells 45Q 0.1/day (Bernard et al. 2003) 
Death rate of proliferation 
CML stem cells 
. 32 0.04-0.18/day (Colijn and Mackey 2005) 
Number of leukocytes N 3.55-7xlO'cells/kg (Beutler et al. 1995) 
Amplification factor for 
leukocytes in normal BM 
AN 75200 (Bernard et al. 2003) 
Amplification factor for 
leukocytes in CML BM 
AN 68800-763000 (Colijn and Mackey 2005) 
Death rate of leukocytes (51 2.4/day (Bernard et al. 2003) 
Number of erythrocytes R 3.5xlO"cellslkg (Mahaffy et al. 1998) 
Amplification factor for 
erythrocytes 
AR 563000 (Beutler et al. 1995) 
Death rate of erythrocytes 95, 0.001/day (Mahaffy et al. 1998) 
Number of platelets P 2.94xlO'Ocellslkg (Santillan et al. 2000) 
Amplification factor for 
platelets in normal BM 
Ap 282000 (Santillan et al. 2000) 
Amplification factor for 
platelets in CML BM 
Ap 42100-559700 (Colijn and Mackey 2005) 
Death rate of platelets 45, 0.15/day (Santillan et al. 2000) 
Dela Terms 
Time delay for stem cells 
proliferation 
TS 2.8 days (Bernard et al. 2003) 
Time delay for leukocyte 
maturation Ty 
3.5 days (Bernard et al. 2003) 
Time delay for erythrocyte 
maturation T&W 
6 days (Mahaffy et al. 1998) 
Time delay for reticulocyte 
maturation 
2.8 days Beutler et al. 1995) 
rjtw + Tý, + rits 120 days (Mahaflyet al. 1998) 
Time delay for platelet 
maturation r PM 
7 days (Santillan et al. 2000) 
9.5 days (Santillan et al. 2000) 
Constants 
k. in normal BM 3.0/day (Bernard et al. 2003) 
ký inCMLBM 0.98-3.88/day (Colijn and Mackey 2005) 
02 0.5xlO6cells/kg (Bernard et al. 2003) 
.6 4 (Bernard et al. 2003) 
fo in normal BM 0.4/day (Colijn and Mackey 2005) 
fo inCMLBM 0.53-20.48/day (Colijn and Mackey 2005) 
01 0.36xlVcellslkg (Bernard et al. 2003) 
A I I (Bernard et al. 2003) 
KP in normal BM 1.17/day 
F(Colijn 
and Mackey 2005) 
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Kp in CML BM 0.05-5.06/day (Colijn and Mackey 2005) 
KTpo 11.66xlO'Ocells/kg-l" (Santillan et al. 2000) 
1.29 (Santillan et al. 2000) 
1.1/day (Colijn and Mackey 2005) 
KEpo 0.0382xlO" cells/kg"*' (Mahaffy et al. 1998) 
6.96 (Mahaffy et al. 1998) 
Growth Factors 
GCSF MM constant kGCSF 427 pg/ml Calculated* 
TPO MM constant kTpO 0.095 mU/ml Calculated* 
EPO MM constant kEpo 28 mU/ml Calculated* 
G-CSF at in vivo state G 30 Dg/ml (Shochat et al. 2006) 
G-CSF at ex vivo state G lOng/ml (13hatia et al. 2000) 
N dissociation constant kN 0.5xI06cells/ral (Shochat ct al. 2006) 
Elimination rate of G-CSF 45GCSF 6 pgrams/cell/day (Shochat ct al. 2006) 
TPO at in vivo state T 5 mU/ml (Santillan et al. 2000) 
TPO at ex vivo state T 10 ng/ml (Bhatia ct al. 2000) 
Elimination rate of TPO 9TPO 0.69/day (Santillan et al. 2000) 
EPO at in vivo state E 10mu/ml (Mahaffy c al. 1998) 
EPO at ex vivo state E 3 U/ml (Luna-Bautista et al. 2 3) 
Elimination rate of EPO (5EPO 6Air (Mahaffy et al. 1998) 






The feedback function for G-CSF is represented by: 
F(N) = fo 
OA 
OIA + N'ý 
as describe in Chapter 3, Equation 3.38. Bernard et al. suggested (Bernard et al. 2003), 
F(G) = F(N), and 
F(G) = 
Gý 
* Gý +kGCSF'ý 
where 
kGCSF is the reaction coefficient. 
Using F(N) value obtained value from Colijn et al. (2005), we have 
F(N) = 0.026day-' = F(G) and f=0.4 day". According to Shochat's paper, G-CSF 
normal value (steady state value) is 30 pgIml, therefore, 






kc --427pglml , csF 
The sarne approach has been used to calculate kEpO and kTpO . 
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Parameter Symbol Value Reference 
Flow Parameters 
Viscosity JU 6.92 x 10-4 kg/m s (Perry and Green 1997) 
Density p 993.37 kg/m' (Perry and Green 1997) 
Temperature T 37'C 
Perfusion Rate v 1.5 mm/S 
Porous Material Parameters 
Volume Porosity Y 80,90% 
Pore Sizes (Diameter) di, 250,350 pn 
Mass Transfer Parameters (G-CSF) 
G-CSF Diffusivity DGCSF 1.551 x 10-'Om'/s Calculated" 
Molecular Weight of G-CSF MGCSF 20kDa (Kozutsurni 1996) 
Mass Transfer Parameters ( 
TPO Diffusivity Dm T 9.773 xI 0-'lm2/s Cýalculated** 
Molecular Weight of TPO MTPO 80kDa (Jelkmann2001) 
Mass Transfer Parameters 
EPO Diffusivity DFýyo 1.355 x 10*10m% Calculated" 
Molecular Weight of EPO MF. Po 30kDa (Jelkmann 2001) 
Table A6: Model Parameters for CML BM cells in a 3-D perfused vessel. 
** Calculation of Diffusivities of G-CSF, TPO and EPO 
Diffusivities of different growth factors were calculated using the Polson equation suggested 




where T is the absolute temperature, M is the dimer molecular weight and P is the viscosity 
of the medium. 
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Parameter Symbol I Value T Reference 
Porous Material Parameters 
Volume Porosity Y 1.0 
Cell Parameters 
Inoculum Cell Density IxWcells/ml 
I 
K562 Growth Rate 0.582 
1 
(McGahon et al. 1994) 
Transfer Param rs (Glucose) 
Glucose DiffUsivity Do 6.6 x 10'10 m2/s (Gruetter ct al. 1998; Botchwey et al. 2003) 
Initial Concentration Co 22.5mmolA Obtained from experiment 
Table A7: Model parameters for K562 cells in a RWPB using dilution protocol. 
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Appendix B 
Model Implementation and 
Validation 
In the following sections the underlying implementation procedure for the models presented 
in Chapters 4,5 and 6 are presented. Firstly, in addition to the model validation presented in 
Chapter 5, a simplified analytical model of the fluid flow in a rotating tube is offered (See 
Chapter 7, Section 2.3). Secondly, the procedure for implementing the model equations in 
CFX 4.4 is described. Thirdly, the grid sensitivity aspects of the numerical scheme are 
presented. Finally, simplified models implemented in other commercial software (gPROMS) 
are compared to the results obtained from CFX4.4. All the data provided here further support 
the model results and validation offered in the earlier part of this thesis. 
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BI Comparison with Analytical Solutions 
This section offers a simplified analytical solution to the flow through a rotating annular tube. 
In the bioreactor, nutrients are transported by fluid flow and molecular diffusion and it is 
possible that molecular diffusion may result from both axial and radial gradients. The 
analysis for nutrient transport requires the knowledge of flow conditions within the 
bioreactor. The velocity profile depends upon the rheological properties of the culture 
medium, pressure drop and flow rate through the system. 
To study the flow inside the annular tube in Figure B1.1, the Navier-Stokes equation is 
solved with a set of boundary conditions (Equations B1.1) and the following assumptions: 
larninar flow, incompressible fluid and no slip velocity at the walls of the inner and outer 
tubes. 
B. C. 1 at r=R, v., =0 
B. C. 2 at r= icR, iý, =0 
B. C. 3 at z=0, v, = 0.000 13 5m /s (B 1.1) 
B. C. 4 at z =I 0, 
az 0 
c "n 
where n is the normal outward vector. With the above conditions and the assumptions, the 
analytical solution is shown to be (Bird et al. 1960): 
vz 4pL 
1-(r), +( 
I-1c, In( r (B1.2) 
R ln(Ilic)-- R 
The above model was implemented in CFX 4.4 with the geometry meshed using hexahedral 
grid; the velocity profile within the annulus cylinder is shown in Figure in B1.2. It is seen that 
Poiseuille flow was achieved in the studied model geometry. 
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The analytical solution represented by Equation 131.2 was compared to that of' the CIA 
numerical model. It is evident in Figure B 1.33 that the numerical results are accurate and the 
numerical error was found to be less than I%. 
To incorporate the rotation effect, the classical problern presented in Bird, et al (1960) has 
been employed here (Figure B 1.4). 
The analytical solution to the above model was shown to be (Bird et al. 1960): 
b 4X)v 
(13 1. -)) 
where V=ý, Q , ý, is the outer radius, 0 
is the angular velocity, b is the slit ýk idth, F is the 
velocity of top surface. 
The analytical result (Equation B1.33) has been compared to that of CFX and is sho\Nn in 










Figure B 1.1: Annular geometry. Symbols: R, outer tube radius. KR. inner tube radius. The 
structure dimensions are, R=0.033182 rn, 0=0.0105 m. length =10m. 
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Figure B 1.3 ): Comparing analytical solution (Equation B 1.2) and numerical flow model using 
CFX4.4. The parameters used are, p=6.92A 0-'kg / ni -sp= 99' ). 3 )7kg / in'; 
v=1.35x]O "m1s - 
Outer cylinder moves with angular velocity 0 
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Figure BIA: Rotating annular cylinder [taken from Bird et al. 1960]. Symbols: b, tube 
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Figure B1.5: Analytical and numerical rotational model comparison for velocity. Parameters: 
p =IxIO'3kg I m-s; p= I kg/M3; Inlet/outlet mass flow rate= 10kg/s. 
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B2 Model Implementation Using CFX 
The mass transfer equation of oxygen within the vessel can be expressed as (Pathi et al. 2005; 
Coletti et al. 2006): 
LC2L 
+ -v-VC02 =V-D, ý, 2 
VC02 
-k (B2.1) at 
where C02 is the oxygen concentration, v is the fluid velocity and k is the source term, the 
consumption kinetics of cells which depends on the concentration of oxygen. 
The scalar equation in CFX 4.4 was used to model mass transport: 
ao - p(ý+vV-O)=VFOVO+ko 
t t 
(B2.2) 
where p is the density, ý is any conserved intensive property (for mass conservation, ý =1; 
for momentum conservation, ý=v; for conservation of a scalar, ý represents the conserved 
property per unit mass), r is the diffusivity and k is the source/sink term. 






-k = ko 
The same method has been applied to the mass transport of other nutrients and the porous 
model presented in Chapters 4 and S. 
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B3 Grid Sensitivity Test 
The size of numerical grids determines the accuracy of the model results and also the 
computational time, therefore, it is necessary to find a suitable compromise between the 
accuracy and time. 
Grid sensitivity analysis was carried out with 4 different grid densities. Grid I is the coarse 
grid with the lowest number of nodes and elements, whereas Grid 4 is the finest grid with the 
highest number of nodes and elements in this study (Table B3.1). In Figure B3.1, percentage 
differences were calculated by comparing the results of average velocity in the vessel 
obtained from Grid 2 to Grid 1, Grid 3 to Grid 2, and Grid 4 to Grid 3 for various axial 
positions. Though, there is a huge difference between Grid 2 and Grid I at the two ends, the 
differences are small and less than 5% between Grid 3 to Grid 2, and Grid 4 to Grid 3 (Figure 
B3.1). Furthermore, the average velocity, oxygen and total cell number in the vessel are 
compared between each successive grid (Figure B3.2). It is shown that the least change in the 
solution was between Grids 4 and 3, therefore, Grid 3 was thought to be adequate for 
accurate prediction of the flow and mass transfer within the bioreactor culture sYstem. Thus, 
final grid chosen for the simulation is Grid 3. This grid sensitivity test was carried out for 
every geometry used in this work. A set of files is listed in Appendix C to show the 
implementation methods of the model in CFX 4.4. 
Parameters Number of nodes 
Grid 1 109424 
Grid 2 193896 
Grid 3 230204 
Grid 4 300888 
Table 133.1: Information of different grid geometries with varying grid densities 
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B4 Validation Using gPROMS 
Comparing the numerical scheme of CFX 4 to other readily available and independently 
validated commercial software; such studies are merely to add further validity of the 
numerical scheme within CFX 4.4. gPROMS, a process modelling, process simulation and 
optimisation software, was chosen for this purpose. The interface is a more user friendly 
environment to implement a large set of differential equations. There are deficiencies with 
using gPROMS, but as the solution time is comparatively much lower, such an approach 
provides a 'quick' way checking the accuracy of the implementation process. Growth kinetics 
models are implemented in both CFX and gPROMS environment and the simulations 
solution of total cell numbers were checked and compared. 
Figure B4.1 shows a comparison between the total cell numbers output from CFX and the 
gPROMS. It is demonstrated that results between the two codes are in good agreement, 






Figure 1333.1: Comparison of solution (velocity) of different grids for various axial positions 
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Figure B4.1: Numerical verification of total cell numbers using CFX 4.4 and gPROMS. tn 
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Appendix C 
Sample CFX Files 
168 
/* A COMBINED FLUID DYNAMICS, MASS TRANSPORT AND CELL GROWTH MODEL 
/* FOR A THREE-DIMENSIONAL PERFUSED BIORECTOR 
/* FOR TISSUE ENGINEERING OF HAEMATOPOIETIC CELLS 
/* POROSITY = 90%, PORE SIZE = 250um, ID =I E7 cells/cm^3 
1* 
*1 
FLDPOR - Fluid Porosity 
PORITY - Porosity 
WATDEN = Water Density 
VISCOS - Viscosity 
NRMVEL - Velocity 
ITER - Iteration 
MST = Mass source tolerance 
INGLUCON - Initial Glucose Concentration 
INOXYCON = Initial Oxygen Concentration 
GLUDIF - Glucose Diffusivity 
OXYDIF - Oxygen Diffusivity 
RESIST - Body Force 
#CALC 
FLDPOR - 1.0; 
PORITY - 0.9; 
VISCOS - 6.90E-04; 
WATDEN - 1; 
NRMVEL - I. OE-02; 
ITER - 5; 
MST - 1. OE-15; 
INGLUCON - 1.0; 
INOXYCON = 0.00987392; 
GLUDIF - 6.6E-10; 
OXYDIF - 1.5E-09; 
ZDIFF - 1. OE-200; 
RESIST - 2.45E5; 
NSTEPS - 10; 


















USER SCALAR16 'XY NODAL SHEAR STRESS' 
USER SCALAR17 'YZ NODAL SHEAR STRESS' 
USER SCALAR18 'ZX NODAL SHEAR STRESS' 
>>MODEL TOPOLOGY 
>>MODIFY PATCH 
OLD PATCH NAME 'PORl' 
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NEW PATCH NAME 'PORl' 
NEW PATCH TYPE 'POROUS' 
NEW PATCH GROUP NUMBER 1 
>>MODIFY PATCH 
OLD PATCH NAME 'POR21 
NEW PATCH NAME 'POR21 
NEW PATCH TYPE 'POROUS' 
NEW PATCH GROUP NUMBER 2 
>>MODIFY PATCH 
OLD PATCH NAME 'INV 
NEW PATCH NAME 'INV 
NEW PATCH TYPE 'INLET' 
NEW PATCH GROUP NUMBER I 
>>MODIFY PATCH 
OLD PATCH NAME 'IN21 
NEW PATCH NAME 'IN2' 
NEW PATCH TYPE 'INLET' 
NEW PATCH GROUP NUMBER 2 
>>MODIFY PATCH 
OLD PATCH NAME 'IN31 
NEW PATCH NAME 'IN31 
NEW PATCH TYPE 'INLET' 
NEW PATCH GROUP NUMBER 3 
>>MODIFY PATCH 
OLD PATCH NAME 'IN4' 
NEW PATCH NAME 'IN4' 
NEW PATCH TYPE 'INLET' 
NEW PATCH GROUP NUMBER 4 
>>MODEL DATA 
>>DIFFERENCING SCHEME 
USER SCALAR3 'NO CONVECTION' 
USER SCALAR4 'NO CONVECTION' 
USER SCALAR5 'NO CONVECTION' 
USER SCALAR6 'NO CONVECTION' 
USER SCALAR7 'NO CONVECTION' 
USER SCALARB 'NO CONVECTION' 
USER SCALAR9 'NO CONVECTION' 
USER SCALAR10 'NO CONVECTION' 
USER SCALAR11 'NO CONVECTION' 
USER SCALAR12 'NO CONVECTION' 
USER SCALAR13 'NO CONVECTION' 
USER SCALAR14 'NO CONVECTION' 






>>FIXED TIME STEPPING 
TIME STEPS #NSTEPS * #DELTAT 
INITIAL TIME 0.0 
>>SCALAR PARAMETERS 
>>DIFFUSIVITIES 
USER SCALAR1 #GLUDIF 
USER SCALAR2 #OXYDIF 
USER SCALAR3 #ZDIFF 
USER SCALAR4 #ZDIFF 
USER SCALAR5 #ZDIFF 
USER SCALAR6 #ZDIFF 
USER SCALAR7 #ZDIFF 
USER SCALAR8 #ZDIFF 
USER SCALAR9 #ZDIFF 
USER SCALAR10 #ZDIFF 
USER SCALAR11 #ZDIFF 
USER SCALAR12 #ZDIFF 
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USER SCALAR13 #ZDIFF 
USER SCALAR14 #ZDIFF 
USER SCALAR15 #ZDIFF 
>>POROUS REGION PARAMETERS 
PATCH GROUP NUMBER I 
VOLUME POROSITY #PORITY 
>>POROUS REGION PARAMETERS 
PATCH GROUP NUMBER 2 
VOLUME POROSITY #FLDPOR 
>>BODY FORCES 
PATCH NAME 'PORl' 
RESISTANCE CONSTANT #RESIST #RESIST #RESIST 
>>SOLVER DATA 
>>PROGRAM CONTROL 
MAXIMUM NUMBER OF ITERATIONS #ITER 
PRESSURE REFERENCE POINT 111 
OUTPUT MONITOR POSITION 1.3E-02 1.3E-02 3. OE-02 
MASS SOURCE TOLERANCE #MST 
>>ALGEBRAIC MULTIGRID PARAMETERS 
WORK SPACE FACTOR 3. OOOOE+00 
>>EQUATION SOLVERS 
U VELOCITY 'AMG' 
V VELOCITY 'AMG' 
W VELOCITY 'AMG' 
USER SCALAR1 'AMG' 
USER SCALAR2 'AMG' 
USER SCALAR3 'AMG' 
USER SCALAR4 'AMG' 
USER SCALAR5 'AMG' 
USER SCALAR6 'AMG' 
USER SCALAR7 'AMG' 
USER SCALAR8 'AMG' 
USER SCALAR9 'AMG' 
USER SCALAR10 'AMG' 
USER SCALAR11 'AMG' 
USER SCALAR12 'AMG' 
USER SCALAR13 'AMG' 
USER SCALAR14 'AMG' 
USER SCALAR15 'AMG' 
>>MODEL BOUNDARY CONDITIONS 
>>INLET BOUNDARIES 
PATCH NAME 'IN1' 
NORMAL VELOCITY #NRMVEL 
USER SCALAR1 #INGLUCON 
USER SCALAR2 #INOXYCON 
>>INLET BOUNDARIES 
PATCH NAME 'IN21 
NORMAL VELOCITY #NRMVEL 
USER SCALAR1 #INGLUCON 
USER SCALAR2 #INOXYCON 
>>INLET BOUNDARIES 
PATCH NAME 'IN3' 
NORMAL VELOCITY #NRMVEL 
USER SCALAR1 #INGLUCON 
USER SCALAR2 #INOXYCON 
>>INLET BOUNDARIES 
PATCH NAME 'IN4' 
NORMAL VELOCITY #NRMVEL 
USER SCALARI #INGLUCON 
USER SCALAR2 #INOXYCON 
>>OUTPUT OPTIONS 
>>DUMP FILE FORMAT 
UNFORMATTED 
DOUBLE PRECISION 
>>DUMP FILE OPTIONS 
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ALL USER SCALARS 
>>STOP 
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SUBROUTINE USRINT(U, V, W, P, VFRAC, DEN, VIS, TE, E0, RS, T, H, RF, SCAL, CONV, 
+ XC, YC, ZC, XP, YP, ZP, VOL, AREA, VPOR, ARPOR, WFACT, 
+ DISWAL, IPT, IBLK, IPVERT, IPNODN, IPFACN, IPNODF, 
+ IPNODB, IPFACB, WORK, IWORK, CWORK) 
C 
C 
C UTILITY SUBROUTINE FOR USER-SUPPLIED INITIAL FIELD. 
C 
C 
C THIS SUBROUTINE IS CALLED BY THE FOLLOWING SUBROUTINE 
C CUSR INIT 
C 
C CREATED 
C 13/06/90 ADB 
C MODIFIED 
C 07/08/91 IRH NEW STRUCTURE 
C 10/09/91 IRH CORRECTION TO IUSED 
C 26/09/91 IRH ALTER ARGUMENT LIST 
C 01/10/91 DSC REDUCE COMMENT LINE GOING OVER COLUMN 72. 
C 03/10/91 IRH CORRECT COMMENTS 
c 28/01/92 PHA UPDATE CALLED BY COMMENT, ADD RF ARGUMENT, 
C CHANGE LAST DIMENSION OF RS TO 6 AND IVERS TO 2 
C 03/06/92 PHA ADD PRECISION FLAG AND CHANGE IVERS TO 3 
C 08/02/93 NSW REMOVE REDUNDANT COMMENTS 
C 23/11/93 CSH EXPLICITLY DIMENSION IPVERT ETC. 
c 03/02/94 PHA CHANGE FLOW3D TO CFDS-FLOW3D, REMOVE COMMA 
c FROM BEGINNING OF DIMENSION STATEMENT 
C 03/03/94 FHW CORRECTION OF SPELLING MISTAKE 
C 09/08/94 NSW CORRECT SPELLING 
C MOVE 'IF(IUSED. EQ. 0) RETURN' OUT OF USER AREA 
C 19/12/94 NSW CHANGE FOR CFX-F3D 
C 30/01/95 NSW INCLUDE NEW EXAMPLE 
c 02/07/97 NSW UPDATE FOR CFX-4 
C 
C 
c SUBROUTINE ARGUMENTS 
C 
CU-U COMPONENT OF VELOCITY 
CV-V COMPONENT OF VELOCITY 
CW-W COMPONENT OF VELOCITY 
Cp- PRESSURE 
C VFRAC - VOLUME FRACTION 
C DEN - DENSITY OF FLUID 
C VIS - VISCOSITY OF FLUID 
c TE - TURBULENT KINETIC ENERGY 
C ED - EPSILON 
C RS - REYNOLD STRESSES 
CT- TEMPERATURE 
cH- ENTHALPY 
C RF - REYNOLD FLUXES 
C SCAL - SCALARS (THE FIRST 'NCONC' OF THESE ARE MASS FRACTIONS) 
C CONV - CONVECTION COEFFICIENTS 
C XC -X COORDINATES OF CELL CORNERS 
C YC -Y COORDINATES OF CELL CORNERS 
C zC -Z COORDINATES OF CELL CORNERS 
C Xp -X COORDINATES OF CELL CENTRES 
C Yp -Y COORDINATES OF CELL CENTRES 
C ZP -Z COORDINATES OF CELL CENTRES 
C VOL - VOLUME OF CELLS 
C AREA - AREA OF CELLS 
C VPOR - POROUS VOLUME 
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C ARPOR - POROUS AREA 
C WFACT - WEIGHT FACTORS 
C DISWAL - DISTANCE OF CELL CENTRE FROM WALL 
C 
C IPT - 1D POINTER ARRAY 
C IBLK - BLOCK SIZE INFORMATION 
C IPVERT - POINTER FROM CELL CENTERS TO 8 NEIGHBOURING VERTICES 
C IPNODN - POINTER FROM CELL CENTERS TO 6 NEIGHBOURING CELLS 
c IPFACN - POINTER FROM CELL CENTERS TO 6 NEIGHBOURING FACES 
c IPNODF - POINTER FROM CELL FACES TO 2 NEIGHBOURING CELL CENTERS 
C IPNODB - POINTER FROM BOUNDARY CENTERS TO CELL CENTERS 
C IPFACB - POINTER FROM BOUNDARY CENTERS TO BOUNDARY FACES 
c 
C WORK - REAL WORKSPACE ARRAY 
c IWORK - INTEGER WORKSPACE ARRAY 
c CWORK - CHARACTER WORKSPACE ARRAY 
c 
c SUBROUTINE ARGUMENTS PRECEDED WITH A 1*1 ARE ARGUMENTS THAT MUST 
C BE SET BY THE USER IN THIS ROUTINE. 
c 
C LOGICAL VARIABLE LRDISK IN COMMON BLOCK IOLOGC INDICATES WHETHER 
C THE RUN IS A RESTART AND CAN BE USED SO THAT INITIAL INFORMATION 
C IS ONLY SET WHEN STARTING A RUN FROM SCRATCH. 
c 
C NOTE THAT OTHER DATA MAY BE OBTAINED FROM CFX-4 USING THE 
c ROUTINE GETADD, FOR FURTHER DETAILS SEE THE VERSION 4 
C USER MANUAL. 
C 
DOUBLE PRECISION U 
DOUBLE PRECISION V 
DOUBLE PRECISION W 
DOUBLE PRECISION P 
DOUBLE PRECISION VFRAC 
DOUBLE PRECISION DEN 
DOUBLE PRECISION VIS 
DOUBLE PRECISION TE 
DOUBLE PRECISION ED 
DOUBLE PRECISION RS 
DOUBLE PRECISION T 
DOUBLE PRECISION H 
DOUBLE PRECISION RF 
DOUBLE PRECISION SCAL 
DOUBLE PRECISION CONV 
DOUBLE PRECISION XC 
DOUBLE PRECISION YC 
DOUBLE PRECISION Zc 
DOUBLE PRECISION XP 
DOUBLE PRECISION YP 
DOUBLE PRECISION ZP 
DOUBLE PRECISION VOL 
DOUBLE PRECISION AREA 
DOUBLE PRECISION VPOR 
DOUBLE PRECISION ARPOR 
DOUBLE PRECISION WFACT 
DOUBLE PRECISION DISWAL 
DOUBLE PRECISION WORK 
DOUBLE PRECISION TIME 
DOUBLE PRECISION DT 
DOUBLE PRECISION DTINVF 
DOUBLE PRECISION TPARM 
LOGICAL LDEN, LVIS, LTURB, LTEMP, LBUOY, LSCAL, LCOMP, LRECT, LCYN, LAXIS, 
+ LPOROS, LTRANS 





C ................ USER AREA 1 ......................................... 
C ---- AREA FOR USERS EXPLICITLY DECLARED VARIABLES 
DOUBLE PRECISION CONVERTO, CONVERTG, C1, C2, INDEN, CELLWEIGHT, 
+ BASEUNIT, CONVERTC, C3, C7, C9, Cll 
C ................ END OF USER AREA 1 .................................. 
C 
COMMON /ALL/NBLOCK, NCELL, NBDRY, NNODE, NFACE, NVERT, NDIM, 
+ /ALLWRK/NRWS, NIWS, NCWS, IWRFRE, IWIFRE, IWCFRE, /ADDIMS/NPHASE, 
+ NSCAL, NVAR, NPROP, NDVAR, NDPROP, NDXNN, NDGEOM, NDCOEF, NILIST, 
+ NRLIST, NTOPOL, /CHKUSR/IVERS, IUCALL, IUSED, /DEVICE/NREAD, 
+ NWRITE, NRDISK, NWDISK, /IDUM/ILEN, JLEN, /IOLOGC/LRDISK, LWDISK, 
+ /LOGIC/LDEN, LVIS, LTURB, LTEMP, LBUOY, LSCAL, LCOMP, LRECT, LCYN, 
+ LAXIS, LPOROS, LTRANS, /MLTGRD/MLEVEL, NLEVEL, ILEVEL, 
+ /SGLDBL/IFLGPR, ICHKPR, /TRANSI/NSTEP, KSTEP, MF, INCORE, 
+ /TRANSR/TIME, DT, DTINVF, TPARM 
C 
C ................ USER AREA 2 ......................................... 
C ---- AREA FOR USERS TO DECLARE THEIR OWN COMMON BLOCKS 
C THESE SHOULD START WITH THE CHARACTERS 'UC' TO ENSURE 
C NO CONFLICT WITH NON-USER COMMON BLOCKS 
C 
C ................ END OF USER AREA 2 .................................. 
C 
DIMENSION U(NNODE, NPHASE), V(NNODE, NPRASE), W(NNODE, NPHASE), 
+ P(NNODE, NPRASE), VFRAC(NNODE, NPRASE), TE(NNODE, NPHASE), 
+ ED(NNODE, NPRASE), RS(NNODE, NPRASE, 6), T(NNODE, NPHASE), 
+ H(NNODE, NPHASE), RF(NNODE, NPRASE, 4), 
+ SCAL(NNODE, NPRASE, NSCAL), DEN(NNODE, NPHASE), 
+ VIS(NNODE, NPHASE), CONV(NFACE, NPRASE) 
DIMENSION XC(NVERT), YC(NVERT), ZC(NVERT), XP(NNODE), YP(NNODE), 
+ ZP(NNODE), VOL(NCELL), AREA(NFACE, 3), VPOR(NCELL), 
+ ARPOR(NFACE, 3), WFACT(NFACE), DISWAL(NCELL) 
DIMENSION IPT(*), IBLK(5, NBLOCK), IPVERT(NCELL, 8), IPNODN(NCELL, 6), 
+ IPFACN(NCELL, 6), IPNODF(NFACE, 4), IPNODB(NBDRY, 4), 
+ IPFACB(NBDRY) 
DIMENSION IWORK(NIWS), WORK(NRWS), CWORK(NCWS) 
C 
C ............... USER AREA 3 ......................................... 
C ---- AREA FOR USERS TO DIMENSION THEIR ARRAYS 
C 
C ---- AREA FOR USERS TO DEFINE DATA STATEMENTS 
C 
C ................ END OF USER AREA 3 .................................. 
C 
C ---- STATEMENT FUNCTION FOR ADDRESSING 
IP(I, J, K) - IPT((K-1)*ILEN*JLEN+ (J-1)*ILEN+I) 
C 





C ................ USER AREA 4 ......................................... 




C ................ END OF USER AREA 4 .................................. 
C 
IF (IUSED. EQ. 0) RETURN 
C 
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C ---- FRONTEND CHECKING OF USER ROUTINE 
IF (IUCALL. EQ. 0) RETURN 
C 
C ................ USER AREA 5 ......................................... 
C 
C SCALI - Glucose 
C SCAL2 - Oxygen 
C SCAL3 - PSC 2% 
C SCAL4 - SC 
C SCAL5 = MYSC 
C SCAL6 - LYSC 
C SCAL7 = CFUGM 10% 
C SCALS - CFUMEG 
C SCAL9 = BFUE 8% 
C SCAL10 - CFUEO 




C GET SCALAR VARIABLE 
C 
CALL GETSCA(IUSER SCALARII, ISC1, CWORK) 
CALL GETSCA(IUSER SCALAR2', ISC2, CWORK) 
CALL GETSCA('USER SCALAR31, ISC3, CWORK) 
CALL GETSCA(IUSER SCALAR7', ISC7, CWORK) 
CALL GETSCA(IUSER SCALAR9', ISC9, CWORK) 
CALL GETSCA(IUSER SCALAR11', ISC11, CWORK) 
C 
C INITIALISE SCAL VARIABLE ONLY IF NO RESTART IS USED 
C 
IF(. NOT. LRDISK) THEN 
C 
C USE IPALL TO FIND 1D ADDRESSES OF ALL CELL CENTRES 
C 
C 
CALL IPALL('*', '*', 'BLOCKI, 'CENTRES', IPT, NPT, CWORK, IWORK) 
DO 150 IPHASE - 1, NPHASE 
C 
C LOOP OVER ALL INTERIOR CELLS 
C 
DO 160 I=1, NPT 
C 




C VARIABLE FOR THE PARAMETERS 
C 
C SCALl - Glucose 
C SCAL2 - Oxygen 
C SCAL3 - PSC 2% 
C SCAL7 - CFUGM 10% 
C SCAL9 = BFUE 8% 
C SCAL11 - Blast Cell 80% 
C 
C ----- CONVERSION PARAMETERS 
CONVERTO=2.03E-9*32*1000 
CONVERTG=0.001 




SCAL(INODE, IPHASE, ISC1)=Cl 






CALL IPALL('PORl', 'POROUS', 'PATCH', 'CENTRESI, IPT, NPT, CWORK, IWORK) 
C 
DO 200 IPRASE - 1, NPHASE 
C 
Do 210 I-1, NPT 
C 
c ----- CONVERSION PARAMETERS 
INDEN - 2ES 
CELLWEIGHT - 2.8E-12 
BASEUNIT - 1000000 
CONVERTC - CELLWEIGHT*BASEUNIT 
C 
SCALE - CONVERTC1 
C 
C ------ INOCULUM DENSITY FOR DIFFERENT CELLS 
C3 - INDEN*CONVERTC*0.02 
C7 - INDEN*CONVERTC*0.1 





SCAL(INODE, IPHASE, ISC3)-C3 
SCAL(INODE, IPHASE, ISC7)=C7 
SCAL(INODE, IPHASE, ISC9)-C9 












SUBROUTINE USRSRC(IEQN, ICALL, CNAME, CALIAS, AM, SP, SU, CONV, U, V, W, P, 
+ VFRAC, DEN, VIS, TE, ED, RS, T, H, RF, SCAL, XP, YP, ZP, VOL, 
+ AREA, VPOR, ARPOR, WFACT, IPT, IBLK, IPVERT, IPNODN, 
+ IPFACN, IPNODF, IPNODB, IPFACB, WORK, IWORK, CWORK) 
C 
C 
C UTILITY SUBROUTINE FOR USER-SUPPLIED SOURCES 
C 
C >>> IMPORTANT <<< 
C >>> <<< 
C >>> USERS MAY ONLY ADD OR ALTER PARTS OF THE SUBROUTINE WITHIN <<< 
C >>> THE DESIGNATED USER AREAS <<< 
C 
C 
C THIS SUBROUTINE IS CALLED BY THE FOLLOWING SUBROUTINES 
C CUSR SCDF SCDS SCED SCENRG SCHF SCMOM SCPCE SCSCAL 
C SCTE SCVF 
C 
C CREATED 
C 08/03/90 ADB 
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C MODIFIED 
c 04/03/91 ADB ALTERED ARGUMENT LIST. 
C 28/08/91 IRH NEW STRUCTURE 
C 28/09/91 IRH CHANGE EXAMPLE + ADD COMMON BLOCKS 
C 10/02/92 PHA UPDATE CALLED BY COMMENT, ADD RF ARGUMENT, 
C CHANGE LAST DIMENSION OF RS TO 6 AND IVERS TO 2 
C 03/06/92 PHA ADD PRECISION FLAG AND CHANGE IVERS TO 3 
C 23/11/93 CSH EXPLICITLY DIMENSION IPVERT ETC. 
C 07/12/93 NSW INCLUDE CONV IN ARGUMENT LIST AND CHANGE IVERS 
C TO 4 
C 03/02/94 PRA CHANGE FLOW3D TO CFDS-FLOW`3D 
C 03/03/94 FHW CORRECTION OF SPELLING MISTAKE 
c 08/03/94 NSW CORRECT SPELLING 
c 09/08/94 NSW CORRECT SPELLING. 
c MOVE 'IF(IUSED. EQ. 0) RETURN' OUT OF USER AREA. 
C INCLUDE COMMENT ON MASS SOURCES. 
c 19/12/94 NSW CHANGE FOR CFX-F3D 
C 02/07/97 NSW UPDATE FOR CFX-4 
c 
C 
C SUBROUTINE ARGUMENTS 
C 
C IEQN - EQUATION NUMBER 
C ICALL - SUBROUTINE CALL 
C CNAME - EQUATION NAME 
C CALIAS - ALIAS OF EQUATION NAME 
C AM - OFF DIAGONAL MATRIX COEFFICIENTS 
C SU - SU IN LINEARISATION OF SOURCE TERM 
c SP - SP IN LINEARISATION OF SOURCE TERM 
c CONV - CONVECTION COEFFICIENTS 
cU-U COMPONENT OF VELOCITY 
CV-V COMPONENT OF VELOCITY 
CW-W COMPONENT OF VELOCITY 
CP- PRESSURE 
C VFRAC - VOLUME FRACTION 
C DEN - DENSITY OF FLUID 
C VIS - VISCOSITY OF FLUID 
C TE - TURBULENT KINETIC ENERGY 
C ED - EPSILON 
C RS - REYNOLD STRESSES 
CT- TEMPERATURE 
CH- ENTHALPY 
C RF - REYNOLD FLUXES 
c SCAL - SCALARS (THE FIRST INCONCI OF THESE ARE MASS FRACTIONS) 
C XP -X COORDINATES OF CELL CENTRES 
C YP -Y COORDINATES OF CELL CENTRES 
C ZP -Z COORDINATES OF CELL CENTRES 
C VOL - VOLUME OF CELLS 
C AREA - AREA OF CELLS 
C VPOR - POROUS VOLUME 
C ARPOR - POROUS AREA 
C WFACT - WEIGHT FACTORS 
C 
c IPT - 1D POINTER ARRAY 
C IBLK - BLOCK SIZE INFORMATION 
c IPVERT - POINTER FROM CELL CENTERS TO 8 NEIGHBOURING VERTICES 
C IPNODN - POINTER FROM CELL CENTERS TO 6 NEIGHBOURING CELLS 
C IPFACN - POINTER FROM CELL CENTERS TO 6 NEIGHBOURING FACES 
C IPNODF - POINTER FROM CELL FACES TO 2 NEIGHBOURING CELL CENTERS 
C IPNODB - POINTER FROM BOUNDARY CENTERS TO CELL CENTERS 
C IPFACB - POINTER FROM BOUNDARY CENTERS TO BOUNDARY FACESS 
c 
C WORK - REAL WORKSPACE ARRAY 
C IWORK - INTEGER WORKSPACE ARRAY 
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C CWORK - CHARACTER WORKSPACE ARRAY 
C 
C SUBROUTINE ARGUMENTS PRECEDED WITH A '*' ARE ARGUMENTS THAT MUST 
C BE SET BY THE USER IN THIS ROUTINE. 
C 
C NOTE THAT WHEN USING MASS SOURCES, THE FLOWS THROUGH MASS FLOW 
C BOUNDARIES ARE UNCHANGED. THE USER SHOULD THEREFORE INCLUDE AT 
C LEAST ONE PRESSURE BOUNDARY FOR SUCH A CALCULATION. 
C 
C NOTE THAT OTHER DATA MAY BE OBTAINED FROM CFX-4 USING THE 
C ROUTINE GETADD, FOR FURTHER DETAILS SEE THE VERSION 4 
C USER MANUAL. 
C 
C 
DOUBLE PRECISION AM 
DOUBLE PRECISION SP 
DOUBLE PRECISION SU 
DOUBLE PRECISION CONV 
DOUBLE PRECISION U 
DOUBLE PRECISION V 
DOUBLE PRECISION W 
DOUBLE PRECISION P 
DOUBLE PRECISION VFRAC 
DOUBLE PRECISION DEN 
DOUBLE PRECISION VIS 
DOUBLE PRECISION TE 
DOUBLE PRECISION ED 
DOUBLE PRECISION RS 
DOUBLE PRECISION T 
DOUBLE PRECISION H 
DOUBLE PRECISION RF 
DOUBLE PRECISION SCAL 
DOUBLE PRECISION XP 
DOUBLE PRECISION YP 
DOUBLE PRECISION ZP 
DOUBLE PRECISION VOL 
DOUBLE PRECISION AREA 
DOUBLE PRECISION VPOR 
DOUBLE PRECISION ARPOR 
DOUBLE PRECISION WFACT 
DOUBLE PRECISION WORK 
DOUBLE PRECISION SMALL 
DOUBLE PRECISION SORMAX 
DOUBLE PRECISION TIME 
DOUBLE PRECISION DT 
DOUBLE PRECISION DTINVF 
DOUBLE PRECISION TPARM 
LOGICAL LDEN, LVIS, LTURB, LTEMP, LBUOY, LSCAL, LCOMP, LRECT, LCYN, LAXIS, 
+ LPOROS, LTRANS 
C 
CHARACTER*(*) CWORK 
CHARACTER CNAME*6, CALIAS*24 
C 
C ................. USER AREA 1 ......................................... 
C ---- AREA FOR USERS EXPLICITLY DECLARED VARIABLES 
C 
C ---- michaelis-Menten Kinetics 
C 
DOUBLE PRECISION VMAXGLC, VMAXOXY, GLC, OXY, A1, A2, KMAX, PSC, SC, 
" MYSC, LYSC, CFUGM, CFUMEG, BFUE, CFUEO, TOTALCELL, CONVERTC, SKECFUEO, 
" KG, KO, MATURE1, CONVERTDAY, CONVERTV, RECONVERTC, VESSELVOL, 
" ALPHA, SKEPSC, SKESC, SKEMYSC, SKELYSC, SKECFUGM, SKECFUMEG, SKEBFUE, 
" SKKPSC, SKKSC, SKKMYSC, SKKLYSC, SKKCFUGM, SKKCFUMEG, SKKBFUE, SKKCFUEO, 
" SKDSC, SKDMYSC, SKDLYSC, SKDCFUGM, SKDCFUMEG, SKDBFUE, SKDCFUEO, GROWTH, 
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" DEATH, EQ3, EQ4, EQ5, EQ6, EQ7, EQ8, EQ9, EQ10, CELLPERM3, MATURE2, MATURE3, 
" MATURE4, MATURE5, GROWTH, DEATH 
c 
C ................. END OF USER AREA 1 .................................. 
C 
COMMON /ALL/NBLOCK, NCELL, NBDRY, NNODE, NFACE, NVERT, NDIM, 
+ /ALLWRK/NRWS, NIWS, NCWS, IWRFRE, IWIFRE, IWCFRE, /ADDIMS/NPRASE, 
+ NSCAL, NVAR, NPROP, NDVAR, NDPROP, NDXNN, NDGEOM, NDCOEF, NILIST, 
+ NRLIST, NTOPOL, /CHKUSR/IVERS, IUCALL, IUSED, /DEVICE/NREAD, 
+ NWRITE, NRDISK, NWDISK, /IDUM/ILEN, JLEN, /LOGIC/LDEN, LVIS, 
+ LTURB, LTEMP, LBUOY, LSCAL, LCOMP, LRECT, LCYN, LAXIS, LPOROS, 
+ LTRANS, /MLTGRD/MLEVEL, NLEVEL, ILEVEL, /SGLDBL/IFLGPR, ICHKPR, 
+ /SPARM/SMALL, SORMAX, NITER, INDPRI, MAXIT, NODREF, NODMON, 
+ /TRANSI/NSTEP, KSTEP, MF, INCORE, /TRANSR/TIME, DT, DTINVF, TPARM 
c 
c ................. USER AREA 2 ......................................... 
c ---- AREA FOR USERS TO DECLARE THEIR OWN COMMON BLOCKS 
c THESE SHOULD START WITH THE CHARACTERS 'UC' TO ENSURE 
c NO CONFLICT WITH NON-USER COMMON BLOCKS 
C 
C ................. END OF USER AREA 2 .................................. 
C 
DIMENSION AM(NCELL, 6, NPRASE), SP(NCELL, NPRASE), SU(NCELL, NPRASE), 
+ CONV(NFACE, NPRASE) 
c 
DIMENSION U(NNODE, NPHASE), V(NNODE, NPRASE), W(NNODE, NPliASE), 
+ P(NNODE, NPRASE), VFRAC(NNODE, NPHASE), DEN(NNODE, NPRASE), 
+ VIS(NNODE, NPRASE), TE(NNODE, NPHASE), ED(NNODE, NPRASE), 
+ RS(NNODE, NPRASE, 6), T(NNODE, NPHASE), H(NNODE, NPHASE), 
+ RF(NNODE, NPHASE, 4), SCAL(NNODE, NPHASE, NSCAL) 
c 
DIMENSION XP(NNODE), YP(NNODE), ZP(NNODE), VOL(NCELL), AREA(NFACE, 3), 
+ VPOR(NCELL), ARPOR(NFACE, 3), WFACT(NFACE), IPT(*), 
+ IBLK(5, NBLOCK), IPVERT(NCELL, 8), IPNODN(NCELL, 6), 
+ IPFACN(NCELL, 6), IPNODF(NFACE, 4), IPNODB(NBDRY, 4), 
+ IPFACB(NBDRY), IWORK(*), WORK(*), CWORK(*) 
c 
C ................. USER AREA 3 ......................................... 
C ---- AREA FOR USERS TO DIMENSION THEIR ARRAYS 
C 
C ---- AREA FOR USERS TO DEFINE DATA STATEMENTS 
c 
C ................. END OF USER AREA 3 .................................. 
c 
C ---- STATEMENT FUNCTION FOR ADDRESSING 
IP(I, J, K) = IPT((K-1)*ILEN*JLEN+ (J-I)*ILEN+I) 
c 





C ................. USER AREA 4 ......................................... 




C ................. END OF USER AREA 4 .................................. 
C 
IF (IUSED. EQ. 0) RETURN 
C 
C ---- FRONTEND CHECKING OF USER ROUTINE 
IF (IUCALL. EQ. 0) RETURN 
C 
C ---- ADD TO SOURCE TERMS 
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IF (ICALL. EQ. 1) THEN 
C 
C ................. USER AREA 5 ......................................... 
C 
C SOURCES TERM ABBEV. 
C 
C SCALAR1 - Glucose 
C SCALAR2 - Oxygen 
C SCALAR3 - PSC (Pluripotent Stem Cell) 
C SCALAR4 = SC (Stem Cell) 
C SCALAR5 = MYSC (Myeloid Stem Cell) 
C SCALAR6 = LYSC (Lymphoid Stem Cell) 
C SCALAR7 - CTUGM (Colony-Forming Unit - Granulocyte, Macrophage) 
C SCALARB = CFUMEG (Colony-Forming Unit - Megakaryocyte) 
C SCALAR9 = BFUE (Colony-Forming Unit - Erythroid) 
C SCALAR10 - CFUEO (Colony-Forming Unit - Eosinophils) 
C 
C GLC - Glucose Concentration 
C OXY = Oxygen Concentration 
C 
C VMAXGLC = VMax for Glucose 
C VMAXOXY = VMax for Oxygen ***ONLY VMAXOXY USED 
C ***(FOR COMBINED SOURCES, USE THE LIMITING SOURCE'S VMAX FOR KMAX)*** 
C 
C KMAX = KMAX (Rate Constant in the M-M expression) 
C KI = KM for GLC (Rate Constant in denominator of M-M for glucose) 
C K2 - KM for OXY (Rate Constant in denominator of M-M for oxygen) 
C 
C Al - Kl+GLC 
C A2 = K2+OXY 
C 
C KG = 0.9 (Km for Glucose in Separate Source) 
C KO - 8.61E-04 (Km for Oxygen in Separate Source) 
C Kl - I/KG 
C K2 - 1/KO 
C 
C TOTALCELL = Total Cell Number 
C VESSELVOL - 50.0585 ml 
C 
C GLC Source - -(KMAX*GLC/(Kl+GLC) 
C OXY Source = -(KMAX*OXY/(K2+OXY) 




C ------ VESSEL VOLUME PER M^3 
VESSELVOL - 50.0585/(100*100*100) 
C ------ GROWTH RATE 
CONVERTDAY = 86400 
SKEPSC - 3.8/CONVERTDAY 
SKESC = 1.3/CONVERTDAY 
SKEMYSC - 2.8E-02/CONVERTDAY 
SKELYSC - 1.0E-01/CONVERTDAY 
SKECFUGM - 2.1E-01/CONVERTDAY 
SKECFUMEG - 1.7E-03/CONVERTDAY 
SKEBFUE - 4.2E-03/CONVERTDAY 
SKECFUEO - 4.9E-Ol/CONVERTDAY 
SKKPSC = 9.5E-04/CONVERTDAY 
SKKSC = 8.2E-04/CONVERTDAY 
SKKMYSC = 1.5E-04/CONVERTDAY 
SKKLYSC = 1.4E-03/CONVERTDAY 
SKKCFUGM - 1.0E-01/CONVERTDAY 
SKKCFUMEG = 2.9E-03/CONVERTDAY 
SKKBFUE = 3.2E-Ol/CONVERTDAY 
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SKKCFUEO - 9. lE-02/CONVERTDAY 
SKDSC - 4.2/CONVERTDAY 
SKDMYSC - 1.6/CONVERTDAY 
SKDLYSC - 3.3E-02/CONVERTDAY 
SKDCFUGM - 9.1E-01/CONVERTDAY 
SKDCFUMEG - 1.4E-Ol/CONVERTDAY 
SKDBFUE = 1.2E-Ol/CONVERTDAY 
SKDCFUEO - 4.4E-02/CONVERTDAY 
GROWTH 0.35/CONVERTDAY 
DEATH 0.5/CONVERTDAY 








C USE IPALL TO FIND 1D ADDRESSES OF ALL CELL CENTRES 
c 
CALL IPALL('PORl', 'POROUS', 'PATCH', 'CENTRES', IPT, NPT, CWORK, IWOPK) 
c 
CALL GETVAR('USRSRC', 'SCAL ', ISCAL) 
C 
C FIND VARIABLE NUMBER FOR SCALAR1 (GLUCOSE) 
C 
CALL GETSCA('USER SCALARV, ISC1, CWORK) 
ISCA-ISCAL+ISCl-1 
C 
C FIND VARIABLE NUMBER FOR SCALAR2 (OXYGEN) 
C 
CALL GETSCA('USER SCALAR21, ISC2, CWORK) 
ISCB-ISCAL+ISC2-1 
C 
C FIND VARIABLE NUMBER FOR SCALAR3 (PSC) 
C 
CALL GETSCA('USER SCALARV, ISC3, CWORK) 
ISCC=ISCAL+ISC3-1 
c 
C FIND VARIABLE NUMBER FOR SCALAR4 (SC) 
C 
CALL GETSCAPUSER SCALARV, ISC4, CWORK) 
ISCD=ISCAL+ISC4-1 
C 
C FIND VARIABLE NUMBER FOR SCALAR5 (MYSC) 
c 
CALL GETSCA('USER SCALARV, ISC5, CWORK) 
ISCE=ISCAL+ISC5-1 
C 
C FIND VARIABLE NUMBER FOR SCALAR6 (LYSC) 
C 
CALL GETSCA('USER SCALARV, ISC6, CWORK) 
ISCF=ISCAL+ISC6-1 
c 
C FIND VARIABLE NUMBER FOR SCALAR7 (CFU-GM) 
C 
CALL GETSCA('USER SCALAR71, ISC7, CWORK) 
ISCG=ISCAL+ISC7-1 
C 
C FIND VARIABLE NUMBER FOR SCALARS (CFU-MEG) 
C 




C FIND VARIABLE NUMBER FOR SCALAR9 (BFU-E) 
C 
CALL GETSCA('USER SCALAR9', ISC9, CWORK) 
ISCI-ISCAL+ISC9-1 
c 
C FIND VARIABLE NUMBER FOR SCALAR10 (CFU-Eo) 
C 
CALL GETSCACUSER SCALAR10', ISC10, CWORK) 
ISCJ=ISCAL+ISC10-1 
C 
C FIND VARIABLE NUMBER FOR SCALAR11 (Mature Compartmentl - Blast) 
C 
CALL GETSCA('USER SCALAR11', ISC11, CWORK) 
ISCK=ISCAL+ISC11-1 
C 
C FIND VARIABLE NUMBER FOR SCALAR12 (Mature Compartment2) 
c 
CALL GETSCA(IUSER SCALAR121, ISC12, CWORK) 
ISCL=ISCAL+ISC12-1 
C 
c FIND VARIABLE NUMBER FOR SCALAR13 (Mature Compartment3) 
C 
CALL GETSCA(IUSER SCALAR131, ISC13, CWORK) 
ISCM=ISCAL+ISC13-1 
c 
C FIND VARIABLE NUMBER FOR SCALAR14 (Mature Compartment4) 
c 
CALL GETSCA(IUSER SCALAR141, ISC14, CWORK) 
ISCN-ISCAL+ISC14-1 
C 
C FIND VARIABLE NUMBER FOR SCALAR15 (Mature Compartment 5- Death) 
C 
CALL GETSCA('USER SCALAR15', ISC15, CWORK) 
ISCO-ISCAL+ISC15-1 
C 
C IF SCALARI EQUATION (ISCA) ADD SOURCE TERMS 
C 
IF (ISCA. EQ. IEQN) THEN 
C 
C LOOP OVER ALL INTERIOR CELLS 
c 
DO 300 I-1, NPT 
C 
C USE ARRAY IPT TO GET ADDRESS 
C 





GLC - MAX (SCAL(INODE, IPHASE, ISCl), SMALL) 
OXY - MAX (SCAL(INODE, IPHASE, ISC2), SMALL) 
TOTALCELL = (MAX (SCAL(INODE, IPHASE, ISC3), SMALL)+mAx (SCAL 
" (INODE, IPHASE, ISC4), SMALL)+MAX (SCAL(INODE, IPHASE, ISC5), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC6), SMALL)+MAX (SCAL(INODE, IPHASE, ISC 
" 7), SMALL)+MAX (SCAL(INODE, IPHASE, ISC8), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC9), SMALL)+MAX (SCAL(INODE, IPHASE, ISC10), SMALL) 
*+ MAX (SCAL(INODE, IPHASE, ISC11), SMALL)+ MAX (SCAL(INODE, 
* IPHASE, ISC12), SMALL)+ MAX (SCAL(INODE, IPIiASE, ISC13), SMALL)+ 
* MAX (SCAL(INODE, IPliASE, ISC14), SMALL)+MAX (SCAL(INODE, 
* IPHASE, ISC15), SMALL))*RECONVERTC*0.9 
VMAXOXY - 33.55E-14*CONVERTV*TOTALCELL*(100**3) 
KMAX - VMAXOXY*KO*KG 
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C 
Al - (I+GLC*0.9*KO) 
A2 - (1+OXY*0.9*KG) 
C 
C OVERWRITE SOURCE TERMS 




C IF SCALAR2 EQUATION (ISCB) ADD SOURCE TERMS 
C 
ELSE IF (ISCB. EQ. IEQN) THEN 
C 
C LOOP OVER ALL INTERIOR CELLS 
C 
DO 400 I-1, NPT 
C 
C USE ARRAY IPT TO GET ADDRESS 
C 
INODE - IPT(l) 
C 
GLC - MAX (SCAL(INODE, IPHASE, ISCl), SMALL) 
OXY - MAX (SCAL(INODE, IPRASE, ISC2), SMALL) 
c 
TOTALCELL - (MAX (SCAL(INODE, IPIiASE, ISC3), SMALL)+MAX (SCAL 
+ (INODE, IPRASE, ISC4), SMALL)+MAX (SCAL(INODE, IPHASE, ISCS), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC6), SMALL)+MAX (SCAL(INODE, IPHASE, ISC 
" 7), SMALL)+MAX (SCAL(INODE, IPHASE, ISC8), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC9), SMALL)+MAX (SCAL(INODE, IPHASE, ISC10), SMALL) 
"+ MAX (SCAL(INODE, IPHASE, ISC11), SMALL)+ MAX (SCAL(INODE, 
" IPHASE, ISC12)fSMALL)+ MAX (SCAL(INODE, IPHASE, ISC13), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC14), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC15), SMALL))*RECONVERTC*0.9 
C 
VMAXOXY - 33.55E-14*CONVERTV*TOTALCELL*(100**3) 
C 
KMAX - VMAXOXY*KO*KG 
C 
Al - (1+GLC*0.9*KO) 
A2 - (1+OXY*0.9*KG) 
c 
C OVERWRITE SOURCE TERMS 
C 






C IF SCALAR3 EQUATION PSC (ISCC) ADD SOURCE TERMS 
C 
ELSE IF (ISCC. EQ. IEQN) THEN 
C 
C LOOP OVER ALL INTERIOR CELLS 
C 
DO 500 1-1, NPT 
C 




INODE - IPT(I) 
C 
PSC - MAX (SCAL(INODE, IPHASE, ISC3), SMALL) 
TOTALCELL - (MAX (SCAL(INODE, IPHASE, ISC3), SMALL)+MAX (SCAL 
" (INODE, IPHASE, ISC4), SMALL)+MAX (SCAL(INODE, IPHASE, ISC5), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC6), SMALL)+MAX (SCAL(INODE, IPHASE, ISC 
" 7), SMALL)+MAX (SCAL(INODE, IPHASE, ISC8), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC9), SMALL)+MAX (SCAL(INODE, IPHASE, ISC10), SMALL) 
"+ MAX (SCAL(INODE, IPHASE, ISC11), SMALL)+ MAX (SCAL(INODE, 
" iPliASE, ISC12), SMALL)+ MAX (SCAL(INODE, IPHASE, ISC13), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC14), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC15), SMALL))*RECONVERTC*0.9 
C 





C OVERWRITE SOURCE TERMS 
C 
SU(INODE, IPHASE)-SU(INODE, IPHASE)+((EQ3I)*VOL(INODE)) 
C 





C IF SCALAR4 EQUATION SC (ISCD) ADD SOURCE TERMS 
C 
ELSE IF (ISCD. EQ. IEQN) THEN 
c 
C LOOP OVER ALL INTERIOR CELLS 
c 
DO 560 I-1, NPT 
C 
C USE ARRAY IPT TO GET ADDRESS 
C 
INODE = IPT(I) 
C 
PSC - MAX (SCAL(INODE, IPHASE, ISC3), SMALL) 
SC - MAX (SCAL(INODE, IPHASE, ISC4), SMALL) 
C 
TOTALCELL - (MAX (SCAL(INODE, IPHASE, ISC3), SMALL)+MAX (SCAL 
" (INODE, IPHASE, ISC4), SMALL)+MAX (SCAL(INODE, IPHASE, ISC5), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC6), SMALL)+MAX (SCAL(INODE, IPHASE, ISC 
" 7), SMALL)+MAX (SCAL(INODE, IPHASE, ISC8), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC9), SMALL)+MAX (SCAL(INODE, IPHASE, ISC10), SMALL) 
"+ MAX (SCAL(INODE, IPHASE, ISCII), SMALL)+ MAX (SCAL(INODE, 
" IPHASE, ISC12), SMALL)+ MAX (SCAL(INODE, IPHASE, ISC13), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC14), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC15), SMALL))*RECONVERTC*0.9 
C 





C OVERWRITE SOURCE TERMS 
C 
SU(INODE, IPHASE)-SU(INODE, IPHASE)+((EQ41)*VOL(INODE)) 
C 






C IF SCALAR5 EQUATION MYSC (ISCE) ADD SOURCE TERMS 
C 
ELSE IF (ISCE. EQ. IEQN) THEN 
C 
C LOOP OVER ALL INTERIOR CELLS 
C 
DO 610 I-1, NPT 
c 
C USE ARRAY IPT TO GET ADDRESS 
C 
C 
INODE - IPT(I) 
SC - MAX (SCAL(INODE, IPHASE, ISC4), SMALL) 




TOTALCELL - (MAX (SCAL(INODE, IPHASE, ISC3), SMALL)+MAX (SCAL 
" (INODE, IPHASE, ISC4), SMALL)+MAX (SCAL(INODE, IPHASE, ISCS), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC6), SMALL)+MAX (SCAL(INODE, IPHASE, ISC 
" 7), SMALL)+MAX (SCAL(INODE, IPHASE, ISC8)fSMALL)+MAX (SCAL(INODEf 
" IPHASE, ISC9), SMALL)+MAX (SCAL(INODE, IPHASE, ISC10), SMALL) 
"+ MAX (SCAL(INODE, IPHASE, ISCII), SMALL)+ MAX (SCAL(INODEf 
" IPHASE, ISC12), SMALL)+ MAX (SCAL(INODE, IPHASE, ISC13), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC14), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC15), SMALL))*RECONVERTC*0.9 








SU(INODE, IPHASE)=SU(INODE, IPHASE)+((EQSI)*VOL(INODE)) 




C IF SCALAR6 EQUATION LYSC (ISCF) ADD SOURCE TERMS 
C 
ELSE IF (ISCF. EQ. IEQN) THEN 
C 
C LOOP OVER ALL INTERIOR CELLS 
C 
DO 650 I=1, NPT 
C 
C USE ARRAY IPT TO GET ADDRESS 
C 
C 
INODE = IPT(I) 
SC = MAX (SCAL(INODE, IPHASE, ISC4), SMALL) 
LYSC - MAX (SCAL(INODE, IPHASE, ISC6), SMALL) 
C 
TOTALCELL - (MAX (SCAL(INODE, IPHASE, ISC3), SMALL)+MAX (SCAL 
(INODE, IPHASE, ISC4), SMALL)+MAX (SCAL(INODE, IPHASE, ISC5), SMALL)+ 
MAX (SCAL(INODE, IPHASE, ISC6), SmALL)+mAx (SCAL(INODE, IPHASE, ISC 
+ 7), SMALL)+MAX (SCAL(INODE, IPHASE, ISCB), SMALL)+MAX (SCAL(INODE, 
+ IPHASE, ISC9), SMALL)+MAX (SCAL(INODE, IPHASE, ISC10), SMALL) 
++ MAX (SCAL(INODE, IPHASE, ISC11), SMALL)+ MAX (SCAL(INODE, 
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" IPHASE, ISC12), SMALL)+ MAX (SCAL(INODE, IPHASE, ISC13), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC14), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC15), SMALL))*RECONVERTC*0.9 
C 
C 




C OVERWRITE SOURCE TERMS 
c 
C 
SU(INODE, IPRASE)-SU(INODE, IPRASE)+((EQ6I)*VOL(INODE)) 





C IF SCALAR7 EQUATION CFU-GM (ISCG) ADD SOURCE TERMS 
ELSE IF (ISCG. EQ. IEQN) THEN 
c 
C LOOP OVER ALL INTERIOR CELLS 
DO 700 I=1, NPT 
c 
C USE ARRAY IPT TO GET ADDRESS 
c 
INODE - IPT(I) 
c 
MYSC - MAX (SCAL(INODE, IPHASE, ISC5), SMALL) 




TOTALCELL - (MAX (SCAL(INODE, IPHASE, ISC3), SMALL)+MAX (SCAL 
" (INODE, IPHASE, ISC4), SMALL)+MAX (SCAL(INODE, IPRASE, ISC5), SMALL)+ 
" MAX (SCAL(INODE, IPRASE, ISC6), SMALL)+MAX (SCAL(INODE, IPHASE, ISC 
" 7), SMALL)+MAX (SCAL(INODE, IPHASE, ISCB), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC9), SMALL)+MAX (SCAL(INODE, IPHASE, ISC10), SMALL) 
"+ MAX (SCAL(INODE, IPHASE, ISC11), SMALL)+ MAX (SCAL(INODE, 
" IPHASE, ISC12), SMALL)+ MAX (SCAL(INODE, IPHASE, ISC13), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC14), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC15), SMALL))*RECONVERTC*0.9 




C OVERWRITE SOURCE TERMS 
C 
SU(INODE, IPRASE)-SU(INODE, IPHASE)+((EQ71)*VOL(INODE)) 
C 





C IF SCALAR8 EQUATION CFU-MEG (ISCH) ADD SOURCE TERMS 
ELSE IF (ISCH. EQ. IEQN) THEN 
C 
C LOOP OVER ALL INTERIOR CELLS 
c 
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DO 710 I-1, NPT 
c 
C USE ARRAY IPT TO GET ADDRESS 
c 
INODE - IPT(l) 
C 
MYSC - MAX (SCAL(INODE, IPRASE, ISC5), SMALL) 
CFUMEG - MAX (SCAL(INODE, IPHASE, ISC8), SMALL) 
C 
TOTALCELL - (MAX (SCAL(INODE, IPHASE, ISC3), SMALL)+MAX (SCAL 
" (INODE, IPHASE, ISC4), SMALL)+MAX (SCAL(INODE, IPHASE, ISC5), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC6), SMALL)+MAX (SCAL(INODE, IPHASEISC 
" 7), SMALL)+MAX (SCAL(INODE, IPHASE, ISC8), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC9), SMALL)+MAX (SCAL(INODE, IPHASE, ISC10), SMALL) 
"+ MAX (SCAL(INODE, IPHASE, ISCII), SMALL)+ MAX (SCAL(INODE, 
" IPHASE, ISC12), SMALL)+ MAX (SCAL(INODE, IPHASE, ISC13), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC14), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC15), SMALL))*RECONVERTC*0.9 
C 
ALPHA - (TOTALCELL*50.0585)/(-1.996E+09)+(2. OE+09/1.996E+09) 
EQ81 ALPHA*SKECFUMEG*CFUMEG+SKDCFUMEG*MYSC 
EQ811 -SKKCFUMEG 
C OVERWRITE SOURCE TERMS 
C 
SU(INODE, IPHASE)=SU(INODE, IPHASE)+((EQ8I)*VOL(INODE)) 
C 





C IF SCALAR9 EQUATION BFU-E (ISCI) ADD SOURCE TERM 
c 
ELSE IF (ISCI. EQ. IEQN) THEN 
C 
C LOOP OVER ALL INTERIOR CELLS 
c 
DO 720 I=1, NPT 
c 
C USE ARRAY IPT TO GET ADDRESS 
c 
INODE - IPT(I) 
C 
MYSC - MAX (SCAL(INODE, IPHASE, ISC5), SMALL) 
BFUE - MAX (SCAL(INODE, IPHASE, ISC9), SMALL) 
C 
TOTALCELL - (MAX (SCAL(INODE, IPHASE, ISC3)*SMALL)+MAX (SCAL 
" (INODE, IPHASE, ISC4), SMALL)+MAX (SCAL(INODE, IPHASE, ISC5), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC6), SMALL)+MAX (SCAL(INODE, IPHASE, ISC 
" 7), SMA. LL)+MAX (SCAL(INODE, IPHASE, ISCB), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC9), SMALL)+MAX (SCAL(INODE, IPHASE, ISC10), SMALL) 
++ MAX (SCAL(INODE, IPliASE, ISC11), SMALL)+ MAX (SCAL(INODE, 
" IPHASE, ISC12), SMALL)+ MAX (SCAL(INODE, IPHASE, ISC13), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC14), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC15), SMALL))*RECONVERTC**0.9 
C 
ALPHA - (TOTALCELL*50.0585)/(-1.996E+09)+(2. OE+09/1.996E+09) 
C 
EQ91 - ALPHA*SKEBFUE*BFUE+SKDBFUE*MYSC 
EQ911 - -SKKBFUE 
c 
C OVERWRITE SOURCE TERMS 
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C 
SU(INODE, IPHASE)-SU(INODE, IPHASE)+((EQ9I)*VOL(INODE)) 
c 





C IF SCALAR10 EQUATION CFU-Eo (ISCJ) ADD SOURCE TERMS 
C 
ELSE IF (ISCJ. EQ. IEQN) THEN 
C 
C LOOP OVER ALL INTERIOR CELLS 
C 
DO 740 I-1, NPT 
c 
C USE ARRAY IPT TO GET ADDRESS 
C 
INODE - IPT(I) 
c 
MYSC - MAX (SCAL(INODE, IPHASE, ISC5), SMALL) 
CFUEO - MAX (SCAL(INODE, IPHASE, ISCIO), SMALL) 
C 
TOTALCELL = (MAX (SCAL(INODE, IPHASE, ISC3), SMALL)+MAX (SCAL 
" (INODE, IPHASE, ISC4), SMALL)+MAX (SCAL(INODE, IPHASE, ISC5), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC6), SMALL)+MAX (SCAL(INODE, IPHASE, ISC 
" 7), SMALL)+MAX (SCAL(INODE, IPHASE, ISC8), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC9), SMALL)+MAX (SCAL(INODE, IPHASE, ISC10), SMALL) 
"+ MAX (SCAL(INODE, IPHASE, ISC11), SMALL)+ MAX (SCAL(INODE, 
" IPHASE, ISC12), SMALL)+ MAX (SCAL(INODE, IPHASE, ISC13), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC14), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC15), SMALL))*RECONVERTC*0.9 
C 
ALPHA - (TOTALCELL*50.0585)/(-1.996E+09)+(2. OE+09/1.996E+09) 
C 
EQ10I - ALPHA*SKECFUEO*CFUEO+SKDCFUEO*MYSC 
EQ10II - -SKKCFUEO 
c 
C OVERWRITE SOURCE TERMS 
c 
SU(INODE, IPHASE)=$U(INODE, IPHASE)+((EQ9I)*VOL(INODE)) 
C 





C IF SCALAR11 EQUATION Mature Compartment (ISCK) ADD SOURCE TERMS 
C 
ELSE IF (ISCK. EQ. IEQN) THEN 
C 
C LOOP OVER ALL INTERIOR CELLS 
C 
DO 780 1=1, NPT 
c 
C USE ARRAY IPT TO GET ADDRESS 
c 
INODE - IPT(I) 
c 
CFUGM = MAX (SCAL(INODE, IPIiASE, ISC7), SMALL) 
CFUMEG = MAX (SCAL(INODE, IPHASE, ISC8), SMALL) 
BFUE MAX (SCAL(INODE, IPHASE, ISC9), SMALL) 
CFUEO MAX (SCAL(INODE, IPHASE, ISCIO), SMALL) 
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MATURE1 - MAX (SCAL(INODE, IPHASE, ISC13), SMALL) 
C 
C OVERWRITE SOURCE TERMS 
C 
SU(INODE, IPHASE)-SU(INODE, IPHASE)+((2*GROWTH) 
+ *(CFUMEG+CFUGM+BFUE+CFUEO))*VOL(INODE) 
c 





C IF SCALAR12 EQUATION Mature Compartment I (ISCL) ADD SOURCE TERMS 
C 
ELSE IF (ISCL. EQ. IEQN) THEN 
c 
C LOOP OVER ALL INTERIOR CELLS 
c 
DO 790 I-1, NPT 
c 
C USE ARRAY IPT TO GET ADDRESS 
C 
INODE - IPT(I) 
c 
MATURE1 - MAX (SCAL(INODE, IPHASE, ISC13), SMALL) 
MATURE2 - MAX (SCAL(INODE, IPHASE, ISC14), SMALL) 
C 
C OVERWRITE SOURCE TERMS 
c 
SU(INODE, IPHASE)-SU(INODE, IPHASE)+((2*GROWTH) 
+ *(MATUREl))*VOL(INODE) 
C 





C IF SCALAR13 EQUATION Mature Compartment 2 (ISCM) ADD SOURCE TERMS 
C 
ELSE IF (ISCM. EQ. IEQN) THEN 
c 
C LOOP OVER ALL INTERIOR CELLS 
C 
DO 800 I=I, NPT 
C 
C USE ARRAY IPT TO GET ADDRESS 
C 
INODE - IPT(I) 
C 
mATURE2 - MAX (SCAL(INODE, IPHASE, ISC14), SMALL) 
MATURE3 = MAX (SCAL(INODE, IPHASE, ISC15), SMALL) 
C 
c OVERWRITE SOURCE TERMS 
c 
SU(INODE, IPHASE)-SU(INODE, IPHASE)+((2*GROWTH) 
+ *(MATURE2))*VOL(INODE) 
C 






C IF SCALAR14 EQUATION Mature Compartment 3 (ISCN) ADD SOURCE TERMS 
C 
ELSE IF (ISCN. EQ. IEQN) THEN 
C 
C LOOP OVER ALL INTERIOR CELLS 
C 
DO 810 I-1, NPT 
C 
C USE ARRAY IPT TO GET ADDRESS 
C 
INODE = IPT(I) 
C 
MATURE3 - MAX (SCAL(INODE, IPHASE, ISC15), SMALL) 
MATURE4 - MAX (SCAL(INODE, IPHASE, ISC16), SMALL) 
C 
C OVERWRITE SOURCE TERMS 
C 
SU(INODE, IPHASE)-SU(INODE, IPHASE)+((2*GROWTH) 
+ *(MATURE3))*VOL(INODE) 
C 





C IF SCALAR15 EQUATION Mature Compartment 4 (ISCO) ADD SOURCE TERMS 
c 
ELSE IF (ISCO. EQ. IEQN) THEN 
C 
C LOOP OVER ALL INTERIOR CELLS 
C 
DO 820 I-1, NPT 
c 
C USE ARRAY IPT TO GET ADDRESS 
C 
INODE - IPT(I) 
C 
MATURE4 - MAX (SCAL(INODE, IPHASE, ISC16), SMALL) 
MATURE5 = MAX (SCAL(INODE, IPHASE, ISC17), SMALL) 
C 
C OVERWRITE SOURCE TERMS 
C 
SU(INODE, IPHASE)=SU(INODE, IPHASE)+((2*GROWTH) 
+ *(MATURE4))*VOL(INODE) 
C 





C ................. END OF USER AREA 5 .................................. 
C END IF 
C 
C ---- OVERWRITE SOURCE TERMS 
c IF (ICALL. EQ. 2) THEN 
C ................. USER AREA 6 ......................................... 





SUBROUTINE USRTRN(U, V, W, P, VFRAC, DEN, VIS, TE, ED, RS, T, H, RF, SCAL, XP, 
+ YP, ZP, VOL, AREA, VPOR, ARPOR, WFACT, CONV, IPT, IBLK, 
+ IPVERT, IPNODN, IPFACN, IPNODF, IPNODB, IPFACB, WORK, 
+ IWORK, CWORK) 
C 
C 
C USER SUBROUTINE TO ALLOW USERS TO MODIFY OR MONITOR THE SOLUTION AT 
C THE END OF EACH TIME STEP 
C THIS SUBROUTINE IS CALLED BEFORE THE START OF THE RUN AS WELL AS AT 
C THE END OF EACH TIME STEP 
C 
C >>> IMPORTANT <<< 
C >>> <<< 
C >>> USERS MAY ONLY ADD OR ALTER PARTS OF THE SUBROUTINE WITHIN <<< 
C >>> THE DESIGNATED USER AREAS <<< 
C 
C 
C THIS SUBROUTINE IS CALLED BY THE FOLLOWING SUBROUTINES 
C CUSR TRNMOD 
C 
C CREATED 
C 27/04/90 ADB 
C MODIFIED 
C 05/08/91 IRH NEW STRUCTURE 
C 01/10/91 DSC REDUCE COMMENT LINE GOING OVER COLUMN 72. 
C 29/11/91 PRA UPDATE CALLED BY COMMENT, ADD RF ARGUMENT, 
C CHANGE LAST DIMENSION OF RS TO 6 AND IVERS TO 2 
c 05/06/92 PHA ADD PRECISION FLAG AND CHANGE IVERS TO 3 
C 03/07/92 DSC CORRECT COMMON MLTGRD. 
C 23/11/93 CSH EXPLICITLY DIMENSION IPVERT ETC. 
C 03/02/94 PRA CHANGE FLOW3D TO CFDS-FLOW3D 
C 22/08/94 NSW MOVE 'IF(IUSED. EQ. 0) RETURN' OUT OF USER AREA 
C 19/12/94 NSW CHANGE FOR CFX-F3D 
C 02/07/97 NSW UPDATE FOR CFX-4 
C 02/07/99 NSW INCLUDE NEW EXAMPLE FOR CALCULATING FLUX OF A 
C SCALAR AT A PRESSURE BOUNDARY 
C 
c 
C SUBROUTINE ARGUMENTS 
C 
CU-U COMPONENT OF VELOCITY 
CV-V COMPONENT OF VELOCITY 
cW-W COMPONENT OF VELOCITY 
CP- PRESSURE 
C VFRAC - VOLUME FRACTION 
C DEN - DENSITY OF FLUID 
C VIS - VISCOSITY OF FLUID 
C TE - TURBULENT KINETIC ENERGY 
C ED - EPSILON 
C RS - REYNOLD STRESSES 
cT- TEMPERATURE 
CH- ENTHALPY 
C RF - REYNOLD FLUXES 
C SCAL - SCALARS (THE FIRST 'NCONC' OF THESE ARE MASS FRACTIONS) 
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c Xp -X COORDINATES OF CELL CENTRES 
C Yp -Y COORDINATES OF CELL CENTRES 
c Zp -Z COORDINATES OF CELL CENTRES 
c VOL - VOLUME OF CELLS 
c AREA - AREA OF CELLS 
c VPOR - POROUS VOLUME 
c ARPOR - POROUS AREA 
C WFACT - WEIGHT FACTORS 
c CONV - CONVECTION COEFFICIENTS 
C 
C IPT - 1D POINTER ARRAY 
C IBLK - BLOCK SIZE INFORMATION 
c IPVERT - POINTER FROM CELL CENTERS TO 8 NEIGHBOURING VERTICES 
C IPNODN - POINTER FROM CELL CENTERS TO 6 NEIGHBOURING CELLS 
C IPFACN - POINTER FROM CELL CENTERS TO 6 NEIGHBOURING FACES 
C IPNODF - POINTER FROM CELL FACES TO 2 NEIGHBOURING CELL CENTERS 
C IPNODB - POINTER FROM BOUNDARY CENTERS TO CELL CENTERS 
C IPFACB - POINTER FROM BOUNDARY CENTERS TO BOUNDARY FACESS 
c 
C WORK - REAL WORKSPACE ARRAY 
C IWORK - INTEGER WORKSPACE ARRAY 
C CWORK - CHARACTER WORKSPACE ARRAY 
C 
C SUBROUTIN E ARGUMENTS PRECEDED WITH A '*' ARE ARGUMENTS THAT MUST 
C BE SET B Y THE USER IN THIS ROUTINE. 
c 
C NOTE THAT OTHER DATA MAY BE OBTAINED FROM CFX-4 USING THE 
C ROUTINE GETADD, FOR FURTHER DETAILS SEE THE VERSION 4 




DOUBLE PRECISION U 
DOUBLE PRECISION V 
DOUBLE PRECISION W 
DOUBLE PRECISION P 
DOUBLE PRECISION VFRAC 
DOUBLE PRECISION DEN 
DOUBLE PRECISION VIS 
DOUBLE PRECISION TE 
DOUBLE PRECISION ED 
DOUBLE PRECISION RS 
DOUBLE PRECISION T 
DOUBLE PRECISION H 
DOUBLE PRECISION RF 
DOUBLE PRECISION SCAL 
DOUBLE PRECISION XP 
DOUBLE PRECISION YP 
DOUBLE PRECISION ZP 
DOUBLE PRECISION VOL 
DOUBLE PRECISION AREA 
DOUBLE PRECISION VPOR 
DOUBLE PRECISION ARPOR 
DOUBLE PRECISION WFACT 
DOUBLE PRECISION CONV 
DOUBLE PRECISION WORK 
DOUBLE PRECISION SMALL 
DOUBLE PRECISION SORMAX 
DOUBLE PRECISION DTUSR 
DOUBLE PRECISION TIME 
DOUBLE PRECISION DT 
DOUBLE PRECISION DTINVF 
DOUBLE PRECISION TPARM 
DOUBLE PRECISION SGNWL 
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C ................ USER AREA 1 ......................................... 
C ---- AREA FOR USERS EXPLICITLY DECLARED VARIABLES 
LOGICAL TIME1 
C ---- Michaelis-Menten Kinetics 
C 
DOUBLE PRECISION RECONVERTG, RECONVERTO, RECONVERTC, TOTALCELL, G1, 
+ G2,01,02, VESSELVOL 
C ................ END OF USER AREA 1 .................................. 
C 
COMMON /ALL/NBLOCK, NCELL, NBDRY, NNODE, NFACE, NVERT, NDIM, 
+ /ALLWRK/NRWS, NIWS, NCWS, IWRFRE, IWIFRE, IWCFRE, /ADDIMS/NPRASE, 
+ NSCAL, NVAR, NPROP, NDVAR, NDPROP, NDXNN, NDGEOM, NDCOEF, NILIST, 
+ NRLIST, NTOPOL, /CHKUSR/IVERS, IUCALL, IUSED, /CONC/NCONC, 
+ /DEVICE/NREAD, NWRITE, NRDISK, NWDISK, /IDUM/ILEN, JLEN, 
+ /LOGIC/LDEN, LVIS, LTURB, LTEMP, LBUOY, LSCAL, LCOMP, LPECT, LCYN, 
+ LAXIS, LPOROS, LTRANS, /MLTGRD/MLEVEL, NLEVEL, ILEVEL, 
+ /SGLDBL/IFLGPR, ICHKPR, /SPARM/SMALL, SORMAX, NITER, INDPRI, 
+ MAXIT, NODREF, NODMON, /TIMUSR/DTUSR, /TRANSI/NSTEP, KSTEP, MF, 
+ INCORE, /TRANSR/TIME, DT, DTINVF, TPARM 
c 
C ................ USER AREA 2 ......................................... 
C ---- AREA FOR USERS TO DECLARE THEIR OWN COMMON BLOCKS 
C THESE SHOULD START WITH THE CHARACTERS 'UC' TO ENSURE 
c NO CONFLICT WITH NON-USER COMMON BLOCKS 
c 
C ................ END OF USER AREA 2 .................................. 
C 
DIMENSION U(NNODE, NPRASE), V(NNODE, NPRASE), W(NNODE, NPHASE), 
+ P(NNODE, NPRASE), VFRAC(NNODE, NPRASE), DEN(NNODE, NPHASE), 
+ VIS(NNODE, NPRASE), TE(NNODE, NPRASE), ED(NNODE, NPHASE), 
+ RS(NNODE, NPRASE, 6), T(NNODE, NPHASE), H(NNODE, NPHASE), 
+ RF(NNODE, NPHASE, 4), SCAL(NNODE, NPRASE, NSCAL) 
DIMENSION XP(NNODE), YP(NNODE), ZP(NNODE), VOL(NCELL), AREA(NFACE, 3), 
+ VPOR(NCELL), ARPOR(NFACE, 3), WFACT(NFACE), 
+ CONV(NFACE, NPHASE), IPT(*), IBLK(5, NBLOCK), 
+ IPVERT(NCELL, 8), IPNODN(NCELL, 6), IPFACN(NCELL, 6), 
+ IPNODF(NFACE, 4), IPNODB(NBDRY, 4), IPFACB(NBDRY), IWORK(*), 
+ WORK(*), CWORK(*) 
DIMENSION SGNWL(6) 
c 
C ................ USER AREA 3 ......................................... 
c ---- AREA FOR USERS TO DIMENSION THEIR ARRAYS 
c 
C ---- AREA FOR USERS TO DEFINE DATA STATEMENTS 
C 
c ................ END OF USER AREA 3 .................................. 
C 
DATA SGNWL/1.000,1. ODO, 1. ODO, -l. ODO, -l. ODO, -l. ODO/ 
c 
C ---- STATEMENT FUNCTION FOR ADDRESSING 
IP(I, J, K) - IPT((K-1)*ILEN*JLEN+ (J-1)*ILEN+I) 
c 





C ................ USER AREA 4 ......................................... 
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C ................ END OF USER AREA 4 .................................. 
c 
IF (IUSED. EQ. 0) RETURN 
C 
C---- FRONTEND CHECKING OF USER ROUTINE 
IF (IUCALL. EQ. 0) RETURN 
c 
c ................ USER AREA 5 ......................................... 
c 
c 












OPEN (500, FILE-I.. /partial. txt', STATUS-'NEW') 
OPEN (501, FILE='.. /conc. txt', STATUS-'NEW') 
OPEN (502, FILE='.. /TotalCell. txt', STATUS-'NEW') 
TIME1 - FALSE. 
INQUIRE (FILE-ICFX4. STP', EXIST=TIMEl) 
IPHASE -1 
CALL GETSCA('USER SCALARV, ISC1, CWORK) 
CALL GETSCAOUSER SCALARV, ISC2, CWORK) 
CALL GETSCAOUSER SCALARV, ISC3, CWORK) 
CALL GETSCA('USER SCALARV, ISC4, CWORK) 
CALL GETSCAOUSER SCALAR5', ISC5, CWORK) 
CALL GETSCAOUSER SCALAR61, ISC6, CWORK) 
CALL GETSCAOUSER SCALARV, ISC7, CWORK) 
CALL GETSCA('USER SCALARV, ISC8, CWORK) 
CALL GETSCAOUSER SCALARV, ISC9, CWORK) 
CALL GETSCAMSER SCALAR10', ISC10, CWORK) 
CALL GETSCAOUSER SCALAR11', ISC11, CWORK) 
CALL GETSCACUSER SCALAR121, ISC12, CWORK) 
CALL GETSCA('USER SCALAR131, ISC13, CWORK) 
CALL GETSCA('USER SCALAR14', ISC14, CWORK) 
CALL GETSCAMSER SCAIAR15', ISC15, CWORK) 
CALL IPALL('PORl', 'POROUS', 'PATCH', 'CENTRES', IPT, NPT, CWORK, IWORK) 
DO 601 I-1, NPT 
INODE - IPT(I) 
Gl - SCAL(INODE, IPHASE, ISCl) 
01 - SCAL(INODE, IPHASE, ISC2) 
G2 - SCAL(INODE, IPHASE, ISC1)*CONVERTG 
02 = SCAL(INODE, IPHASE, ISC2)*CONVERTO 
C 
C 
TOTALCELL - (MAX (SCAL(INODE, IPHASE, ISC3), SMALL)+MAX (SCAL 
+ (INODE, IPHASE, ISC4), SMALL)+MAX (SCAL(INODE, IPHASE, ISC5), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC6), SMALL)+MAX (SCAL(INODE, IPHASE, ISC 
" 7), SMALL)+MAX (SCAL(INODE, IPHASE, ISC8), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC9), SMALL)+MAX (SCAL(INODE, IPHASE, ISC10), SMALL) 
"+ MAX (SCAL(INODE, IPHASE, ISC11), SMALL)+ MAX (SCAL(INODE, 
" IPHASE, ISC12), SMALL)+ MAX (SCAL(INODE, IPHASE, ISC13), SMALL)+ 
" MAX (SCAL(INODE, IPHASE, ISC14), SMALL)+MAX (SCAL(INODE, 
" IPHASE, ISC15), SMALL))*RECONVERTC*VESSELVOL 
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WRITE (500, *) 01,02 
WRITE (501, *) Gl, G2 
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